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ABBREVIATIONS AND SYMBOLS 
 
ACC, advanced colorectal cancer  
ADEPT, antibody-directed enzyme-prodrug  
    therapy  
AIF, arterial input function 
3-APP, 3-aminopropylphosphonate 
a.u., arbitrary units 
B, time between start of  the measurement and 
    appearance of the resonances 
B0, static magnetic field  
BAU, 5-benzylacyclouridine  
BCG, bacille Calmette-Guérin 
Beff, effective magnetic field  
BOLD, blood oxygenation dependent 
BrdUrd, bromodeoxyuridine 
13C, carbon-13 
C225, cetuximab 
CA-IX, carbonic anhydrase IX 
Canab, maximum concentration of anabolites 
CCI-103F, 1-(2-hydroxy-3-hexafluoroisopropxy- 
    propyl)-2-nitroimidazole 
CFBAL, maximum concentration of FBAL 
CFU, maximum concentration of FU 
CFUPA, maximum concentration of FUPA  
CNDP, 3-cyano-2,6-dihydroxypyridine 
COX, cyclooxygenase 
Cp, plasma concentration 
CSI, chemical shift imaging 
Ct, tissue concentration 
CT, computer tomography 
d,  difference in kep between two sessions 
DCE-MRI, dynamic contrast enhanced MRI 
5′-DFCR, 5′-deoxy-5-fluorocytidine  
5′-DFUR, 5′-deoxy-5-fluorouridine  
DHFU, 5,6-dihydro-5-fluorouracil 
D-MEM, Dulbecco’s Modified Eagle Media  
DMSO, dimethyl sulfoxide 
DPD, dihydropyrimidine dehydrogenase  
dTDP, 2′-deoxythymidine-5′-diphosphate  
dTMP, 2′-deoxythymidine-5′-monophosphate  
dTTP, 2′-deoxythymidine-5′-triphosphate  
dUMP, 2′-deoxyuridine-5′-monophosphate  
EGFR, epidermal growth factor receptor 
EM-FU, 1-ethoxymethyl-5-fluorouracil  
EU, 5-ethynyluracil, eniluracil 
A 
 
9F1, a rat monoclonal to mouse endothelium  
18F, fluorine-18 
19F, fluorine-19  
F-, fluoride  
FAC, fluoroacetate  
FBAL, α-fluoro-β-alanine  
FCS, fetal calf sera 
FCyt, 5-fluorocytosine 
FDG, 2-deoxy-2-18F-fluoro-D-glucose 
FdUDP, 5-fluoro-2′-deoxyuridine-5′-diphosphate  
FdUMP, 5-fluoro-2′-deoxyuridine-5′- 
    monophosphate 
FdUrd, 5-fluoro-2′-deoxyuridine 
FdUTP, 5-fluoro-2′-deoxyuridine-5′-triphosphate 
FHPA, α-fluoro-β-hydroxypropionate 
FID, free induction decay  
FITC, fluorescein isothiocyanate 
FLASH, fast low-angle shot 
Fnucs, fluoronucleosides  
Fnuct, fluoronucleotides  
FoV, field of view 
FU, 5-fluorouracil  
FUDP, 5-fluorouridine-5′-diphosphate  
FUMP, 5-fluorouridine-5′-monophosphate  
FUPA, α-fluoro-β-ureidopropionic acid  
FUrd, 5-fluorouridine  
FUTP, 5-fluorouridine-5′-triphosphate  
γ, magnetogyric ratio  
Gd-DTPA, Gadolinium-DTPA 
GDEPT, gene-dependent enzyme-prodrug    
    therapy  
GLUT, glucose transporter 
1H, proton 
HCFU, 1-hexylcarbamoyl-5-fluorouracil  
H&E, hematoxylin and eosin 
HF, hypoxic fraction 
HIF-1, hypoxia-inducible factor-1 
HK, hexokinase 
IdUrd, iododeoxyuridine 
IFNα, interferon-alpha 
i.p., intraperitoneal  
IR, inversion recovery  
i.v., intravenous   
kep, rate constant between extravascular 
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    extracellular space and blood plasma 
kep(aorta), kep determined with an AIF from the  
    aorta 
kep(spleen), kep determined with a VNF from the 
    spleen 
Ktrans, volume transfer constant 
L6-CD, L6 cytosine deaminase  
LI, labeling index 
LV, leucovorin  
M, vector of magnetization  
MLD, monoclonal liquid diluent 
MR, magnetic resonance 
MRI, magnetic resonance imaging 
MRS, magnetic resonance spectroscopy 
MRSI, magnetic resonance spectroscopic  
    imaging 
MTX, methotrexate  
MVD, microvascular density 
NADP(H), nicotinamide adenine dinucleotide  
    phosphate (reduced form) 
NTP, nucleoside triphosphate 
15O, oxygen-15 
OPRTase, orotic acid phosphoribosyl- 
    transferase 
31P, phosphorus-31 
P, permeability of capillaries  
PAL-E, Pathologie Anatomie Leiden-Endotheel 
PBS, phosphate buffered saline 
PCr, phosphocreatine  
PDE, phosphodiesters  
PET, positron emission tomography  
PF, perfused fraction 
pHe, extracellular pH 
pHi, intracellular pH 
Pi, inorganic phosphate 
pimonidazole,1-((2-hydroxy-3-piperidinyl)propyl)- 
    2-nitroimidazole hydrochloride 
PLD, polyclonal liquid dilutant 
PME, phosphomonoesters 
ppm, parts per million  
PRPP, 5-phosphoribosyl-1-pyrophosphate 
PS, permeability surface area product 
PVI, protracted venous infusion 
r, repeatability coefficient 
R, percentage of the between variance to the 
    sum of within variance and between variance 
R1, 1/T1 
RECIST, response evaluation criteria in solid  
    tumors 
RF, radiofrequency  
ROI, region of interest 
RVA, relative vascular area 
S, total surface area of vessels  
σ, shielding constant  
s.e.m., standard error of the mean 
SLT, slice thickness 
SNR, signal-to-noise ratio 
st. dev., standard deviation 
T, Tesla 
t½, half life 
T1, longitudinal spin-lattice relaxation time 
T1*, apparent T1 
T2, transverse, spin-spin relaxation time 
T2*, effective T2 
TA, tumor area 
TAPET-CD, attenuated Salmonella typhimurium 
    strain recombinant to provide cytosine  
    deaminase  
TBF, tumor blood flow  
TE, echo time 
Thd, thymidine  
TI, inversion time 
TK, thymidine kinase   
TMTX, trimetrexate  
T/NT, tumor to non-tumor ratio 
TP, thymidine phosphorylase  
TR, repetition time 
TRICKS, time-resolved imaging of contrast 
    kinetics 
TS, thymidylate synthase 
tuptake, time to 50% of maximum FU resonance  
    amplitude in the tumor 
UFT, uracil and ftorafur  
UrdPase, uridine phosphorylase   
USPIO, ultra small superparamagnetic particles  
    of iron oxide 
VD, vascular density 
ve, extravascular extracellular space per unit  
    volume of tissue 
VEGF, vascular endothelial growth factor 
VNF, vascular normalization function 
VOI, voxel of interest 
ω, Larmor frequency or MR frequency  
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Colorectal cancer is the fourth commonest cancer in the world and its incidence has 
been increasing rapidly since 1975.1 Once metastasized the prognosis of colorectal 
cancer is poor. Annually, approximately 394 000 deaths from colorectal cancer occur 
worldwide.1 In selected cases surgical resection of metastases is feasible, but for 
advanced colorectal cancer systemic chemotherapy is often the treatment of choice. 
Since chemotherapy is effective only in a subset of patients with colorectal cancer, 
prediction of response of a particular tumor to chemotherapy (‘chemosensitivity’) at an 
early stage would prevent unnecessary toxicity in non-responding patients.  
A critical factor in the success of systemic treatment of advanced colorectal 
cancer may be the adequate delivery of the drugs to the metastases by its vascular 
network. Compared to healthy tissue, the vasculature of malignant tumors frequently 
consists of fragile and leaky vessels, which easily collapse. They are insufficient to 
meet the demands for oxygen and nutrient delivery and the removal of waste products 
in a rapidly growing tumor. In contrast to healthy tissue, malignant tumors often contain 
hypoxic areas, which are already present early in the development of the tumor.2 Those 
tumor cells that survive a hypoxic microenvironment by anaerobic glucose utilization, 
adaptation to a low energy status and an acidic microenvironment will be selected and 
become constitutive of a malignant phenotype.2 Several mechanisms have been 
described by which tumor hypoxia contributes to drug resistance.3 Also, the specific 
energy status and tissue pH of a tumor may have an impact on therapy outcome.4,5  
 
RATIONALE OF THE THESIS  
Since vascularization, oxygenation, and metabolism play such a prominent role in the 
development and treatment response of tumors, characterization of a tumor by its 
specific vascularization, oxygen level, and metabolism could enable the identification of 
chemosensitive tumors, as well as tumors which could benefit from the modulation of 
these parameters. Therefore, the first aim of this thesis was to characterize 
vascularization, oxygenation and metabolism in colorectal cancer both in animal 
models and in humans. The second aim was to modulate these parameters by 
nicotinamide and carbogen (a gas mixture of 95% O2 and 5% CO2) which have 
vasoactive properties, in order to improve the delivery of cytotoxic drugs to the tumor 
and consequently improve the cytotoxic effects.  
In these studies advanced immunohistochemical methods were used, as well 
as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), 
which are attractive noninvasive techniques to study tumor physiology and metabolism. 
A specific question asked was whether vascularization as measured by MRI could 
predict response to cytotoxic treatment. In addition to these methods positron emission 
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tomography (PET) with 2-deoxy-2-18F-fluoro-D-glucose (FDG) was used, which is a 
commonly employed imaging modality to detect tumors by their hyper-metabolism.  
Conventionally, treatment efficacy is expressed in terms of the effect of 
cytotoxic treatment on tumor growth. To predict treatment outcome in an early phase of 
treatment the quantification of the amount of intracellular uptake, metabolic activation, 
and catabolism of the supplied cytotoxic drugs may be used. Therefore, a further aim of 
this project was to assess the uptake, activation and catabolism of the cytotoxic drugs 
5-fluorouracil (FU) and capecitabine, which are part of the standard treatment for 
colorectal cancer, using fluorine-19 MR spectroscopy (19F MRS). The question was 
addressed whether 19F MRS parameters measured after intravenous FU administration 
could predict treatment outcome.  
 
OUTLINE OF THE THESIS 
For advanced colorectal cancer FU based chemotherapy has been the standard for 
several decades. Chapter 1 reviews the strategies to improve the results of FU 
treatment by biochemical modulation and adaptation of the treatment schedule, as well 
as the development of new classes of drugs. 19F MRS offers unique possibilities to 
monitor the pharmacokinetics of FU and other fluoropyrimidines in vivo in tumors and 
normal tissue in a noninvasive way. In chapter 2 the principles of MR and 19F MRS are 
explained and the role of in vivo 19F MRS in the monitoring of FU and other 
fluoropyrimidines in rodents and patients is discussed.  
 Nicotinamide and carbogen are used as modulators of tumor vascularization, 
oxygenation and metabolism. In chapter 3 the effect of nicotinamide and carbogen on 
tumor blood perfusion, hypoxia and proliferation are described for two subcutaneously 
implanted murine colon carcinomas, using immunohistochemical methods. In chapter 4 
the effect of carbogen on blood plasma volume, pH, energy status, FU 
pharmacokinetics and effectivity in these two tumor lines is reported, using MR 
techniques. Since murine liver metastases are a more adequate model for advanced 
colorectal cancer in patients compared to subcutaneously implanted tumors, in chapter 
5 the effect of nicotinamide and carbogen on tumor blood perfusion, hypoxia and 
proliferation of murine liver metastases is presented, using the same 
immunohistochemical methods as described in chapter 3. 
 Immunohistochemical methods can also be used to characterize human liver 
metastases of colorectal cancer in terms of vascularization, oxygenation, and 
proliferative activity. The results of this characterization are described in chapter 6. 
Dynamic contrast enhanced MRI is one of the most commonly used MR methods for 
noninvasive in vivo characterization of tumor vasculature. Using a pharmacokinetic 
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model the data can be interpreted in physiological terms like blood flow, vascular 
permeability and surface area. The reproducibility of this technique for liver metastases 
in patients with colorectal cancer is presented in chapter 7. A possible correlation 
between glucose uptake, as measured by FDG-PET, and tumor vasculature, as 
characterized by DCE-MRI, was explored in liver metastases, and the results are 
described in chapter 8.  
In vivo 19F MRS is often used to monitor the pharmacokinetics of FU after 
intravenous administration. In patients with advanced colorectal cancer, the oral FU 
prodrug capecitabine is used with increasing frequency as an alternative to intravenous 
FU treatment. In chapter 9 the feasibility of 19F MRS to monitor capecitabine kinetics is 
shown. Finally, in chapter 10 the relation between tumor vascularization as 
characterized by DCE-MRI, 5-fluorouracil uptake and metabolism as measured by 19F 
MRS and response to treatment is described in patients with liver metastases of 
colorectal cancer.  
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ABSTRACT 
For advanced colorectal cancer (ACC), 5-fluorouracil (FU)-based chemotherapy has 
been the standard for some decades, and attempts have been made to improve its 
results by biochemical modulation and schedule modulation of FU. FU in combination 
with leucovorin (LV) has been regarded as standard chemotherapy for almost two 
decades. The oral preparations capecitabine and uracil with ftorafur combined with LV 
may be regarded as a useful alternative to FU/LV for the first-line treatment of ACC. 
Irinotecan is widely accepted as the standard second-line treatment. Oxaliplatin with 
FU/LV has been used in the neoadjuvant setting in patients with initially irresectable 
liver metastases. Both irinotecan and oxaliplatin with FU/LV are also used in first-line 
treatment. However, it is still an open question whether the concomitant use of 
irinotecan or oxaliplatin with FU/LV is really superior to the sequential use of these 
drugs. In patients with ACC anecdotal responses have been documented in small-
scale studies with different types of cancer vaccines, either alone, or in combination as 
radioimmunotherapy. Favorable results were reported for the monoclonal antibody 
C225 (cetuximab) against the epidermal growth factor receptor in patients with 
irinotecan-refractory ACC. Vascular endothelial growth factor (VEGF) is an important 
angiogenic factor in colorectal cancer and is a marker for poor prognosis. Preliminary 
results of treatment with anti-VEGF antibody in combination with FU/LV have shown 
encouraging results. 
 
KEYWORDS 
advanced colorectal cancer, capecitabine, chemotherapy, fluoropyrimidines,                
5-fluorouracil, irinotecan, oxaliplatin, review 
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INTRODUCTION 
Although palliative chemotherapy for the treatment of advanced colorectal cancer 
(ACC) has become a well-accepted clinical practice, only recently its benefit was 
shown in a meta-analysis of 866 patients entered in seven studies, showing an 
absolute improvement in survival for chemotherapy of 16% at both six and 12 months 
with an increase in median survival benefit of 3.7 months.1 Oral fluoropyrimidines, 
irinotecan and oxaliplatin have been included in the standard treatment although the 
debate on the timing of their use continues. Current clinical research focuses on drugs 
with immunological and antiangiogenic properties. This review will critically evaluate 
the rationale for currently widely used drugs, as well as address experimental treatment 
options.  
 
5-FLUOROURACIL (FU) 
Since drugs other than FU were not available for a long time, various attempts have 
been made to improve the results of FU treatment. Two main approaches can be 
distinguished: biochemical modulation and schedule modulation of FU. 
 
BIOCHEMICAL MODULATION OF FU 
Different agents have been tested for their FU-modulating capacities, but failed when 
tested in randomized studies. In this respect one of the most striking examples has 
been interferon-alpha (IFNα), which interacts with FU possibly through the enzyme 
thymidylate synthase as a target. In combination with FU/leucovorin, IFNα showed 
response rates in phase II studies up to 75%. However, a meta-analysis of 12 studies 
with 1766 patients did not show any clinical benefit and even an inferior response rate 
with higher toxicity for IFNα-containing regimens.2 Of the agents tested for their FU-
modulating capacities only methotrexate and leucovorin have permeated into clinical 
practice.  
Methotrexate (MTX) is a tight-binding inhibitor of dihydrofolate reductase, 
interfering with de novo thymidylate and purine nucleotide biosynthesis. A meta-
analysis of eight randomized studies involving 1178 patients showed a statistically 
significant benefit for biochemical modulation of FU by MTX over FU alone, both in 
terms of response rate (19% versus 10%) and median overall survival (10.7 months 
versus 9.1 months).3 Whether this benefit has any clinical relevance may be 
questioned. In one subsequent study no advantage of FU/MTX over FU alone was 
observed.4 Trimetrexate, a new antifolate drug with similar mechanisms of action 
compared to methotrexate, does not need active transport to enter the cell and does 
not need to undergo polyglutamation. It was therefore expected to have a higher 
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efficacy. However, two randomized studies with 746 patients comparing FU/LV with or 
without trimetrexate did not show a survival benefit for the addition of trimetrexate.5-7 
Leucovorin  (LV) exerts its biomodulating effect by forming a ternary complex 
with the FU metabolite 5-fluoro-2′-deoxyuridine-5′-monophosphate and the enzyme 
thymidylate synthase, resulting in an inhibition of thymidine synthesis. A meta-analysis 
of nine randomized studies involving 1381 patients demonstrated a significant increase 
in response rate for FU/LV over FU alone (23% versus 11%), without improving median 
overall survival.8 The advantage in response was most notably in those studies which 
used an equal FU dose in both study arms. However, since addition of LV to FU 
increases FU toxicity, FU/LV and FU should actually be compared at equitoxic doses. 
In the few studies that have compared FU with FU/LV when FU is given at equitoxic 
dose or maximum tolerated dose, no difference in clinical outcome was observed.8,9 
Different doses of LV have been investigated, as well as oral versus intravenous 
administration and administration of the I-isomer of leucovorin, but no clear advantage 
for any regimen has been demonstrated.10-12 Despite these and other similar 
observations, FU/LV therapy has been regarded as standard chemotherapy for ACC 
for almost two decades.  
 
SCHEDULE MODULATION OF FU 
Schedule modulation with FU, most often in combination with leucovorin, is based on 
the observation that both the mechanism of action and the mechanism of resistance to 
FU may differ for bolus and continuous infusion. Moreover, with continuous infusion 
much higher dose-intensities of FU can be achieved. A meta-analysis of six 
randomized studies involving 1219 patients comparing continuous infusion to bolus 
schedules did indeed show a significant increase in response rate (14% versus 22%) 
and a significant but marginal increase in median overall survival from 11.3 to 12.1 
months for the continuous infusion schedules.13 The incidence of hematological toxicity 
is much less in patients who receive continuous infusion, but hand-foot syndrome is 
seen more frequently. In this meta-analysis two common continuous infusion 
schedules, the so-called De Gramont schedule14 and the AIO schedule15 which involve 
higher FU dose-intensities, were not included. In more recent studies neither of these 
infusion schedules showed a survival benefit, although the response rate for the De 
Gramont schedule was superior (32.6% versus 14.4%).16,17 By and large, FU 
continuous infusion schedules may be tolerated somewhat better and may result in a 
higher response rate compared to FU bolus schedules, which should be balanced 
against the morbidity and extra costs of the infusion pumps and central venous access 
devices which are necessary to allow ambulatory treatment. As to the different FU 
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bolus schedules, the weekly schedules have a higher incidence of diarrhea while the 
monthly schedules produce more myelosuppression and stomatitis.18 When using 
bolus schedules, care should be taken to limit the infusion time of FU to less than 4 
min, since longer infusion times may compromise its efficacy.19  
Schedule modulation has also been based on the knowledge that cellular 
metabolism and proliferation mechanisms have biologic 24-hour rhythms. 
Chronotherapy consists of chemotherapy delivery according to these rhythms, which 
may increase the tolerability and antitumor efficacy of chemotherapy. This approach 
requires the use of central venous access devices and programmable portable pumps. 
In most studies oxaliplatin has been used in addition to FU/LV. In randomized studies 
comparing chronotherapy versus a constant infusion rate, no obvious survival 
advantage has been demonstrated for chronotherapy although it may increase 
tolerability and relative response rate.20,21 
 
From these studies on biochemical modulation and schedule modulation of FU 
administration it can be concluded that different FU/LV schedules may be used. The 
choice for a particular schedule may depend on the experience of the oncologist or the 
specific needs of the patient. 
 
OTHER FLUOROPYRIMIDINES  
Although the mechanism of action of fluoropyrimidines other than FU is comparable to 
FU, their advantage may lie in an easier scheduling and/or administration or a more 
favorable toxicity profile. 
Raltitrexed is a specific inhibitor of thymidylate synthase with, compared to 
FU/LV, a more convenient intravenous administration schedule of once every three 
weeks. In four randomized studies it was compared to two regimens of bolus FU/LV 
(Mayo Clinic and Machover)22-24 and to two infusional FU regimens (De Gramont and 
Lokich).25 In three of these studies the results on survival were comparable. In one out 
of these four studies the median overall survival was significantly worse for treatment 
with raltitrexed.23 Concern about the use of raltitrexed was raised after a high incidence 
of toxic deaths, which subsequently resulted in the premature closure of a large 
adjuvant study.26 However, these toxic deaths may be have been due to a neglect in 
safety precautions. When patients in whom protocol guidelines were not followed were 
excluded, the overall raltitrexed related death rates were in line with those of bolus 
FU/LV.27 In general, toxicity of raltitrexed is comparable to bolus FU/LV, with a lower 
incidence of mucositis and leucopenia.27 Of note, in one study raltitrexed showed 
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increased toxicity and inferior quality of life compared with the De Gramont FU/LV 
regimen.25 
Capecitabine is an oral fluoropyrimidine derivative that is converted into FU by a 
three-step enzymatic conversion which mainly occurs within tumor tissue as a result of 
the high intratumoral concentration of thymidine phosphorylase.28 Because of this it 
mimics FU continuous infusion. Two independent randomized phase III studies 
comparing capecitabine to intravenous bolus FU/LV (Mayo Clinic schedule) showed 
comparable efficacy in terms of overall survival.29,30 In one of these studies a significant 
increase in response rate was demonstrated.29 Pooled results of the two studies 
demonstrated a significantly superior response rate for capecitabine compared with 
FU/LV.31 Although the total incidence of grade 3-4 toxicities was comparable for both 
treatments,29 capecitabine appears to be better tolerated than bolus FU/LV due to a 
decreased incidence of stomatitis, diarrhea, nausea, alopecia and grade 3-4 
neutropenia, leading to significantly fewer neutropenic fever/sepsis cases and fewer 
hospitalizations. The only toxicities that occur more frequently with capecitabine are 
hyperbilirubinemia and hand-foot syndrome.32 
UFT is an orally administrated combination of uracil and ftorafur in a 1:4 molar 
ratio. In vivo, ftorafur is metabolized to FU, predominantly in the liver by the cytochrome 
P-450 system, but also by thymidine phosphorylase and through spontaneous 
degradation. When given with ftorafur, uracil enhances intracellular FU concentrations 
by inhibiting the degradation of FU through competitive binding to the catabolizing 
enzyme dihydropyrimidine dehydrogenase (DPD).33 In two randomized phase III 
studies UFT/LV was compared with a bolus regimen of FU/LV demonstrating 
comparable results both in terms of response rate and overall survival.34,35 In both 
studies UFT/LV was better tolerated, with a lower incidence of leucopenia, nausea and 
vomiting, diarrhea, stomatitis and mucositis.36  
Because of these results as well as its ease of administration capecitabine 
monotherapy or UFT/LV may be regarded as a useful alternative to FU/LV as first-line 
treatment of ACC. Comparing the results of capecitabine and UFT/LV in terms of study 
design, clinical results and administration schedule (two versus three times daily) the 
use of capecitabine may have some advantage, although a definite conclusion cannot 
be made since no direct comparison between these oral compounds has been 
performed. 
Oral FU given as an single agent has unpredictable kinetics which prevents its 
clinical application. When combined with oral eniluracil, an inhibitor of DPD, stable 
plasma concentrations are achieved.37 However, when compared to FU/LV in two 
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independent randomized studies this oral combination therapy showed inferior efficacy 
in one study38 and failed to show equivalence in the other.39 
 
IRINOTECAN 
Irinotecan is a semisynthetic derivative of camptothecin which is enzymatically 
converted in vivo to the active metabolite 7-ethyl-10-hydroxycamptothecin, a 
topoisomerase-I inhibitor.40 Its main toxicities are a cholinergic syndrome, late onset 
diarrhea, nausea and vomiting, bone marrow suppression and alopecia. In a phase III 
study comparing two dosing regimens of irinotecan (125 mg/m2 weekly x 4, q 6 weeks 
versus 350 mg/m2, q 3 weeks) in second-line treatment no significant differences in 
toxicity were found, except for a lower incidence of grade 3-4 late diarrhea in the three-
weekly arm.41 Irinotecan became the standard second-line treatment after two 
randomized studies showed a small but significant increase in median overall survival 
in patients who failed on first-line FU bolus therapy.42,43 Subsequently, two randomized 
studies were performed comparing first-line irinotecan/FU/LV with the De Gramont or 
AIO FU/LV regimen44 and with the Mayo Clinic regimen.45 In both studies a small but 
significant survival advantage of 17.4 versus 14.1 and 14.8 versus 12.6 months, 
respectively, for the irinotecan-containing treatment arms was observed. A high 
incidence of toxic deaths using irinotecan in combination with bolus FU/LV (Saltz 
regime) has been reported46 and lead to discontinuation of studies in the USA and 
Canada. It should be noted, however, that the mortality data were reported as 60-day 
instead of 30-day all-cause mortality rate. When the 60-day all-cause mortality of 
irinotecan/FU/LV in the two pivotal studies44,45 was compared with that of FU/LV, no 
apparent difference was noted.47 
 
OXALIPLATIN 
Oxaliplatin is a platinum compound with a reversible sensory neuropathy as its main 
toxicity. Although oxaliplatin has activity in ACC as a single agent, it also has 
synergistic activity with FU/LV and is therefore commonly used in this combination. In 
the first two randomized studies of FU/LV with or without oxaliplatin a significant 
increase in response rates and progression-free survival was demonstrated, but not in 
overall survival.48,49 Preliminary results of the N9741 study also showed a significant 
overall survival benefit of 18.6 versus 14.1 months for oxaliplatin/FU/LV (FOLFOX 
regimen) in comparison with irinotecan/FU/LV (Saltz regimen).50 Preliminary results of 
another study, which was not designed to demonstrate a benefit in overall survival, 
showed a significant improvement in response rate and progression-free survival for 
oxaliplatin/FU/LV compared to FU/LV (Mayo Clinic regimen).51 According to interim 
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results of a recent study the FOLFOX regimen proved superior to FU/LV as second-line 
treatment after failure on irinotecan/FU/LV in terms of response rate and time to 
progression.52 Oxaliplatin/FU/LV has also been used in the neoadjuvant setting in 
patients with initially irresectable liver metastasis.53,54 Surgery with curative intent was 
attempted in 51% leading to a median survival of 48 months in the operated patients.  
 
INTERPRETATION OF CURRENT STUDY RESULTS ON FLUOROPYRIMIDINES, IRINOTECAN AND 
OXALIPLATIN IN ACC 
Since the publications of the studies by Douillard et al.44 and Saltz et al.45 the use of 
irinotecan in first-line therapy has been advocated. However, it should be noted that 
neither of the two studies had planned for second-line treatment with irinotecan in the 
control arm in a prospective way. Therefore it is still an open question whether the 
concomitant use of irinotecan with FU/LV is really superior to its sequential use.55 
Obviously, the concomitant use of these drugs may increase toxicity and costs.  
The same line of reasoning applies for the use of oxaliplatin in first-line 
treatment. In the N9741 study50 oxaliplatin was not even available to patients for 
salvage treatment, and the observed survival difference in the FOLFOX arm may be 
explained by the fact that 52% of these patients received irinotecan as second-line 
treatment, as opposed to only 17% of patients who received oxaliplatin as salvage 
treatment following irinotecan/FU/LV. Obviously, such imbalances in the use of 
regimens with proven efficacy introduce a bias in the final study results. Two studies 
are currently addressing the question whether combination therapy is superior to 
sequential therapy, with a prospective evaluation of drugs with known efficacy. The 
FOCUS study in the UK is a four-arm study which compares irinotecan or oxaliplatin 
concomitant with FU/LV in first-line, or sequential to FU/LV in second-line. The CAIRO 
study of the Dutch Colorectal Cancer Group compares capecitabine followed by 
irinotecan followed by oxaliplatin/capecitabine versus irinotecan/capecitabine followed 
by oxaliplatin/capecitabine. Preliminary results of a study in which the optimal 
sequence of irinotecan and oxaliplatin in combination with FU/LV was investigated did 
not show a clear preference for either sequence.56  
With respect to the use of oxaliplatin/FU/LV as neoadjuvant regimen,54 it should 
be noted that these results are predominantly from retrospective, single-center studies. 
Although a 35% five-year survival was reported for patients in whom resection of liver 
metastases was achieved upon neoadjuvant chemotherapy,54 this group of long term 
survivors comprised only 5% of the original intention-to-treat population. Although 
randomized studies on neoadjuvant treatment of liver metastasis will impose logistic 
problems, prospective series on this issue are warranted.57 
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BIOLOGICAL THERAPY 
Although colorectal cancer has not been regarded as an immunogenic tumor, there 
exists sufficient evidence to explore immunological therapy in ACC.58 For example,      
T-cell infiltrates in colorectal cancer tissue have been shown to be of prognostic value59 
and naturally occurring cellular and humoral responses against tumor-associated 
antigens have been reported.60,61 However, this treatment modality is likely to be more 
effective in the setting of minimal residual disease compared to bulky metastases. This 
is supported by the promising results of adjuvant active specific immunotherapy in 
stage II and III colon cancer patients, in which autologous irradiated tumor cells mixed 
with BCG were compared with observation.62 Since this study concerned only a small 
number of patients these results have to be confirmed. The anti-17-1A monoclonal 
antibody edrecolomab63 showed initially promising results in the adjuvant setting when 
compared with observation only, but these results were not confirmed in a much larger 
randomized study which compared edrecolomab alone with edrecolomab in 
combination with FU/LV and FU/LV only.64 In this study, addition of edrecolomab to 
FU/LV did not result in improvement of overall survival, while edrecolomab 
monotherapy resulted in a significantly shorter overall survival. In a comparable 
adjuvant study the combination of edrecolomab with FU did not show a benefit over FU 
based therapy.65  
In patients with ACC anecdotal responses have been documented in small-
scale studies with different types of cancer vaccines, either alone, or in combination as 
radioimmunotherapy.66-69 C225 (cetuximab), a monoclonal antibody against the 
epidermal growth factor receptor (EGFR) inhibits cell repair mechanisms, which makes 
its concomitant use with chemotherapy attractive. Preliminary results of a study in 
which patients with irinotecan-refractory EGFR-positive colorectal cancer were treated 
with either cetuximab/irinotecan or cetuximab alone showed a significant benefit in 
terms of response rate and progression-free survival for the combination.70 
Antiangiogenic treatment is based on the dependence of tumor growth and 
metastasis on angiogenesis. Vascular endothelial growth factor (VEGF) is an important 
angiogenic factor in colorectal cancer and is a marker for poor prognosis.71,72 First 
results of treatment with the anti-VEGF antibody bevacizumab in combination with 
irinotecan/FU/LV showed an increase of 4.7 months in overall survival compared with 
chemotherapy alone.73 
A role for cyclooxygenase (COX) in colon carcinoma induced angiogenesis has 
also been described74 with COX-2 modulating the production of angiogenic factors and 
COX-1 regulating angiogenesis in endothelial cells. Clinical studies are currently 
ongoing. 
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In summary, biological therapy does show promising insights into the treatment 
of ACC, but its efficacy or even superiority in comparison with standard treatments 
remains to be proven in randomized phase III studies. 
 
CONCLUSIONS 
Intravenous administration of FU/LV has become the standard therapy for ACC. 
Among the many different ways to administer FU/LV no clear preference exists for one 
particular schedule. From the new insights into treatment of ACC the oral 
fluoropyrimidines capecitabine and UFT are good candidates to replace intravenous 
FU/LV schedules within the near future. Other cytotoxic drugs with different 
mechanisms of action also have shown activity in ACC. Currently, irinotecan can be 
regarded as the standard second-line treatment of ACC after failure on FU/LV. 
Oxaliplatin in combination with FU/LV is an active regimen, which however has not 
been tested as rigorously in second-line as irinotecan, but may well have comparable 
activity in this setting. Although the use of these agents in first-line schedules with 
FU/LV is strongly promoted, there exists no definite proof to date that the sequential 
use of these agents in second-line or third-line is inferior to their use in first-line. 
Obviously, this has significant consequences for patient morbidity and health care 
resources. Several novel approaches in biologic therapy have shown encouraging 
results, of which the preliminary results of the anti-EGFR antibody cetuximab and the 
anti-VEGF antibody bevacizumab are noteworthy. It should be noted that with several 
active new drugs available the overall survival in current studies will be influenced by 
the administration of second-line and third-line treatments. Therefore, in randomized 
studies with new drugs the use of subsequent effective treatments should ideally be an 
integral prospective part of the study design in order to provide reliable data on the 
frequency and quality of their use.  
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ABSTRACT 
Fluorine-19 magnetic resonance spectroscopy (19F MRS) offers unique possibilities for 
monitoring the pharmacokinetics of fluoropyrimidines in vivo in tumors and normal 
tissue in a noninvasive way, both in animals and in patients. This method may 
therefore be useful for predicting response to fluoropyrimidine based therapy with or 
without the effects of modulating agents, and this may be of value for the 
individualization of anticancer therapy and the strategic development of new anticancer 
drugs. 19F MRS has been very valuable in elucidating the basic aspects of 
fluoropyrimidine metabolism, especially in animal studies. Studies in humans have 
indicated its clinical potential, but widespread application has been hampered by the 
relatively low detection sensitivity of the method. The recent introduction of clinical MR 
scanners with magnetic fields above 1.5 T may stimulate increased clinical use of 19F 
MRS. 
 
KEYWORDS 
capecitabine, 19F, 5-fluorouracil, MR spectroscopy, review, tegafur 
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INTRODUCTION 
In the past decades increasing numbers of chemotherapeutic agents have become 
available for cancer treatment. However, chemotherapy is often effective in only a 
subgroup of patients. A method for predicting the sensitivity of a tumor to 
chemotherapy would enable individualized therapy and minimization of systemic 
toxicity in nonresponding patients. Parameters by which (non)response can be 
determined in an early stage are not only of interest for individual patients but also for 
drug development strategy. The initial extra effort in establishing patient selection 
criteria may far outweigh the costs of taking a drug through phase II and III trials in an 
unselected patient population.  
The response of a tumor to chemotherapy depends not only on the intrinsic 
sensitivity of the tumor to a specific drug but also on the achieved concentration of the 
drug in the tumor, which in turn depends on influx of the drug into the tumor, 
intracellular uptake, metabolic activation and catabolism, and clearance of the drug 
from (tumor) tissue and the vasculature. Plasma levels of a drug or its metabolites may 
not correlate well with clinical response,1 since active metabolites may be trapped 
within the cell.2 Magnetic resonance spectroscopy (MRS) is a noninvasive technique 
that can, in principle, be applied in vivo to determine the concentration of drugs in 
tumor tissue and to monitor the conversion of the parent drug to active metabolites 
and/or inactive catabolites. The drug 5-fluorouracil (FU), a fluoropyrimidine used in 
many chemotherapy regimens, can be monitored by fluorine-19 (19F) MRS. Several 
reviews have been published concerning 19F MRS of fluoropyrimidines.3-7 However, 
since the publication of the most recent review in 2000,7 several new in vivo preclinical 
and clinical 19F MRS studies have emerged. This review summarizes the major in vivo 
19F MRS studies dealing with FU and other fluoropyrimidines in rodents and patients, 
including the new studies, and discusses their impact on our understanding of 
fluoropyrimidine pharmacokinetics, metabolism and therapy outcome. The basic 
principles of fluoropyrimidine metabolism and MRS are presented as background 
material prior to the discussion of 19F MRS of fluoropyrimidines in solid tumors. 
 
1. FLUOROPYRIMIDINE METABOLISM 
Because of the limited efficacy of FU as a single agent for tumor treatment, various 
attempts have been made to improve the results of FU treatment by modulating the 
uptake and/or metabolism of FU. More recently, fluoropyrimidines other than FU have 
been developed which may have the advantage of easier scheduling and/or 
administration or a more favorable toxicity profile. Therefore, in the following the 
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metabolism of FU, methods of its modulation, and the most important fluoropyrimidines 
other than FU will be summarized.8 
 
1.1 5-FLUOROURACIL 
Although many new drugs have been developed since the introduction of FU by 
Heidelberger et al.,9 it still remains one of the most important drugs in the treatment of 
colorectal cancer.8 Combined with other drugs, it is also commonly employed for the 
treatment of other types of gastrointestinal cancers, breast cancer and head and neck 
cancer. FU is rapidly extracted from the circulation (ca. 85% during each passage) and 
metabolized in the liver.10 In advanced colorectal cancer improved efficacy and 
tolerability for FU have been reported for continuous infusion of FU versus bolus 
treatment schedules.11 However, this apparent advantage must be weighed against the 
morbidity and extra costs of infusion pumps and the central venous access devices 
which are necessary to allow ambulatory treatment. FU itself is, in fact, a prodrug which 
is (a) converted intracellularly to cytotoxic anabolites and (b) detoxified by catabolic 
pathways, mainly in the liver.  
 
1.1.1 Anabolites 
In general, FU can participate in all of the biochemical pathways that involve uracil. FU 
is activated by anabolic conversion to fluorine-containing ribonucleotides or 
deoxyribonucleotides (figure 1). The formation of fluororibonucleotides can follow two 
pathways. 5-fluorouridine-5′-monophosphate (FUMP) can be formed directly from FU 
via the enzyme orotic acid phosphoribosyltransferase (OPRTase) or may first be 
converted to fluorouridine via uridine phosphorylase (UrdPase). Subsequent enzymatic 
steps convert FUMP to 5-fluorouridine-5′-diphosphate (FUDP) and 5-fluorouridine-5′-
triphosphate (FUTP), which can be incorporated into RNA. The presence of FU units in 
place of uracil in RNA has been associated with the antitumor effect of FU12 and with 
gastrointestinal toxicity.13 It is thought that cytotoxicity is induced by a combination of 
the numerous modifications of RNA due to incorporation of FU rather than alteration of 
a single function.14 
Deoxyribonucleotides are formed by the conversion of FU into 5-fluoro-2′-
deoxyuridine (FdUrd) by the enzyme thymidine phosphorylase (TP). FdUrd is used in 
clinical practice, mainly for intra-arterial infusion.15,16 FdUrd is converted by thymidine 
kinase into 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP) which is further 
metabolized via two enzymatic steps into 5-fluoro-2′-deoxyuridine-5′-triphosphate 
(FdUTP), which can  be  incorporated  into  DNA.  However,  the  extent  to  which  
such  incorporation  contributes  to FU cytotoxicity is not yet clear.17 Probably, the most              
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Figure 1 FU anabolism. The various pathways for intracellular anabolism and cytotoxic action are 
depicted schematically. The key enzymes involved are: 1, UrdPase; 2, OPRTase; 3, TP; 4, 
uridine kinase; 5, TK; 6, ribonucleotide reductase; 7, TS; 8, dihydrofolate reductase; 9, serine 
transhydroxymethylase. Modulators are printed bold grey; solid arrows indicate stimulation; 
dashed arrows indicate inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
important cytostatic/cytotoxic mechanism for FU is via FdUMP which in the presence of 
the cofactor 5,10-methylene tetrahydrofolate forms a stable ternary complex with the 
enzyme thymidylate synthase (TS).18 This blocks the formation of dTMP (figure 1), 
thereby decreasing the availability of dTTP for DNA replication and repair which may 
activate pathways for programmed cell death.14 TS inhibition has been correlated to 
clinical response.19 
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Figure 2  FU catabolism. The stepwise catabolism of FU to FBAL occurs mainly in the liver. High plasma 
concentrations of FBAL result in the nonenzymatic formation of adducts with bicarbonate and 
glucose and stimulate further metabolism of FBAL to toxic FHPA and FAC. The release of 
fluoride from FBAL is minor in humans but extensive in the rat. The key enzymes involved are: 
1, DPD; 2, dihydropyrimidinase; 3, β-ureidopropionase; 4, alanine glyoxylate transferase; 5, N-
acylCoA transferase; 6, alanine transaminase. Modulators are printed bold grey; dashed arrows 
indicate inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2 Catabolites 
The first step of FU catabolism is the conversion to 5,6-dihydro-5-fluorouracil (DHFU) 
by the enzyme dihydropyrimidine dehydrogenase (DPD) (figure 2). DPD is present in a 
variety of tissues including tumors, but it is most predominant in the liver, which is the 
major site of FU catabolism. Further enzymatic steps, again mainly in the liver, lead to 
α-fluoro-β-ureidopropionic acid (FUPA) and α-fluoro-β-alanine (FBAL), the major 
catabolite which is excreted in large amounts in the urine. When a treatment protocol 
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leads to high plasma concentrations of FBAL, then the adducts N-carboxy-FBAL and 
FBAL glucoside can be detected (in equilibrium with FBAL). High levels of FBAL have 
been associated with neurotoxicity and cardiotoxicity, possibly due to its conversion 
into α-fluoro-β-hydroxypropionate (FHPA) and fluoroacetate (FAC).20-22 Finally, fluoride 
(F–) can be released from FBAL via enzymatic reactions which are particularly efficient 
in rat liver.23 
 
1.1.3 Modulation of FU metabolism 
Several different agents have been tested as modulators of the anabolic or catabolic 
pathways of FU (figures 1 and 2). The aim is generally to enhance anabolism in tumors 
or reduce catabolism. For example, it has been shown that the enzyme OPRTase can 
be inhibited by allopurinol, thus reducing FU toxicity in gastrointestinal mucosa and 
bone marrow.24 Thymidine has been found (figures 1 and 2): (a) to enhance FU 
incorporation into RNA in tumor cells, but not in bone marrow or gut cells;25 (b) to 
diminish DNA-directed toxicity by opening the salvage pathway of deoxynucleotide 
biosynthesis;26 and (c) to inhibit DPD, leading to increased levels of FUTP by 
prolonging the plasma half life of FU.27,28 It should be noted that neurotoxicity due to 
inhibition of DPD by eniluracil (EU) has been described.29  
Various agents have been tested in clinical trials for their FU-modulating 
capacities, but have generally failed to provide improved therapy when tested in 
randomized studies. A striking example is interferon-alpha (IFNα). Several effects of 
IFNα have been found, for example: (a) induction of the enzyme thymidine 
phosphorylase, thereby enhancing the conversion of FU to FdURD and, thus, the 
active metabolite FdUMP (figure 1); (b) prevention of an FU-associated increase in the 
enzyme thymidylate synthase (TS), thus increasing tumor sensitivity to FU; (c) 
augmentation of plasma FU levels.30 The combination of FU with IFNα showed 
response rates of up to 75% in phase II studies for advanced colorectal cancer (ACC) . 
However, a meta-analysis showed an inferior response rate with higher toxicity for 
IFNα-containing regimens.31 Of all agents tested for their FU-modulating capabilities 
only methotrexate (MTX) and leucovorin (LV) are currently used in clinical practice.  
 Positive effects of MTX are (figure 1): (a) increased binding of FdUMP to TS;32 
(b) increased intracellular levels of 5-phosphoribosyl-1-pyrophosphate (PRPP) due to 
inhibition of purine synthesis, resulting in an increase in FUMP, FUTP and RNA-
directed toxicity;32 (c) inhibition of dihydrofolate reductase, thus depleting the cells of 
reduced folates and diminishing DNA-directed toxicity.33 FU/MTX treatment versus FU 
alone resulted in improvement of response rate (19% versus 10%) and median overall 
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survival (10.7 months versus 9.1 months) for ACC.34 Trimetrexate (TMTX), a drug with 
mechanisms of action similar to those of methotrexate, was expected to have a higher 
efficacy since it does not need active transport to enter the cell and does not need to 
undergo polyglutamation. However, two randomized studies comparing FU/LV with or 
without TMTX for treatment of ACC did not show a survival benefit for the addition of 
TMTX.35-37 
LV forms a ternary complex with FdUMP and the enzyme thymidylate synthase, 
resulting in prolonged inhibition of thymidine synthesis. In a meta-analysis of patients 
with ACC a significant increase in response rate for FU/LV over FU alone (23% versus 
11%) was demonstrated, but there was no improvement in the median overall 
survival.38 Further studies compared FU with FU/LV when FU was given at equitoxic 
dose or maximum tolerated dose, and no difference in clinical outcome was 
observed.38,39 Nevertheless, FU/LV therapy was considered to be the standard 
chemotherapy for ACC for almost two decades.  
 
1.2 OTHER FLUOROPYRIMIDINES 
Fluoropyrimidines other than FU have been developed to provide easier scheduling 
and/or administration or a more favorable toxicity profile when compared with FU. For a 
more elaborate review of oral prodrugs of FU the reader is referred to Malet-Martino et 
al.14 The fluoropyrimidines relevant for evaluation by 19F MRS will be discussed below.  
 
1.2.1 Capecitabine 
Oral capecitabine is used with increasing frequency, due to its comparable efficacy, 
ease of administration and more favorable toxicity profile.40,41 Capecitabine is 
preferentially metabolized to FU in tumors and liver by a three-step enzymatic 
process,42 involving conversion to 5′-deoxy-5-fluorocytidine (5′-DFCR), followed by 
conversion to 5′-deoxy-5-fluorouridine (5′-DFUR), which is metabolized to FU by TP 
(figure 3). A strong correlation between TP levels in tumors and tumor response has 
been observed.43 Oral capecitabine treatment is thought to mimic the dynamics of 
continuous FU infusion. The capecitabine metabolite 5′-DFUR is also commercially 
available as an oral prodrug. In one small trial of patients with ACC, 5′-DFUR was 
compared with FU and showed a significantly longer time to progression but no 
difference in overall survival.44 
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Figure 3  Conversion of capecitabine and tegafur into FU. Enzymes involved are: 1, carboxylesterase; 2, 
cytadine deaminase; 3, TP; 4, P-450 isoenzymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 UFT 
UFT is a combination of uracil and ftorafur in a 1:4 molar ratio which can be 
administered orally. Ftorafur is transformed into FU, predominantly in the liver by the 
cytochrome P-450 system, but also by thymidine phosphorylase and through 
nonenzymatic degradation. When given with ftorafur, uracil enhances intracellular FU 
concentrations by inhibiting the degradation of FU through competitive binding to the 
enzyme DPD.45 In two randomized phase III studies of patients with ACC, UFT/LV was 
compared with a bolus regimen of FU/LV and demonstrated comparable results in 
terms of both response rate and overall survival46,47 with a more favorable toxicity 
profile.48 
 
1.2.3 Oral FU (with EU) 
As a single agent oral FU has unpredictable kinetics, but when combined with oral EU, 
stable plasma concentrations are achieved.49 Oral FU with EU was compared to i.v. 
FU/LV in two independent randomized studies in ACC patients and showed inferior 
efficacy in one study50 and could not be shown to be equivalent to FU/LV in the other 
study.51 
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2. BASIC PRINCIPLES OF MR 
The following section presents an introduction to MR which is intended to provide the 
reader with sufficient background for understanding the biological and clinical 
applications of 19F MRS. For a more in-depth review of principles and applications of 
MR in biomedicine the reader is referred to other publications.52,53 
 
2.1 MAGNETIC RESONANCE 
MR is based on the quantized magnetic property of nuclei called spin. Nuclei (isotopes) 
with an odd mass number (sum of neutrons and protons) have half-integral spin 
quantum numbers, while isotopes with even mass number and an odd number of 
protons have integral spin. For MRS, especially in vivo applications, the spin ½ nuclei 
proton (1H), phosphorous-31 (31P) and 19F with 100% natural abundance are of 
greatest utility. Other important isotopes in biochemistry are carbon-12 and oxygen-16, 
which have zero spin (MR inactive), and nitrogen-14 with spin 1. For in vivo metabolic 
or mechanistic studies the spin ½ isotopes carbon-13 (13C) (1.1% natural abundance) 
or nitrogen-15 (0.4% abundance) can be introduced as labels at specific sites in a 
molecule. An example of this technique is the use of 13C-labeled glucose in studies of 
glycolysis and the citric acid cycle.  
Nuclei with spin can be regarded as tiny bar magnets, which normally have 
random orientations. However, when placed in a strong, constant magnetic field (B0) 
the nuclear spins will become aligned either parallel or antiparallel to B0, whose 
orientation is generally referred to as the z-axis in MR experiments (figure 4). The 
aligned nuclei precess at the so-called Larmor or resonance frequency ω0 = γB0, where 
the magnetogyric ratio γ has a specific value for each isotope. For isotopes with a 
positive γ (1H, 31P, 19F, 13C) the parallel state has a lower energy level compared to the 
antiparallel state and the difference in energy is proportional to γB0, i.e. depends on the 
isotope of interest and the field strength. Of the isotopes commonly observed by MRS, 
1H has the highest γ with Larmor frequencies ω0 in the radio-frequency range of 64-400 
MHz for typical B0 fields of 1.5-9.4 T.  
According to Boltzmann’s law the lower energy state will have a higher 
population of spins at thermal equilibrium. The population difference is proportional to 
γB0 and results in a net macroscopic magnetization M0 aligned parallel to B0 (the so-
called longitudinal magnetization). For ω0 in the range mentioned above, the population 
difference represents only a small fraction (10-6 to 10-5) of the total spin population, 
which explains why MR is a relatively insensitive technique. Only the net magnetization   
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A B 
Figure 4  Cartoon illustrating the random orientation of nuclear spins without an external magnetic field 
(A) and the parallel and antiparallel orientation of spins in a magnetic field B0 (B). For spins with 
a positive magnetogyric ratio γ (1H, 19F, 31P, 13C), the parallel orientation has the lower energy 
and is more populated according to the Boltzmann distribution. The oriented spins precess at 
the Larmor frequency ω0 = γB0, and the population difference is proportional to ω0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
is detectable, and the achievable signal-to-noise ratio (SNR) for in vivo applications is 
approximately proportional to B0.  
At thermal equilibrium M0 can be treated as a vector aligned along the B0 or z-
axis (figure 5A). A radiofrequency (RF) coil or resonator placed around the sample or 
subject of interest and tuned to the Larmor frequency of the spins of interest can be 
used to apply a short and intense RF pulse at the Larmor frequency (typically 100-1000 
W, 10-1000 µs) with an orientation (vector) perpendicular to M0. While the RF pulse is 
on, the magnetization vector M0 rotates towards the xy-plane, and the pulse length and 
power can be adjusted so that the magnetization just reaches the xy-plane at the end 
of the pulse (a so-called 90° pulse, figure 5B). The resulting transverse magnetization 
is now perpendicular to the B0 field (z-axis) and, after the RF pulse is turned off, 
undergoes so-called free precession about the z-axis at the Larmor frequency. During 
this precession the magnetization gradually returns to its thermal equilibrium orientation 
via the spiral trajectory shown in figure 5C. This so-called relaxation process is 
characterized by  two exponential time constants T1 and T2 (typically 0.1-5 s) for the 
recovery  of the longitudinal  (z)  and  decay of the transverse  (xy)  components  of  
the magnetization, respectively. The  spiral trajectory of the magnetization results in  an 
oscillating and decaying transverse magnetization Mxy which induces a time-dependent 
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Figure 5  Schematic illustration of the alignment of the net magnetization M0 along the magnetic field B0 or 
z-axis at thermal equilibrium with Mz = M0 and Mxy = 0 (A). An RF coil is used to apply a suitable 
radiofrequency pulse at the Larmor frequency with a magnetic field vector B1 along the x-axis, 
causing the sample magnetization vector to rotate toward the y-axis. If the pulse is terminated at 
a time of t = π/(2γB1), the magnetization has rotated 90° (B). The now transverse magnetization 
precesses around B0 and returns to its original equilibrium state via the spiral trajectory shown 
(C). The characteristic relaxation times for the recovery of Mz and the decay of Mxy are T1 and 
T2, respectively. The precessing Mxy component induces a voltage in the RF coil, the time 
dependent MR signal (D). Fourier transformation of this time-domain signal, the free-induction 
decay (FID), results in a frequency-domain spectrum with Lorentzian lineshape and linewidth ∆ν 
(E). The data acquisition represented by (A) - (D) can be repeated N times with coherent 
addition of the transient signals to improve SNR by a factor √N. 
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voltage (signal) in the RF coil (figure 5D). The transient time-domain signal is acquired 
(digitized) and stored in a computer. After recovery of Mz the measurement process 
(pulse-acquire) can be repeated in a coherent manner with addition of N individual 
transients to create a free-induction decay signal (FID) with a SNR improvement of √N. 
The FID can then be manipulated mathematically with a so-called window function to 
optimize SNR, for example, and then subjected to Fourier transformation to give the 
equivalent frequency-domain signal or MR spectrum. The resonance linewidth at half 
height (figure 5E) is related to the relaxation time T2 as ∆ν = 1/(πT2).  
If the MR phenomenon were restricted to the simple case of a single Larmor 
frequency for one particular nucleus, as implied above, MR would not be a useful 
technique. Fortunately, the application of a static magnetic field B0 not only aligns 
nuclei but also induces polarization and currents in the electrons surrounding atoms 
and participating in the bonds within the molecules of interest. Thus, each nucleus in a 
given molecule experiences a weak opposing field (shielding) from the surrounding 
electrons, induced by and proportional to B0. This shielding, which is generally unique 
for each chemically distinguishable site in a molecule, is expressed as the shielding 
constant σ, and the total effective field experienced by a given nucleus is: Beff = B0 (1-
σ). Values of σ are typically in the order of 10-7 to 10-4 and the resulting site specific 
change in the resonance frequency ωeff = ω0(1-σ) relative to that of a chosen reference 
compound is generally referred to as the chemical shift expressed in units of ppm (1 
ppm = 100 Hz at ω0 = 100 MHz). Thus, the magnitude of σ depends on the density and 
spatial distribution of the electron cloud surrounding each nucleus and, hence, on the 
local chemical environment. Therefore, an MR spectrum is a kind of molecular 
fingerprint and may contain many resonance frequencies or peaks, one for each 
chemically distinguishable site or group in a given metabolite or for specific sites in a 
variety of metabolites. Thus, it is possible to distinguish a wide variety of metabolites on 
the basis of their 1H spectra, various phosphorylated metabolites in 31P spectra, or 
various FU metabolites in 19F spectra. Figure 6 compares a 19F MR spectrum obtained 
in vitro (tissue extract, spectrum A) with a spectrum obtained from an implanted tumor 
in vivo at the same B0 field (spectrum B). Each signal represents fluorine in a different 
chemical environment (metabolite) and the signal integrals are proportional to 
metabolite concentrations. Typically, in vivo spectra exhibit broader resonances and 
poorer SNR compared to in vitro spectra of homogenous solutions. In the in vivo 
situation the effective FID decay time T2* is much shorter than the natural T2 due to 
contributions from tissue heterogeneities, B0 inhomogeneity, interaction of metabolites 
with macromolecules or paramagnetic metal cations. 
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A 
B 
Figure 6  (A) Typical in vitro 19F MR spectrum obtained at 7 T (282 MHz) from a perchloric acid extract of 
C38 murine colon carcinoma tissue (2.3 g) excised 50 min after FU injection. Peak 1, Fnuct; 
peak 2, fluoronucleosides (Fnucs); peak 3, FU; peak 4, FUPA; peak 5, FBAL; peak 6, DHFU. 
Inset: peak 1, four resonances of fluoronucleotides (Fnuct) (peaks a - d); peak 2, Fnucs. The 
spectrum represents 50.000 data acquisitions and was obtained with broadband 1H decoupling 
and a pulse repetition time of five seconds. Reproduced with permission from Kamm et al.141 (B) 
Typical in vivo 19F MR spectrum obtained at 7 T with a 10 mm surface coil, taken from a C38 
murine colon carcinoma implanted subcutaneously in the flank of a female C57BL/6 mouse. For 
further details see text. 
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   The MR signal measured by the simple pulse acquire method described above 
originates from all parts of the measured object that are in the field of view of the RF 
coil. For example, when a circular 19F surface coil is placed over the liver region of a 
patient after administration of FU chemotherapy, the measured 19F signals from FU and 
its metabolites come primarily from a half-spherical region below the coil containing 
liver tissue. However, with this crude scheme of localization no distinction can be made 
between metabolite signals coming from normal liver tissue, liver metastases or the gall 
bladder, although spectroscopic data from these specific regions within the liver may 
be of clinical interest. In fact, for in vivo detection of FU metabolites, the employed 
surface coils are usually relatively large compared to the tissue region of interest. To 
obtain tissue-specific information from well-defined volumes imaging-based techniques 
employing spatial-encoding field gradients must be applied, for example multivoxel 
magnetic resonance spectroscopic imaging (MRSI)54 or single-voxel methods.52 It 
should be noted that the detection sensitivity or SNR of the localized MR experiment is 
roughly proportional to both the local metabolite concentration and the selected tissue 
voxel volume. Thus, smaller volumes and better localization generally mean lower SNR 
for the detected metabolite signals.  
Finally, it should be mentioned that MR resonances can exhibit additional fine 
structure (splittings) due to homonuclear (1H-1H) or heteronuclear (1H-19F) spin-spin 
interactions (the so-called J couplings). In proton MRS such couplings complicate the 
spectra considerably but provide much useful structural information. For MR studies 
with 19F, 31P or 13C detection, couplings with the many protons that are typically present 
in biological molecules are frequently suppressed by the application of continuous RF 
irradiation at the 1H Larmor frequency (broadband decoupling), as is the case for the in 
vitro 19F spectrum in figure 6A. This results in a spectrum with one signal per fluorine 
site (per metabolite) with maximum SNR. 1H decoupling can also be applied for in vivo 
MR (with limitations in the applied power), but this is only useful when the 
heteronuclear couplings result in resolved splittings or contribute significantly to the 
observed signal linewidths. For the spectrum in figure 6B 1H decoupling was not 
employed.  
 
2.2 19F AS AN MR-ACTIVE ISOTOPE 
The 19F nucleus has several favorable MR properties. 19F is a spin-½ isotope (narrow 
resonance lines) with 100% natural abundance. The γ value for 19F is 95% of that for 
1H, leading to a detection sensitivity of 83% compared to 1H. In the human body, 19F is 
present in a significant concentration in bone, but the rigidity of the environment results 
in a very broad, virtually undetectable MR signal. While the fluoride anion from tap 
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water or toothpaste can be detected in blood at micromolar levels, almost all signals 
detected in in vivo 19F MR spectra will result from exogenous sources (administered 
drugs). The chemical shift of 19F for compounds of biological interest is exquisitely 
sensitive to its chemical environment (range ca. 150 ppm versus 15 ppm for 1H). Thus, 
different fluorine-containing metabolites are usually well-resolved in 19F MR spectra, 
even when structural differences are relatively minor or remote from the fluorine site. In 
spite of the high relative sensitivity of 19F, the absolute sensitivity of 19F MRS per se 
remains low. In clinical studies in vivo concentrations of fluorine-containing metabolites 
must be larger than ca. 200 nmol/g tissue to be detectable in reasonable measurement 
times (< 5-15 min) at B0 = 1-2 T. For animal studies at 7 T 50 nmol/g can be 
quantitated in 30 min and in ex vivo studies 5-10 nmol can be detected in 0.5-1 g tissue 
samples in 1-2 h at 11.7 T on a high-resolution MR system (see Lutz et al.23 and 
references therein).  Therefore, any method which provides an increase in SNR is 
relevant in 19F MRS, especially in clinical applications. This becomes even more 
important when imaging-based techniques are applied with large-volume coils since 
the use of these localization techniques usually reduces the SNR for metabolites 
signals compared with localization by means of a small surface coil only. In principle, 
the SNR in MR spectra increases with measurement time according to the square-root 
of the number of transients acquired. Thus, a factor two improvement requires a factor 
four increase in time. However, the obtainable improvement of in vivo measurements 
by data accumulation is limited since total measurement times of more than one hour 
may not be tolerable for the patient. Therefore, although 19F MRS is an attractive tool 
for in vivo pharmacokinetic studies, the possibilities for monitoring rapid kinetics are 
limited due to the low SNR obtained with short measurement times.  
To increase the SNR of 19F MR spectra special acquisition techniques may be 
used (see for example the study by Li et al.55 and the interesting in vitro results of 
Swanson56 using magnetization transfer). Recently, an optimized technique for 
localized 19F MRS has been described, combining a dedicated hardware design with 
the precise measurement of 19F metabolite spin relaxation times and an optimized 
averaging of spatial encoding steps in the CSI measurement.57 Li & Gonen58 and 
Gonen et al.59 have described a technique by which localized 19F MRS is combined 
with localized 31P MRS, allowing simultaneous measurement of drug metabolism by 19F 
MRS and energy metabolism by 31P MRS. For an overview of methodological 
developments the reader is referred to the extensive review by Bachert.60 
Currently, MR scanners are available with field strengths higher than the 
conventional 1.5 T for clinical instruments. Human studies have been performed at B0 
as high as 8 T and 3 T MR systems are being rapidly introduced in the clinic. The use 
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of B0 = 3 T versus 1.5 T will generally improve the SNR and the inherent chemical shift 
dispersion (in Hz) by a factor of two. However, at higher field the relaxation time T1 may 
increase (requiring longer repetition times for signal averaging) and signal linewidths (in 
Hz) may increase due to inhomogeneous linebroadening (tissue heterogeneity, 
susceptibility effects). For in vivo 19F MRS the gain in sensitivity at higher fields 
probably outweighs the disadvantages in most cases, as was shown in a recent 
study.61  
It should be noted that FU uptake and biomodulation can also be monitored in 
vivo by means of positron emission tomography (PET) scanning after administration of 
fluorine-18 (18F) labeled FU. The sensitivity of 18F PET is a factor 106 to 109 higher than 
the sensitivity of 19F MRS.62 However, in 18F PET a composite signal for all 18F 
metabolites is measured (see the studies by Moehler et al.63 and Harte et al.64), 
whereas with 19F MRS the individual metabolite signals can be resolved separately. 
Although the lack of chemical specificity in PET can be partly overcome by 
measurement of tissue-specific time courses and the use of pharmacokinetic models,65 
it remains to be seen whether these techniques are clinically applicable for monitoring 
FU kinetics. 
  
2.3. In vivo 19F MRS appearance of fluoropyrimidine metabolites 
Despite the large chemical shift range of 19F in fluorinated compounds, the signals of 
fluoropyrimidine metabolites with only slight differences in structure (for example the 
various fluoronucleotides) may be difficult to resolve in vivo due to linewidth limitations. 
For in vitro measurements of tissue extracts, for example, smaller magnet bore sizes 
can be used with smaller, homogeneous sample volumes and a better B0 homogeneity. 
A typical in vitro spectrum obtained at 7 T is shown in figure 6A, demonstrating a series 
of well-resolved resonances in the FU anabolite region. A typical in vivo spectrum 
obtained on a 7 T animal scanner is shown in figure 6B. FU catabolites are readily 
distinguished with resonances for FUPA at -17.2 ppm (see also section 4.1) and FBAL 
at -19 ppm relative to FU. The FU nucleosides resonate at ca. 3.8 ppm and the FU 
nucleotides at ca. 5 ppm and are not clearly resolved in the in vivo situation. Moreover, 
in vivo 19F MRS cannot distinguish between the various nucleotides (for example FUTP 
and FdUMP) and, therefore, cannot provide information concerning possible RNA-
directed versus DNA-directed cytotoxicity.  
 
3. IN VIVO 19F MRS STUDIES OF FLUOROPYRIMIDINES IN RODENTS 
3.1 FU UPTAKE AND METABOLISM  
The 19F MRS studies concerning FU metabolism in rodents which will be discussed in 
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this section are summarized in table 1 at the end of the section. In 1984 Stevens et 
al.66 were the first to publish 19F MRS results for FU metabolism following i.v. bolus 
injection by monitoring implanted Lewis lung tumor and liver of C57 mice at 4.7 T with a 
7 mm surface coil. In the liver FU was rapidly converted to DHFU and FBAL, according 
to the scheme in figure 2. Anabolites were not observed in liver tissue, either at a low 
(30 mg/kg) or a high dose (180 mg/kg) of FU. In tumor tissue, no catabolite products 
were detected, but at high dose a broad resonance in the anabolite signal region was 
readily observed. These results confirmed that the liver efficiently catabolizes FU 
(detoxification) whereas in tumor anabolism predominates and catabolism is minor or 
not detectable. In later experiments FBAL was detected in tumors, but Prior et al.67 
showed that the FBAL resonance could be observed in rat tumors after direct i.v. 
administration of FBAL. Also, in ex vivo 19F MRS studies of excised tumors the FBAL 
concentration in tumor did not correlate with the total fluorine concentration in these 
tumors but rather with plasma levels or concentrations in kidney.23,68 Thus, FBAL 
detected in tumor may not necessarily have been produced in tumor tissue but may be 
taken up from the circulation after clearance from the liver.69  
The potential importance of the presence of anabolites in tumor for treatment 
effectiveness was shown in subsequent experiments in which the formation of 
anabolites in tumor was associated with tumor cytotoxicity. In Walker carcinosarcoma-
bearing rats, a 50 mg/kg bolus of FU resulted in detectable anabolite formation in the 
tumor (as measured at 1.9 T) and, after seven days of FU treatment, significant tumor 
growth inhibition occurred.70 FU treatment at half of the original dose produced less 
anabolites in the tumor and did not cause significant tumor regression. Also, studies at 
4.7 T by Sijens et al.71,72 suggested that the amount of anabolites formed in a tumor 
may be a factor determining tumor response. When after an intraperitoneal (i.p.) bolus 
of 260 mg/kg of FU in RIF-1 tumor-bearing C3H mice anabolite levels of 40 arbitrary 
units (a.u.) or higher were measured, a decrease in tumor volume of at least 30% was 
observed.  
Not only the intratumoral formation of anabolites appeared to be of potential 
clinical interest, but also the length of time that FU was detectable in the tumor. The 
concept of drug trapping was introduced by Wolf et al.,73 who observed prolonged FU 
retention after a 100 mg/kg bolus in VX2 tumors in rabbits (and in humans, see below). 
The half life of FU in VX2 tumors was estimated to be 1.05-1.22 h, whereas the half life 
of FU in rabbit blood was reported to be in the range 5-15 min. The half life of FU in 
other tissue regions of control rabbits without tumors ranged from 6.5-9 min. It was 
hypothesized that FU is trapped in tumor tissue, but not in tissues that do not 
proliferate rapidly, such as muscle, bone and skin. It is also possible that the pool of 
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trapped FU comprised not only unmetabolized FU, but also FU that had been released 
from intracellularly produced fluoronucleotides. Intratumoral trapping has been 
visualized in rats bearing Morris hepatoma, using 19F MR imaging.74,75 
 The distribution of FU between intra- and extracellular compartments has been 
studied at 1.5 T using the MR contrast agents gadopentate dimeglumine and gadoxetic 
acid.76 Gadopentetate dimeglumine diffuses into the interstitial space and remains 
extravascular, whereas ca. 60% of gadoxetic acid enters hepatocytes. The contrast 
agent will cause an increase in the nuclear spin relaxation rate 1/T1 of fluorine-
containing metabolites only if metabolite and agent are in the same compartment. 
Thus, it was shown that 6 min after injection of a 200 mg/kg bolus, FU was mainly 
present in the extracellular tumor compartment, whereas in the liver FU was mainly 
intracellular. It was suggested that trapping of FU may occur not only in tumor cells but 
also in liver cells. The clinical significance of this finding is still unclear.  
The potential clinical importance of the measurement of catabolites was shown 
in several studies. A negative correlation between the levels of FU catabolites in liver 
and FU anabolites in tumor was found by Sijens et al.,71 suggesting that uptake and 
degradation of FU in the liver competes with uptake and activation of FU in tumor. This 
provides a rationale for inhibition of FU catabolism in order to increase FU tumor 
toxicity (see below). Injection of 260 mg/kg FU compared with 130 mg/kg resulted in a 
slower FU decay in murine liver, which indicates that the catabolic activity of the liver is 
saturated at higher FU doses.71 Making use of the pH dependence of the chemical shift 
difference between the anabolite and FU resonances (see the study by Lutz & Hull77) a 
small but significant drop in pH (0.04-0.08 pH units) in normal liver tissue was noted 
after injection of FU.71 Since the first step of catabolism involves the enzymatic 
reduction of FU to DHFU, with conversion of NADPH to NADP+, the observed drop in 
pH may reflect enhanced anaerobic glycolytic activity to meet increased demands for 
ATP. Increased anaerobic glycolysis in normal liver tissue has also been observed 
after administration of fructose78 and induction of hypoxia.79 
Different routes of administration of FU may influence FU systemic toxicity. In a 
study by Okuno et al.80 performed at 2 T, the MR signal intensities and time courses for 
FU and FBAL in Wistar rat liver were compared after bolus infusion of 50 mg/kg FU via 
the hepatic arterial, portal vein, and tail vein. After hepatic arterial infusion the FU 
resonance was observable for a longer time and the FBAL signal had a lower intensity 
compared with the other two infusion modalities. Although the apparent advantage of 
hepatic arterial infusion (reduced catabolism) could lead to higher FU plasma levels 
and enhanced tumor cell kill, especially for liver metastases which may be supplied by 
the hepatic artery, a substantial increase in systemic toxicity may also occur. Especially 
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biliary toxicity should be considered, since hepatic arteries are connected to the 
peribiliary plexuses (and then drain into the liver sinusoids).  
In summary, in vivo 19F MRS is a powerful technique for the elucidation of 
intracellular uptake and metabolism of FU in laboratory animals. The importance of 
tumoral FU retention and anabolite formation for tumor cytotoxicity has been 
demonstrated, and a link has been made between FU catabolism in the liver and 
availability of FU for uptake into the tumor. The following section will focus on the role 
of 19F MRS in the study of FU modulation. 
 
3.2 MODULATION OF FU UPTAKE AND METABOLISM 
3.2.1 Modulation of FU uptake and retention 
An increase in FU tumor uptake and retention may be achieved by modulating the 
tumor microenvironment, for example by means of radiotherapy, by direct modulation 
of tumor pH or by breathing of carbogen, a mixture of 95% O2 and 5% CO2 (table 1). 
For mice bearing HT29 colon carcinoma 19F MRS experiments at 2 T showed 
that a single γ-radiation dose (10 Gy) applied to the tumor immediately prior to a 100 
mg/kg bolus FU injection resulted in a significant decrease in the tumor clearance rate 
of FU from 0.0178 ± 0.0082/min to 0.0055 ± 0.0027/min.81 It was postulated that the 
well-known synergistic effect of FU and radiation was due to radiation-induced 
potentiation of FU retention and cytotoxicity, rather than an effect of FU on the results 
of irradiation.  
It has been suggested that intracellular versus extracellular pH in tumor, which 
can be measured by 31P MRS, can influence FU uptake and retention. FU is more 
soluble at the alkaline pH commonly found for tumor cells. Intracellular uptake of FU 
may be facilitated by the electrochemical concentration gradient of H+ imposed across 
the cell membrane by a negative intra- to extracellular pH gradient (i.e. ∆pH = pHe - 
pHi < 0). This gradient provides a proton motive force which can be employed by 
transmembrane transport systems.82 In the study by Sijens et al.72 no correlation 
between changes in tumor pH (as measured by the phosphate resonance in the 31P 
MR spectrum) and FU metabolite levels or tumor response was observed in RIF tumor-
bearing mice after 260 mg/kg bolus injection of FU. On the other hand, Guerquin-Kern 
et al.83 showed that the half life of FU measured by 19F MRS was increased 2.5 fold in a 
subcutaneous fibrosarcoma in Wistar rats when the local pH (again, measured by the 
phosphate resonance in the 31P MR spectrum) decreased below 6.9. It should be noted 
that the phosphate resonance in the 31P MR spectrum mainly reflects intracellular 
phosphate and, thus, intracellular pH. The decrease in intracellular pH in the study by 
Guerquin-Kern et al.,83 was probably accompanied by a (larger) decrease in 
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extracellular pH. Lemaire et al.84 found a significant positive correlation between pre-
treatment tumor energy status (NTP/Pi) measured by 31P MRS and FU retention 
measured by 19F MRS as well as tumor response in N-methyl-N-nitrosourea-induced 
primary rat tumors. A higher NTP/Pi was strongly correlated with a higher intracellular 
pH, which is associated with a larger concentration gradient of H+ across the cell 
membrane.85 Further support for the relation between ∆pH and FU retention comes 
from experiments with Bafilomycin A1, a specific inhibitor of vacuolar H+-ATPases, 
which may, therefore, induce an increase in extracellular pH. In GH3 prolactinoma 
xenografts administration of Bafilomycin A1 indeed caused an increase in extracellular 
pH without changing intracellular pH. The resulting positive change in ∆pH (+0.11 
units) was associated with a decrease in the half life (t½) for FU in tumor from 18.1 ± 
2.8 min to 9.4 ± 1.3 min as measured by 19F MRS.86  
Modulation of the tumor microenvironment by means of carbogen has been 
tested in RIF-1-bearing C3H mice which were administered carbogen for 10 min prior 
to 1 mmol/kg bolus FU injection and during the first 20 min after FU administration.87 
The effect of carbogen on FU kinetics differed between mice bearing small tumors (0.8-
1.6 g) and those with large tumors (2-3 g). In the first group carbogen caused an 
increase in FU half life in tumor from 12.5 ± 0.9 min to 14.2 ± 1.4 min, and a 25% 
increase in growth delay. Although the increase in FU half life was not statistically 
significant, the authors explained the increase in growth delay by sustained TS 
inhibition due to increased retention of FU. In the second group of mice bearing large 
tumors the maximum amount of FU and anabolites measured in tumor increased 2-3 
fold and the FU half life increased from 13.7 ± 1.3 min to 20.1 ± 1.5 min. There was an 
increase in growth delay by 45%, as expected if FU retention leads to higher levels of 
or longer exposure to cytotoxic fluoronucleotides. Levels of catabolites in tumor were 
not affected. 31P MRS measurements showed a decrease in extracellular pH after 
carbogen breathing in the second group and no changes in intracellular pH. It was 
suggested that carbogen may transiently open nonfunctional blood vessels in the 
tumor, allowing increased leakage of FU from the plasma into the extravascular 
extracellular space where it is more easily taken up by tumor cells due to an increased 
negative ∆pH. The effect of carbogen on FU efficacy was more pronounced in the 
larger tumors, implying that in larger, more hypoxic tumors more nonfunctional vessels 
are present which may be opened by carbogen breathing. In a recent study, carbogen 
had no effect on FU uptake and metabolism, as measured by 19F MRS in rat GH3 
prolactinomas xenografted into nude mice, nor on the NTP/Pi ratio measured by 31P 
MRS.88 However, in H9618a hepatomas, grown in rats, carbogen induced a significant 
decrease in FU half life compared with controls (19.3 ± 1.6 min versus 31.7 ± 1.5 min, 
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respectively), a significant increase in anabolite/FU ratio (0.84 ± 0.07 versus 0.55 ± 
0.13, respectively), a significant increase in NTP/Pi ratio (1.10 ± 0.09 versus 0.74 ± 
0.08) and a significant decrease in ∆pH (-0.38 ± 0.11 versus -0.27 ± 0.07, 
respectively).88  
Similar studies of carbogen and FU treatment with murine colon carcinoma 
have shown conflicting results. For C38 colon tumor-bearing C57/BL6 mice Kamm et 
al.89 found increased levels of FU and its anabolites and catabolites when carbogen 
breathing was initiated 1 min before and maintained 8.5 min after FU (150 mg/kg) bolus 
injection, as is illustrated in figure 7. Under these conditions no enhanced FU retention 
in tumor was found. No significant effect of carbogen with FU on growth inhibition was 
observed compared with FU as a single agent. It was hypothesized that for this tumor 
type, FU uptake was not a rate-limiting process for growth inhibition, possibly due to 
the relatively small size and well-perfused condition of the tumors. In C26b and C26-10 
tumors in BalbC mice there was no effect of carbogen breathing on FU uptake or 
anabolite production; however, carbogen combined with FU significantly inhibited tumor 
growth in C26-10 tumors.90 The reason for the prolonged growth delay in C26-10 
remained unclear in this study.  
It should be noted that in the three studies discussed above no increase in 
systemic toxicity was reported for carbogen with FU versus FU alone. In fact, Griffiths 
et al.91 demonstrated that there were no significant effects of carbogen breathing on the 
levels of FU and its metabolites in normal rat tissues after a 50 mg/kg bolus of FU. 
However, in a preliminary report five toxicity-related deaths were reported after 
treatment with carbogen and 150 mg/kg bolus FU in a group of seven C38-bearing 
C57/Bl6 mice within 12 days after treatment, whereas no toxicity-related deaths were 
observed in seven mice that received FU only.92 At a FU dose where no differences in 
toxicity were present between the two treatment regimens (100 mg/kg), no differences 
in tumor growth were observed between the group receiving a combination of carbogen 
with FU and the group receiving FU only. 31P MRS showed a drop in energy status of 
the tumor. A possible explanation is that the reduced energy status of the tumor 
compared with normal cells results in reconversion of cytotoxic anabolites back to FU 
which is not active by itself. Such a mechanism was postulated for the vasodilator 
agent hydralazine, which is known to induce the steal effect. With RIF-1-bearing mice 
hydralazine was injected at the time point when an anabolite resonance was detected 
in the 19F MR spectrum; thereafter the anabolite resonance decreased with 
accompanying increase of the FU resonance.93 In conclusion, the effects of carbogen 
breathing on FU uptake and conversion and on tumor response appear to be subtle 
and complex; further investigation is needed. 
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Figure 7  Effect of carbogen breathing on the in vivo 19F MR spectrum (4.3 T) of a C38 murine colon 
tumor. Sequential spectra were acquired over 17-min intervals (sum of two 8.5 min spectra) 
after i.p. injection of 150 mg/kg FU. Each spectrum is labeled with the measurement time after 
injection of FU alone (A) or after treatment with FU plus carbogen breathing during the first 8.5 
min (B). Peak labels are: A, anabolites; C, catabolites; F, FU. Reproduced with permission from 
Kamm et al.89  
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3.2.2 Modulation of FU metabolism  
In the first in vivo 19F MRS study by Stevens et al.66 (see also table 1), low-dose FU (30 
mg/kg) was combined with thymidine (180 mg/kg). Although at the low FU dose no 
anabolites were detected in normal liver tissue, after injection of low-dose FU combined 
with thymidine anabolite resonances were observed in the liver. Tausch-Treml et al.94 
observed enhanced conversion of FU to fluoronucleotides as well as an increased half 
life of FU in both human hypopharynx carcinoma and colon carcinoma xenografts when 
cotreatment with thymidine (400 mg/kg) was performed. The plateau level of 
fluoronucleotides 50-60 min after injection of a FU bolus (130 mg/kg) divided by the 
initial concentration was 0.18 ± 0.086 for the hypopharynx carcinoma with thymidine 
cotreatment, 0.13 ± 0.068 for the corresponding controls and 0.36 ± 0.125 for the colon 
carcinoma with thymidine cotreatment, 0.24 ± 0.11 for the corresponding controls. With 
thymidine cotreatment the half life of FU increased from 28.2 ± 11.2 min to 40.5 ± 9.3 
min in the hypopharynx tumor and from 25.5 ± 9.9 min to 44.6 ± 14.3 in the colon 
carcinoma. Only in the colon carcinoma xenograft was the increase in nucleotides 
statistically significant and accompanied by an increase in growth delay. Thymidine is 
known to reduce DNA-directed cytotoxicity and stimulate RNA-directed cytotoxicity 
(see above, section 1.1.3 and figure 1 and 2). FdUMP (DNA-directed toxicity) is 
present at much lower concentrations than FUTP (RNA-directed toxicity) and is 
expected to make a negligible contribution to the fluoronucleotide resonance. Thus, it 
was speculated by the authors that in tumors for which DNA-directed toxicity is more 
important than RNA-directed toxicity, addition of thymidine to FU therapy may lead to 
an increase in fluoronucleotide levels without affecting tumor cytotoxicity. This seems 
to be the case for hypopharynx carcinoma and may explain why anabolite formation did 
not serve as a predictor for the efficacy of the combined treatment with this tumor.  
In human HT29 tumor xenografts pretreatment with a 500 mg/kg bolus of 
thymidine and a 200 mg/kg bolus FU injection resulted in a significant decrease in FU 
elimination from tumor (t½ increased from 25.4 ± 2 min to 36.5 ± 6.1 min), an increase 
in anabolism and a decrease in catabolism.69 These observations corroborate the 
hypothesis that thymidine competitively inhibits the catabolic enzyme DPD. DPD is also 
effectively inhibited by 5-ethynyluracil (EU).95 When mice bearing C38 colon carcinoma 
were treated with EU (2 mg/kg) and a bolus of FU (200 mg/kg), 19F MR signals for 
FBAL and FUPA were not detected and increased anabolite formation and 
accumulation, compared with FU monotherapy, was observed. Also, the intratumoral 
half life of FU was increased. These results suggest that the therapeutic efficacy of FU 
can be increased by inhibiting DPD. Furthermore, a decrease in FBAL-related toxicity 
could be expected when DPD in the liver is inhibited, as suggested by the reduced 
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neurotoxicity of FU treatment in dogs when EU is administrated.96 However, it should 
be noted that severe neurotoxicity of FU treatment has been described for patients with 
a genetic DPD deficiency97-99 or for patients receiving a DPD inhibitor.29 Therefore, 
clinical implementation of DPD modulation should be considered with caution. In fact, 
when rats on a low-protein diet (2.5%) were treated with FU, higher toxicity (diarrhea, 
weight loss, leukopenia) and mortality were observed compared with rats on a normal 
protein diet (21.5%), an effect attributed to lower DPD activity in the low-protein 
group.100 By means of 19F MRS it was observed that after i.p. injection of FU the mean 
time to initial detection of FBAL and the mean duration of the FU signal in the liver were 
significantly prolonged for rats on a low-protein diet compared with controls. In the low 
protein group, hepatic DPD activity, as measured by high-performance liquid 
chromatography (HPLC), was significantly lower, in agreement with the prolonged 
detection of FU and its higher toxicity in the low-protein group. Low hepatic DPD 
activity may also explain the increased systemic toxicity that is observed clinically with 
malnutritioned patients. 
 5-benzylacyclouridine (BAU), a uridine phosphorylase inhibitor, has been used 
in combination with FU in C38 tumor-bearing C57/BL6 mice.101 Increased formation 
and retention of FU anabolites in tumor and a reduction in FU catabolites in tumor was 
observed. In normal tissue BAU did not significantly alter FU metabolism and levels of 
fluoropyrimidine metabolites, indicating a relatively selective effect on tumor tissues. 
Tumor growth studies showed that the administration of BAU (120 mg/kg) 30 min 
before a bolus of FU (85 mg/kg), once a week, resulted in an increased antineoplastic 
effect after 28 days compared to the same dose of FU alone, and a slight, statistically 
insignificant increase in systemic toxicity.  
 To modulate FU systemic toxicity, administration of a molar equivalent dose of 
allopurinol 15 min before bolus injection of FU was employed with rats bearing Walker 
carcinosarcoma.70 No anabolites were observed in tumor after a FU dose of 50 mg/kg. 
Even after a dose of 120 mg/kg only weak anabolite signals were seen in two out of 
four animals. Therefore, allopurinol reduces the production of cytotoxic 
fluoronucleotides in tumor. Indeed, in a separate group of rats it was shown that the 
combination of allopurinol with FU prevented systemic toxicity but also prevented a 
significant reduction in tumor mass. 
In summary, modulation of FU metabolism can be studied in vivo by means of 
19F MRS and the results can be correlated with tumor response and/or systemic 
toxicity. Although the above-mentioned studies have demonstrated interesting 
protocols for the modulation of FU activity, these modulators have not been tested in 
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randomized clinical trials. However, studies with IFNα and MTX in rodents do have a 
clinical correlate, as discussed below (see also table 1). 
IFNα modulation of a FU bolus (200 mg/kg) has been studied in nude mice 
bearing human HT29.69 Human IFNα (50 000 IU/mouse) significantly increased the half 
life of FU in the tumor (from 25.4 ± 2 min to 48.1 ± 13.6 min), but did not alter the 
amount of anabolites formed in tumor. FU retention and metabolism in mouse liver was 
unchanged. The growth of HT29 tumors was significantly inhibited after treatment with 
IFNα/FU, while either treatment alone did not affect tumor growth. Since human IFNα 
is not expected to affect FU metabolism in murine tissues (confirmed by unchanged 
metabolism in mouse liver), the enhanced retention of FU in tumor is not a result of 
alterations in FU plasma pharmacokinetics. 31P MRS measurements showed an 
increase in intracellular pH after IFNα administration, while extracellular pH remained 
constant. Thus, it may be hypothesized that an increase in the negative ∆pH is a likely 
explanation for the enhanced trapping of FU after IFNα. Such a mechanism, as 
suggested by MRS, provides a new means by which IFNα can modulate FU effects in 
tumor. However, FU modulation by IFNα has not resulted in a clinical benefit to 
colorectal cancer patients.31 It is important to note that in this study, as well as in many 
other MRS animal studies, subcutaneous tumor models were used which may not be 
representative for the clinical situation. For example, the blood supply may be quite 
different in subcutaneous and orthotopic models, which may explain the divergent 
results of some animal and clinical studies. This underscores the importance of 
improvement of animal models and further validation of preclinical results in the clinical 
situation.   
 The effect of a 300 mg/kg bolus of MTX administered 180 min before a 150 
mg/kg bolus of FU was studied in CD8F1 mice with a murine mammary tumor.102 In 
MTX/FU treated animals a significantly higher ratio of FU anabolites to initial total 
fluorine was observed, compared with FU treatment only. The anabolite signal was 
also observed over a longer time interval, following FU/MTX treatment. Similar results 
were found for both i.v. and i.p. injection of FU, although the intensity of the anabolite 
signal was lower after i.p., possibly due to a larger first-pass effect. El-Tahtawy and 
Wolf103 observed faster formation of anabolites in rats bearing Walker 256 
adenocarcinoma after pretreatment with 40 mg/kg bolus MTX either five or 22 h before 
FU (150 mg/kg), and there was no statistically significant difference between these two 
pretreatment protocols. McSheehy et al.104 further explored the effect of MTX and FU 
scheduling in rats bearing Walker 256 carcinosarcoma, injecting a 20 mg/kg bolus of 
MTX 3, 6, 12, or 24 h prior to a 50 mg/kg bolus of FU. For all regimens, very similar 
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patterns of metabolism were found, possibly due to extensive polyglutamation of MTX 
in the Walker carcinosarcoma cells, which prevents MTX efflux and sustains 
intracellular MTX levels irrespective of the administration schedule. In the study by 
Tausch-Treml et al.94 human hypopharynx carcinoma and colon carcinoma xenografts 
were treated with a 100 mg/kg bolus of MTX 15 h before treatment with a 130 mg/kg 
bolus of FU. In both tumor lines enhanced conversion of FU to fluoronucleotides as 
well as an increased half life of FU was observed when cotreated with MTX. The 
plateau level of fluoronucleotides 50-60 min after injection of bolus FU divided by the 
initial concentration was 0.22 ± 0.084 for the hypopharynx carcinoma with thymidine 
cotreatment, 0.13 ± 0.068 for the corresponding controls and 0.38 ± 0.105 for the colon 
carcinoma with MTX cotreatment, 0.24 ± 0.11 for the corresponding controls. With MTX 
cotreatment the half life of FU was not significantly altered. Cotreatment with MTX 
resulted in an increased growth delay for the colon carcinoma xenograft. As for 
thymidine (though via different mechanisms; see section 1.1.3) MTX reduces DNA-
directed cytotoxicity of FU, while increasing RNA-directed cytotoxicity. Assuming that 
the anabolite resonance measured by in vivo 19F MRS contains a larger contribution 
from FUTP than FdUMP (see above), then in tumors for which DNA-directed toxicity is 
more important than RNA-directed toxicity - as seems to be the case for hypopharynx 
carcinoma - cotreatment with MTX may lead to an increase in detectable 
fluoronucleotides without affecting tumor response.  
The in vivo effect of pretreatment with a 300 mg/kg bolus of MTX or a 20 mg/kg 
bolus of TMTX before a 100 mg/kg FU bolus was investigated for Novikoff 
hepatoma.105 Each modulator increased the amounts of anabolites formed compared 
with controls (saline with FU). The increase in anabolite formation after MTX was larger 
than after TMTX, and anabolite levels after TMTX peaked at a later time than after 
MTX. Also, the area under the curve for FU was increased by MTX, but not by TMTX. 
These results suggest that the mechanism or degree of action of these two antifolates 
may be different, which may also explain the clinical observation that addition of TMTX 
to FU/LV protocols did not result in a survival benefit,35-37 whereas survival after 
addition of MTX significantly improved.34 
 
3.3 OTHER FLUOROPYRIMIDINES  
Several cytotoxic fluoropyrimidine prodrugs which are metabolized by enzymatic 
conversion into FU have been tested by 19F MRS in rodent studies (table 1). For 
patients oral intake is one of the advantages of most of these fluoropyrimidines; 
however, in the majority of rodent studies they are administered i.p., i.v. or 
intratumorally.  
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In vivo 19F MRS has been performed after i.p. bolus injection of capecitabine in 
nude mice bearing a subcutaneous human bladder tumor xenograft overexpressing 
TP.106 The intermediate metabolites of capecitabine, 5′-DFCR and 5′-DFUR, were 
present in tumor, but anabolites or catabolites of FU were not observed. The rate of 
conversion of 5′-DFUR to FU was found to be doubled in TP overexpressors compared 
with controls. Since a strong correlation between TP levels in tumors and tumor 
response has been observed,43 it was suggested that 19F MRS could be useful as a 
noninvasive method for determining TP levels in tumors and predicting response to 
capecitabine treatment.  
 19F MRS in rat liver and a rat prolactinoma line has been used to compare 
treatments with the FU prodrugs 5′-DFUR , FdUrd and ftorafur (see section 1.2.2) with 
conventional FU treatment.67 After 0.46 mmol/kg i.v. bolus injection, FU was cleared 
more rapidly from the liver than 5′-DFUR (t½ = 4.7 ± 0.6 min versus 15.8 ± 0.8 min, 
respectively). FBAL production in the liver was almost identical for FU and FdUrd, but 
more sustained with 5′-DFUR and even more so with ftorafur. This is consistent with 
the concept that for the latter two agents conversion to FU is rate limiting for catabolism 
to FBAL. FU and FdUrd treatments (0.92 mmol/kg bolus injection) resulted in 
measurable anabolites in tumor, and a daily dose of 0.19 mmol/kg for seven days 
caused tumor growth inhibition. The presence of anabolites after FdUrd administration 
in tumors has been confirmed by Naser-Hijazi et al.68 for Novikoff hepatoma in Wistar 
rats. The feasibility of monitoring local drug disposition kinetics after intratumoral or 
subcutaneous application has been shown for FdUrd with Morris hepatoma in rats.107 
Apart from FdUrd, FU and FBAL were also detected, although not in all tumors.  
It has been shown by 19F MRS that when ftorafur is combined with uracil, 
catabolism to FBAL is suppressed in rat liver.108 This is in accordance with the 
observation that the combination of ftorafur with uracil enhances intracellular FU 
concentrations by inhibiting the degradation of FU through competitive binding of uracil 
to the enzyme DPD (see section 1.2.2, figure 2).45 Kanazawa et al.109 confirmed the 19F 
MRS findings in mouse liver and in Sarcoma 180 tumor transplanted in ICR mice. It is 
noteworthy that in this study drugs were administered orally as a dispersion in an 
aqueous solution of carboxymethyl cellulose sodium salt. Harada et al.110 studied the 
suppression of catabolism in the liver of Wistar rats by 1-ethoxymethyl-5-fluorouracil 
(EM-FU), a fluorinated pyrimidine derived from FU, in combination with 3-cyano-2,6-
dihydroxypyridine (CNDP), a chemical modulator which inhibits DPD in the liver. It was 
shown that metabolism of EM-FU was very slow and that the production of FBAL was 
very low compared to ftorafur treatment. Catabolic suppression by CNDP was much 
stronger than with uracil. 
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 In summary, rodent studies have shown the feasibility of using 19F MRS to 
investigate fluoropyrimidines other than FU. Differences in the formation of anabolites 
and catabolites and possible modulating steps have been revealed, which could be 
relevant for the prediction of tumor and host toxicity. Further clinical studies are needed 
to corroborate these results. 
An interesting new preclinical application of in vivo 19F MRS in solid tumors is to 
monitor antibody-directed enzyme-prodrug therapy (ADEPT). ADEPT makes use of a 
fusion protein which is linked to an antibody targeted to a specific tumor antigen. The 
enzyme is chosen to be capable of converting a harmless prodrug to a cytotoxic drug 
within the tumor. After administration of the fusion protein time is allowed for 
accumulation of the protein in the tumor and clearance from the rest of the body; the 
prodrug is then administered. Ideally, the fusion protein and, thus, the enzyme for 
activation of the prodrug will be present in tumor tissue only, resulting in localized 
generation of the cytotoxic drug. For example, the prodrug 5-fluorocytosine (FCyt) is 
enzymatically converted to FU by monoclonal antibody L6 cytosine deaminase (L6-
CD). Aboagye et al.111 showed that after pretreatment of H2981 tumor-bearing mice 
with L6-CD, metabolism of FCyt to FU could be detected within tumor. Whole-body 19F 
chemical shift imaging demonstrated that the highest FU signal intensity was within the 
tumor region, supporting the hypothesis that the cytotoxic drug is generated locally in 
the tumor. 
 The conversion of FCyt to FU has also been achieved using the attenuated 
Salmonella typhimurium bacteria, recombinant to provide cytosine deaminase (TAPET-
CD).112 The intratumoral generation of FU was shown to be more efficient when 
TAPET-CD/FCyt was delivered intratumorally than when TAPET-CD was delivered i.v. 
and FCyt i.p. Elimination of the first step of ADEPT, administration of the fusion protein, 
would allow easier application of the therapy in clinical protocols and reduce 
immunological problems. Guerquin-Kern et al.113 showed by means of 19F MRS that 
when a glucurono-conjugated carbamate derivative of FU was injected in necrotic Lovo 
tumors implanted in nude mice, it can be converted into FU without administration of a 
fusion protein, due to the relatively high levels of β-glucuronidase in necrotic areas. 
Recently, Hamstra et al.114 reported the use of 19F MRS for evaluation of gene-
dependent enzyme-prodrug therapy (GDEPT). A bifunctional fusion gene between 
Saccharomyces cerevisiae cytosine deaminase and Haemophilus influenzae uracil 
phosphoribosyltransferase was transfected into glioma cells, and cells were implanted 
subcutaneously in nude mice. After i.p. injection of FCyt high levels of FU were 
observed in tumors, but not in non-tumor bearing muscle.  
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Table 1  Overview of 19F MRS studies concerning FU uptake, metabolism and modulation in rodents. 
 
4. CLINICAL IN VIVO 19F MRS STUDIES OF FLUOROPYRIMIDINES  
After studying the intracellular uptake and metabolism of FU as well as its modulation 
by means of 19F MRS in vivo in preclinical models, the obvious next step was to apply 
these techniques to patients (table 2). 
 
4.1 FU UPTAKE AND METABOLISM 
In 1987 Wolf et al.115 described the first 19F MRS study performed with patients at 1.5 
T, using a 15-cm surface coil placed over the liver. MR spectra from liver in three 
patients were recorded after i.v. infusion of FU (1.5 g; approx. 20 mg/kg) over a 10-15 
min interval. Resonances for both FU and FBAL were observed, but not for FUPA. The 
half life of FU in liver ranged from 18 to 25 min but was less than 15 min in blood. 
Trapping of FU in human tumors was reported in 1990.73 After 600 mg/m2 i.v. bolus 
injection a FU resonance was detected at 1.5 T in the tumors of four out of six patients 
(two patients with liver metastases of colon carcinoma, one patient with lung 
metastases of endometrium carcinoma, two patients with primary breast cancer and 
one patient with primary rectal cancer). No metabolites of FU were detected. The half 
life of FU in tumor ranged from 0.4 to 2.1 h. It was suggested that tumor trapping of FU 
could be related to response to FU therapy. This suggestion was further investigated in 
other studies.116-118 In a group of 57 patients with various primary tumor types a partial 
response was achieved in eight out of nine patients who exhibited a half life for FU in 
tumor of more than 20 min.117 The most commonly studied site containing tumor was 
liver (i.e. liver metastases). Response occurred in only two out of 25 patients whose 
subject references 
proof of principle of monitoring FU metabolism in rodents 66,67 
anabolites and tumor toxicity 70-72 
FU drug trapping 73-76 
relevance of measuring catabolites 71 
importance of different administration routes 80 
modulation of FU uptake and retention by modulation of the 
tumor microenvironment 
72,81,83,84,86-93 
modulation of FU metabolism; modulators not tested in 
clinical trials 
66,69,70,94,95,11,101 
modulation of FU metabolism: IFNα and (T)MTX 69,94,102-105 
other fluoropyrimidines 67,68,106-110 
new drug delivery techniques 111-114 
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tumors did not trap FU, i.e., where t½ was less than 20 min. In another study with 103 
patients with various tumor types, 99 patients had detectable 19F resonances, and 70% 
of the evaluable patients who demonstrated tumor trapping responded to 
chemotherapy, whereas none of the non-trappers responded.  
A relation between 19F MRS parameters at 1.5 T and response to treatment 
was also reported by Schlemmer et al.119 for patients with liver metastases of colorectal 
cancer. Six patients with total metastases volume of more than 20 cm3 were treated 
with 650 mg/m2 FU infusion during 10 min. Responders (n = 3) showed enhanced FU 
levels in metastases in comparison with non-responders (n = 3) (no statistics given). 
Recently, Kamm et al.120 reported a positive correlation between the increase in 
metastasis size, after 600 or 500 mg/m2 bolus i.v. treatment with FU for patients with 
relatively large liver metastases in the field of view of the RF coil (n = 7), and the 
maximum 19F signal intensity measured at 1.5 T for catabolites. This correlation 
indicates that a higher degradation of FU into catabolites, results in poorer response to 
treatment. No correlation was found between decrease in metastasis size and FU half 
life in the metastases. Anabolites were observed in the metastases of all patients with 
partial response (three out of 17), but also in two patients with stable disease and two 
patients with progressive disease. Although cytotoxic anabolites are generally thought 
to accumulate to detectable levels only in tumor tissue, two cases have been described 
in which anabolite resonances were detected in normal liver tissue.91 It was 
hypothesized that the effect of combining other agents with FU on normal tissue, i.e. 
systemic toxicity, could be predicted from changes in anabolite signal intensity.  
The lack of a correlation of FU half life in liver metastases and anabolite 
formation with response to treatment the study by Kamm et al.120 may be caused by the 
fact that, despite the image-based selection of relatively large metastases, the field of 
view of the RF coil still included a considerable amount of normal liver tissue. As in all 
other studies mentioned above, no MR localized techniques were applied beyond the 
use of a surface coil. To further explore the correlation between 19F MRS results and 
treatment response and to make 19F MRS applicable for clinical practice, improved MR 
localization techniques, such as MRSI, should be applied. In view of the relatively low 
inherent sensitivity of 19F MRS and the high detection threshold for fluorinated 
compounds, such studies should be performed at the highest available B0 field 
strengths. 
 The feasibility of 19F MRS at 1.5 T to study intra-arterial administration of FU 
(1.5 g) in patients with liver metastases of various tumor types was shown by Semmler 
et al.121 In eight patients with either a primary liver tumor or liver metastases 19F MR 
spectra from the liver region were recorded. In all patients resonances from FU and 
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FBAL were detected, and in one patient a resonance from FU anabolites was also 
observed. Kinetic modeling of these data showed similar kinetics in five patients with 
liver metastases of colorectal carcinoma, but different behavior in two patients with 
cholangiocarcinoma and a patient with metastases of an anaplastic carcinoma of 
unknown origin.122 The authors speculated that 19F MRS may be able to discriminate 
between different tumor types. Schlemmer et al.119 showed that FU levels detected at 
1.5 T from the liver region in patients with liver metastases of colorectal cancer were 
higher after 1000 mg/m2 intra-arterial infusion (n = 2) compared to 650 mg/m2 i.v. 
administration of FU (n = 16): the maximum integrated signal intensity was 10.1 and 
7.0 % (normalized to a reference sample) for the two patients with intra-arterial 
administration of FU and the average for the i.v.-treated patients was 2.5 ± 1.1 %. 
Time-course data for FBAL were similar for the two routes of administration.119 In four 
patients 19F MRS of the liver was performed at 1.5 T after intraperitoneal and after 
intravenous administration of 1 g FU.123 Because of potential contamination from 
peritoneal FU the accumulation of FBAL was considered a more reliable indicator of 
drug catabolism compared to the measurement of unlocalized ‘hepatic’ FU. A larger 
pharmacokinetic variation was found following intraperitoneal administration compared 
to intravenous administration.  
Based on preliminary 19F MRS data for normal liver tissue in 19 patients treated 
with continuous ambulatory FU infusion (300 mg/m2/day), it was suggested that there is 
a relationship between the MR detectability of the FU signal in liver and the absence of 
FU toxicity.124 A similar relationship was observed in a second study with continuous 
FU infusion (300 mg/m2/day). Plasma FU concentrations, measured on the day of the 
in vivo 19F MRS experiments, were available for five patients on a total of 13 occasions. 
In three patients the presence of a liver FU signal coincided with relatively low plasma 
concentrations of FU (< 650 ng/ml), lower liver catabolite signals and no systemic 
toxicity.125 Conversely, high plasma FU concentrations (≥ 650 ng/ml) and higher liver 
catabolite signals without a visible FU signal were observed in two patients who did 
experience toxicity. A positive correlation between the logarithm of the plasma FU 
concentration and the FU catabolite peak area for liver was found. However, a negative 
correlation was observed between the log plasma FU concentration and the liver FU 
signal. The authors speculated on the presence of a negative feedback mechanism in 
which the liver catabolites regulate the FU uptake by the liver. However, the precise 
way by which this mechanism would function, remains unclear.  
 In one study 19F MRS has been performed at 1.5 T on patients who underwent 
radiochemotherapy.126 Seventeen patients with head and neck cancer received 600 or 
1000 mg/m2 FU and 70 mg/m2 carboplatin on days 1-5 (week 1) and 29-33 (week 5) 
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and accelerated hyperfractionated radiotherapy 1.8 Gy/day on days 1-5  (week 1-5) 
and on days 1-3 (week 6) with a concomitant boost of 1.5 Gy as a second daily dose 
(week 4-6). MR examinations were performed at day 1 of therapy. For thirteen patients 
MR measurements were repeated after 43.5 Gy of irradiation at day 1 of the second 
chemotherapy cycle. Spectra with a high SNR were obtained because the surface coil 
was positioned close to the neck metastases. No resonances from FU anabolites were 
detected in the 19F MRS spectra. The median levels of the resolved FU and FBAL 
resonances was more than twofold higher at the second compared with the first 
examination, whereas the level of DHFU did not change. Since tumor volumes did not 
increase between the two examinations, intratumoral drug levels appeared to be 
increased after radiotherapy. This could have been caused by more efficient drug 
delivery from the blood vessels to the interstitium, but also by increased tumor blood 
flow after radiotherapy and/or FU.127,128 However, since no control patients (without 
radiation therapy) were measured, accumulation (especially of FBAL) due to multiple 
infusions cannot be excluded. 
 As described above (section 2.3) the 19F MRS resonance at -17.2 ppm with 
respect to FU is usually assigned to the FU catabolite FUPA. Recently, a contribution 
to this resonance from an FBAL-bile acid conjugate has been described.129 Using 19F 
MRSI in four patients who received protracted venous infusion (PVI) of FU, a catabolite 
resonance was detected at this spectral position, originating from the gallbladder. For 
three other patients where no gall bladder could be identified in the MR images, no 19F 
signals were detected. In two patients who were treated with bolus FU the same 
resonance was observed. Since evidence from both 19F MR spectroscopic studies130 
and high-performance liquid chromatography131 indicate that the major biliary 
metabolites of FU are conjugates of FBAL, this resonance has been identified as such. 
FBAL-bile acid conjugates are thought to be able to undergo entero-hepatic 
recirculation. PVI of FU may establish a larger pool of recirculating catabolites 
compared with bolus infusion of FU, resulting in higher biliary catabolite levels. 
 In summary, in vivo 19F MRS of FU is feasible with patients at 1.5 T field 
strength and FU kinetics can, at least in some studies, be related to therapy response. 
Moreover, 19F MRS has provided some further insight into the catabolism of FU, which 
may be important in the prediction of systemic toxicity. 
 
4.2 FU MODULATION  
In contrast to extensive preclinical 19F MRS studies, only three modulators have been 
studied by 19F MRS in the clinical situation: IFNα, MTX and LV (table 2). 
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In a study of 26 patients with liver metastases of colorectal cancer, the effect of 
IFNα (five million units, three times a week) on FU and its metabolites was monitored 
by 19F MRS with a surface coil placed over the liver.132 Patients were first treated with 
single-agent low-dose infusional FU (300 mg/m2). In these patients only resonances of 
FU and catabolites were observed. Patients with a detectable FU resonance within 
eight weeks after starting single-agent infusional FU were more likely to respond to 
chemotherapy than patients without FU signal (Fisher’s exact test; p = .017). When 
patients became refractory to FU (defined as stable disease over 12 weeks with a rise 
in the carcinoembryonic antigen, or tumor progression), IFNα was added to the FU 
treatment. 19F MRS measurements were performed one to two weeks after initiating 
IFNα treatment and compared with scans performed one to seven days prior to starting 
IFNα. In seven out of 15 patients FU was now detectable or the signal had increased 
and four out of 15 patients showed a resonance for FU anabolites. The patients with 
detectable or increased FU signal were more likely to show further response to 
FU/IFNα (Fisher’s exact test; p = .007). In a subsequent study of patients with liver 
metastases of colorectal cancer, plasma levels of FU were also determined prior to and 
one to two weeks after addition of IFNα (n = 9).125 No consistent trends for plasma FU 
concentration, FU signal or catabolite signal before and after IFNα addition were 
observed. In a study of three patients with liver metastases of colon cancer, an 
increase in the half life of FU in the tumor-containing liver region was observed after 
addition of IFNα (10 IU/m2, three times a week) to 600 mg/m2 bolus FU.133 Two patients 
showed half life increases of 30.2 and 41.0% and partially responded to the therapy, 
while one patient with an increase in FU half life of 5.6% showed tumor progression. 
With only three patients statistically sound conclusions cannot be made. Although the 
results of these IFNα studies might suggest that 19F MRS may be useful in identifying a 
subgroup of patients who will respond to therapy (even though in a large population the 
addition of IFNα to FU treatments has not proven useful), it should be noted that in 
none of the studies a control group was used receiving single agent FU. 
 In a preliminary study of two patients with liver metastases of gastric cancer the 
addition of 1500 mg/m2 MTX to 1500 mg/m2 FU and oral leucovorin increased the 
tumor half life of FU by 13.5% and 41.8%, but both patients showed progression.133 
Without results from a larger patient population and the use of a control group, no 
conclusions can be made about the usefulness of 19F MRS to identify patients who 
might profit from the addition of MTX to FU treatment. Also, as is the case for all other 
clinical 19F MRS studies, no clear timepoint has been identified as to when to perform 
the 19F MRS experiments. Although it is clear that 19F MRS measurements should take 
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place shortly after start of the therapy in order to obtain an indication of drug uptake 
and activation, which may serve as an early marker of response, the exact timing of the 
measurement with respect to the timing of the treatment protocol (route, dose, infusion 
rate) may be critical. This is illustrated by a study of patients with aggressive lymphoma 
and Hodgkin’s disease who were monitored by 18FDG PET.134 Results of 18FDG PET 
after one cycle of chemotherapy correlated better with progression-free survival than 
results obtained at the completion of chemotherapy. 
 An 19F MRS study of the effect of adding 500 mg/m2 LV as a two-hour infusion 
to 600 mg/m2 bolus FU treatment was reported for one patient.73 No change in the half 
life of intratumoral FU was observed nor was a resonance for anabolites detected. This 
was confirmed in a larger study using the same therapy regimen with 21 patients with 
gastrointestinal tumors located within 8 cm of the skin surface. Two 19F MRS studies 
were performed within one to two weeks, the first one with FU as a single agent, the 
second one with addition of LV. No increase in the intratumoral half life of FU was 
observed.135 In fact, only for two patients was the half life altered, and in both cases it 
was decreased. It was concluded that the potentiating effect of LV is not due to any 
effects on FU uptake, metabolism or clearance, but rather that LV only acts far 
‘downstream’ (namely stabilization of the FdUMP-TS complex) with no detectable 
effect on FU kinetics. In fact, this could have been expected from the known 
mechanism of action of LV (figure 1), since no other data are available that suggest 
that LV would affect FU kinetics. Again, in this study each patient served as his/her 
own control and no separate control group was used. Since no solid data are available 
on reproducibility of 19F MRS measurements after repeated infusion no firm 
conclusions can be made yet.  
 
4.3 OTHER FLUOROPYRIMIDINES  
Two studies have demonstrated the feasibility of using 19F MRS to investigate oral 
fluoropyrimidine therapy in patients. Ikehira et al.136 observed an FU signal from the 
liver of patients after oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 
5′-DFUR. FU was detectable from 40-45 min after administration until the end of the 
observation period (2.5 h after administration). Resonances from HCFU and 5′-DFUR 
were also detected. Only after oral administration of FU was FBAL detected. 
 After oral administration of capecitabine, Van Laarhoven et al.61 observed 
resonances for capecitabine, its metabolites 5′-DFCR and 5′-DFUR, and the FU 
catabolites FUPA and FBAL in the liver of patients with advanced colorectal cancer. 
The FU concentration was apparently below MR detectable levels, due to rapid 
catabolism. The resonance frequency for 5′-DFUR was found to be pH dependent: the  
CHAPTER 2 
 70
Figure 8  19F MR spectra obtained in vivo from the liver of a patient using a pulse acquire sequence at 1.5 
T (A) and 3 T (B). In each case the sum of two spectra taken 68-72 and 76-80 min after oral 
capecitabine intake is shown. To facilitate comparison, the vertical scales of the two spectra 
have been adjusted to give equal noise levels. Reproduced with permission from Van Laarhoven 
et al.61   
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Table 2  Overview of 19F MRS studies concerning FU uptake, metabolism and modulation in patients  
 
chemical shift relative to FU decreases as pH decreases.  Since  the largest effect on 
chemical shift occurs for pH ≈ pKa it was proposed that 5′-DFUR (pKa = 7.41) can serve 
as an in vivo marker for tissue pH. From 19F MRS data the pH of liver tissue was 
calculated to be 7.39, in agreement with liver pH values measured by in vivo 31P 
MRS.137 A large peak at ca. -17 ppm (relative to FU) was detected in unlocalized 
spectra from the liver region. In localized spectra from gall bladder voxels this peak 
was even higher, supporting the suggestion of Dzik-Jurasz et al.129 that this peak may 
derive from FBAL-bile acid conjugates. Since oral fluoropyrimidine treatment is 
considered to mimic PVI of FU (see above), capecitabine treatment may establish a 
larger pool of recirculating catabolites compared to bolus FU treatment, resulting in 
higher biliary catabolite levels. The mimicking of conventional PVI of FU is one of the 
claimed properties of oral fluoropyrimidines. Note that an improved SNR and spectral 
resolution in the 19F MRS spectra were observed for measurements performed at B0 = 
3 T compared to those carried out at 1.5 T, as is illustrated in figure 8.   
 
5. CONCLUSIONS 
19F MRS has proven to be a very valuable tool for the in vivo assessment of 
fluoropyrimidine metabolism in rodent studies. It can provide unique insight into 
fundamental aspects of fluoropyrimidine metabolism and the effects of modulators. In 
contrast to plasma pharmacokinetics MRS provides a direct measure of drug uptake in 
tumor and/or normal tissue and may, therefore, be of use for the individualization of 
chemotherapy and the strategic development of new drugs. However, animal model 
studies usually employ extremely high bolus doses of fluoropyrimidines that are 
unrealistic in a clinical setting. Furthermore, the entire palette of long-term infusion 
subject references 
proof of principle of monitoring FU metabolism in patients 115 
FU drug trapping 73,116-118 
19F MRS measurables and therapy response 119,120 
19F MRS measurables in different tumors 122 
importance of different administration routes 119,121,123 
19F MRS of normal tissue 124,125 
radiochemotherapy 126 
assignment of resonances 129 
modulation of FU metabolism: IFNα, MTX and LV 73,125,132,133,135 
other fluoropyrimidines 61,136 
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protocols with low dose rates is inaccessible for in vivo 19F MRS and requires the 
detection sensitivity that can only be achieved with ex vivo measurements at the 
highest field strengths. 
 The majority of published clinical studies involve only small numbers of patients 
and have not presented unequivocal results correlating 19F MRS measurables with 
tumor response and/or systemic toxicity in patients. In order to predict treatment 
outcome or to monitor therapy, variables monitored by 19F MRS should reflect true 
changes in tumor metabolism or physiology and not changes induced by variations in 
the MR protocol or general host physiology.138,139 Therefore, data on the reproducibility 
of 19F MRS measurements are needed. Also, to date no clinical trials have been 
performed to assess the cost-benefit of introducing 19F MRS into clinical practice.140 
 Despite the high relative MR sensitivity of the 19F isotope the low tissue 
concentrations of FU and its metabolites that are achieved in patients with realistic 
treatment protocols  often prevent assessment by MRS. This is especially true for  deep 
lying tissues which cannot be adequately examined or localized by surface coil 
techniques. Therefore, it is critical to increase the sensitivity of 19F MRS in clinical 
studies. Apart from improvements in RF coil technology (quadrature or phased-array 
coils), the application of higher magnetic fields is mandatory. The availability of clinical 
MR scanners with B0 fields of 3 T or higher will certainly provide further impetus for the 
development of 19F MRS techniques and their clinical application. 
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ABSTRACT  
The purpose of this study was to investigate oxygenation, perfusion and cell 
proliferation in two murine colon carcinoma lines with known differences in 
chemotherapy sensitivity and analyze the effect of nicotinamide and carbogen on these 
tumor characteristics. 
Mice with subcutaneously transplanted C38 and C26a murine colon tumors 
were treated with nicotinamide and carbogen and compared with control tumors. Two 
markers of hypoxia, CCI-103F and pimonidazole, were injected before and after 
treatment with nicotinamide/carbogen, respectively, allowing each tumor to serve as its 
own control. Hoechst33342 was used as a perfusion marker and bromodeoxyuridine 
(BrdUrd) as a proliferation marker. Frozen tumors were cut for multistep immuno-
staining and computer-controlled microscope scanning for hypoxic fractions (HF), 
perfused fractions (PF), vascular density (VD) and BrdUrd-labeling index (LI).  
Microscopic observation of C38 and C26a tumors showed extensive differences 
in vascular architecture, distribution patterns of hypoxia and BrdUrd-labeling. 
Quantitative analysis of C38 and C26a tumors showed a decrease in HF in response to 
all treatment modalities. For C38 tumors the average decrease in HF in response to 
carbogen containing treatments was larger than to nicotinamide alone. In C26a tumors 
no difference in average decrease in HF was observed between the treatments. PF of 
C38 and C26a did not change in response to treatment. LI of C38 and C26a decreased 
upon all treatments, which was statistically significant in the combination treatment of 
C38.  
In conclusion, the mechanism that can simultaneously explain all the observed 
changes in response to treatment may be the conversion of metabolism from oxidative 
phophorylation towards (more) glycolysis due to increased glucose levels (Crabtree 
effect), although other mechanisms of action cannot be excluded.  
 
KEYWORDS  
carbogen, colon carcinoma, hypoxia, nicotinamide, vascular architecture 
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INTRODUCTION 
Several studies have shown that tumor hypoxia may have a negative impact on the 
outcome of anticancer treatment. Compared with fully oxygenated cells, chronic 
hypoxic tumor cells are located furthest from functioning blood vessels, which will 
hinder drug delivery. Because of impaired oxygen and glucose delivery tumor cells will 
divide less rapidly, which decreases effectiveness of both radiation and chemotherapy.1 
In clinical studies the relation between hypoxia and impaired therapy outcome has 
been described for various tumor types, i.e. non-small cell lung cancer,2 epithelial 
ovarian tumors,3 breast cancer,4 squamous cell carcinomas of the esophagus,5 soft 
tissue sarcomas,6 squamous cell carcinomas of the cervix,7-9 and head and neck 
carcinomas.10-12 
 Hypoxia-induced therapy resistance can be overcome by hypoxic cytotoxins or 
the reduction of tumor cell hypoxia. Mitomycin C, an aquinone antibiotic requiring 
reductive metabolism for activity, is the prototype of drugs that preferentially kills 
hypoxic cells in comparison with normoxic cells.13 Tirapazamine is a recently 
developed drug with a higher selective toxicity for hypoxic cells than mitomycin C.14 
Hypoxic cells can also be specifically targeted by gene therapies that exploit tumor 
hypoxia, using selective induction of  transcription factor hypoxia-inducible factor-1 
(HIF-1) under hypoxic conditions.15,16 Tumor hypoxia may be reduced by increasing 
oxygen delivery with hyperbaric oxygen17,18 or with the administration of hyperoxic 
hypercapnic gas mixtures, alone,19 or in combination with nicotinamide.20 The latter 
approach has been particularly successful for head and neck cancer21 and bladder 
cancer.22,23 Promising results have also been described in a small series of breast 
cancer.24 Results for non-small cell lung cancer25 and glioblastoma multiforme26,27 were 
negative. 
 Carbogen is thought to reduce diffusion limited hypoxia by increasing the 
amount of dissolved O2 in blood, with the CO2 component causing tachycardia, 
hyperventilation, vasodilatation and a shift of the oxygen dissociation curve to the right, 
favoring unloading of O2 in the tissues.28 However, both in animal and in human studies 
decreases in tumor blood flow as well as decreases in heart rate have been 
described,28-30 sometimes without affecting tumor hypoxia.31  
The rationale for combining nicotinamide with radiotherapy was originally 
supposed to be the inhibition of repair of radiation-induced DNA damage by 
nicotinamide.32 Later, assessment of blood perfusion has indicated that nicotinamide is 
likely to act by decreasing perfusion limited hypoxia through prevention of intermittent 
vascular shut-down,33 possibly by decreasing interstitial fluid pressure34,35 or increasing 
leukocyte filterability.36 However, improved tumor blood flow by nicotinamide has not 
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been observed in all tumor models.37,38 Alternative mechanisms of action include 
effects on metabolic processes,39 particularly glucose metabolism,40 but the precise 
mechanism of action by which nicotinamide enhances the effect of radiotherapy has 
not been fully elucidated.  
In short, animal and clinical studies have shown that tumor hypoxia plays an 
important role in treatment resistance and that the effects and the mechanisms of 
action of nicotinamide and carbogen to reduce tumor hypoxia may differ between tumor 
types. Most of these data are derived from studies of squamous cell carcinomas. 
Tumor hypoxia and the use of nicotinamide and carbogen in adenocarcinoma of the 
colon and rectum have not been widely studied, although chemo- and radioresistance 
is a clinical problem in these tumor types. Even after aggressive preoperative 
chemoradiation followed by maximal surgical resection and intraoperative radiation 
therapy the five-year incidence of distant metastasis in locally advanced irresectable 
rectal cancer remains high, affecting 64% of patients with primary cancer and 75% of 
those with recurrent cancer.41 For advanced colorectal cancer treated with palliative 
chemotherapy an increase in median survival benefit of 3.7 months has been shown.42 
Tumor hypoxia may play an important role in treatment resistance of colorectal cancer.  
The murine colon carcinoma lines C38 and C26a tumors are known as well-
differentiated and poorly differentiated colon carcinoma with relatively high and low 
chemotherapy sensitivity, respectively.43 Therefore, these two tumor lines were 
selected to serve as a model for the clinical situation. The aim of this study was to 
analyze oxygenation, perfusion and cell proliferation in the two murine colon carcinoma 
lines C38 and C26a and investigate the effect of nicotinamide and carbogen on these 
tumor characteristics.  
 
MATERIALS AND METHODS 
TUMORS 
Female C57BL/6 and BalbC mice were obtained from the Central Animal Laboratory of 
the Radboud University Nijmegen, the Netherlands. The C38 and C26a murine colon 
tumors were acquired from Dr. G.J. Peters of the Vrije Universiteit (Amsterdam, the 
Netherlands). Viable C38 and C26a tumor tissue fragments with a diameter of 1-3 mm 
were implanted subcutaneously in the right flank of C57BL/6 and BalbC mice, 
respectively. Animals were kept according to institutional guidelines for animal care. 
Experiments were preformed when tumors had reached an in vivo diameter of 0.6-0.8 
cm (C38 and C26a) and 0.8-1.0 cm (C26a). All experiments were approved by the 
institutional ethical committee for animal use. 
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Figure 1  Treatment schedule and experimental design. Animals were sacrificed at t = 0. See text for 
details. BrdUrd = bromodeoxyuridine.  
 
 
 
 
 
 
 
 
NICOTINAMIDE AND CARBOGEN  
Nicotinamide (Sigma-Aldrich, Zwijndrecht, the Netherlands) (20 mg/ml) was injected 
intraperitoneally (i.p.) at a concentration of 500 mg/kg. For carbogen (95% O2, 5% CO2, 
Hoek Loos, Schiedam, the Netherlands) breathing, animals were put in a perspex box 
with a continuous carbogen flow of 5 l/min. Nicotinamide was administered 20 min 
before the start of carbogen breathing. Carbogen breathing continued for 30 min before 
sacrificing the animals (figure 1). In four groups of n ≥ 5 mice each, the effects of 
nicotinamide alone, carbogen alone and the combination of both on tumor hypoxia, 
perfusion and proliferation were analyzed and compared with normal air breathing, 
both for C38 and for C26a tumors.  
 
MARKERS OF HYPOXIA, PERFUSION AND PROLIFERATION 
CCI-103F (1-(2-hydroxy-3-hexafluoroisopropxy-propyl)-2-nitroimidazole, J.A Raleigh, 
University of North Carolina, Chapel Hill, USA)44,45 and pimonidazole (1-((2-hydroxy-3-
piperidinyl)propyl)-2-nitroimidazole hydrochloride, Natural Pharmacia International, 
Belmont, USA)46-48 were used as markers of hypoxia. Both are bioreductive chemical 
probes with an immuno-recognizable side chain. Complete inhibition of bioreductive 
activation occurs at a pO2 below 10 mmHg.48 With the consecutive employment of the 
two bioreductive markers changes in tumor hypoxia can be studied.49 CCI-103F was 
dissolved in 10% dimethyl sulfoxide (DMSO) and 90% peanut oil to a concentration of 
4 mg/ml; 0.5 ml of this mixture was injected i.p. in each mouse. Pimonidazole (40 
mg/ml) was combined 1:1 with the perfusion marker Hoechst33342 (Serva, Heidelberg, 
Germany) (7.5 mg/ml); 0.1 ml of this solution was injected intra-venously (i.v.) in the tail 
vein of each mouse. As a marker of proliferation the S-phase marker 
bromodeoxyuridine (BrdUrd) (Sigma-Aldrich, Zwijndrecht, the Netherlands) (25 mg/ml) 
was injected i.p. at a dose of 0.5 ml. CCI, pimonidazole/Hoechst33342 and BrdUrd 
Time (min) 
-150 -50 -30 0 -15 -25 
BrdUrd carbogennicotinamide 
pimonidazole/ 
Hoechst33342
CCI-103F 
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were injected 150 min, 25 min and 15 min, respectively, before sacrificing the animals 
by cervical dislocation (figure 1). Tumors were removed immediately and stored in 
liquid nitrogen. Frozen tumor sections of 5 µm thickness were cut for staining and 
further analysis. 
 
IMMUNOHISTOCHEMICAL STAINING 
After thawing, the sections were fixed in cold (4 °C) acetone for 10 min. Then slides 
were scanned (see below) for the Hoechst33342 signal before immunohistochemical 
staining of the other markers. After scanning of the Hoechst33342 signal and between 
all consecutive steps of the staining procedure sections were rinsed three times for 2 
min in phosphate buffered saline (PBS). Sections were mounted in fluorostab 
(Organon, Boxtel, the Netherlands), except for the sections stained for BrdUrd (see 
below). 
The first tissue section was stained for endothelium plus the first hypoxic marker 
(CCI-103F). The next tissue section was stained for endothelium plus the second 
hypoxic marker (pimonidazole). Finally, the third section was stained for the S-phase 
marker BrdUrd. 
 
Endothelial structures and CCI-103F  
Sections were incubated for 60 min at room temperature with rabbit-anti-CCI-103F 
antiserum (J.A. Raleigh)45,50 dissolved 1:50 in 9F1 which is a rat-monoclonal to mouse 
endothelium (Department of Pathology, University Medical Centre Nijmegen, the 
Netherlands51). Then sections were incubated for 30 min at 37 °C with goat-anti-rabbit-
Alexa488 (Molecular Probes, Leiden, the Netherlands) and goat-anti-rat-Alexa546 
(Molecular Probes, Leiden, the Netherlands), diluted 1:200 in polyclonal liquid dilutant 
(PLD, Euro-DPC, Breda, the Netherlands). 
 
Endothelial structures and pimonidazole 
The sections were incubated for 60 min at room temperature with rabbit-anti-
pimonidazole (J.A. Raleigh)47,52 dissolved 1:200 in 9F1. The sections were then 
incubated for 30 min at 37 °C with goat-anti-rabbit-Alexa488 and goat-anti-rat-
Alexa546, diluted 1:200 in PLD. 
 
S-phase marker BrdUrd 
On a third consecutive section DNA was denatured by incubation for 10 min at room 
temperature in 2 M hydrochloric acid. pH was neutralized by rinsing the sections for 10 
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min in 0.1 M borax. Next, sections were incubated for 60 min at 37 °C with mouse-anti-
BrdUrd (Caltag Laboratories, San Francisco, USA) diluted 1:500 in monoclonal liquid 
dilutant (Euro-DPC, Breda, the Netherlands). Then the sections were incubated with 
fluorescein isothiocyanate (FITC)-conjugated rabbit-anti-mouse antibodies (DAKO, 
Glostrup, Denmark) diluted 1:25 in PLD for 45 min at room temperature. Finally, all 
nuclei were stained by incubation of the sections in fast blue (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) diluted 1:1000 in PBS for 15 min at room temperature. 
 
IMAGE ANALYSIS 
Quantitative data for tumor hypoxia, perfusion and proliferation were acquired with a 
semiautomatic method based on a computerized digital image analysis system, which 
has been shown to be a reproducible method, as described previously.53,54 In brief, a 
high-resolution intensified solid-state camera on a fluorescence microscope (Axioskop, 
Zeiss, Weesp, the Netherlands) with a computer-controlled motorized stepping stage 
was used to scan each tumor cross-section using different filters. To analyze hypoxia 
and vascular parameters, whole tumor sections were scanned sequentially three times 
at 100x magnification with a 365 nm excitation and 420 nm emission filter for the 
Hoechst33342 signal, a 495 nm excitation and 519 nm emission filter for the Alexa488 
signal and a 556 nm excitation and 573 nm emission filter for the Alexa546 signal. 
Each scan consisted of 36-144 fields of 1.2 mm2, depending on the size of the tumor 
section. From the individual microscopic fields one composite image was reconstructed 
after each scan. As a final step a contour line was drawn to delineate the tumor area 
thereby excluding non-tumor tissue (such as overlaying skin fragments and necrosis) 
from the analyses, using consecutive H&E stained tumor sections to distinguish 
parenchyma from non-tumor tissue. The hypoxic fraction (HF) of the tumor section was 
computed as the tissue surface area stained by the hypoxic marker relative to the 
viable tumor surface area. Consecutive tumor sections were used for the analysis of 
hypoxia stained by CCI-103F and pimonidazole, respectively. The perfused fraction 
(PF) of the tumor was defined as the area which was stained both by Hoechst33342 
and 9F1 (i.e. perfused vascular area) relative to the total vascular area. The vascular 
density (VD) was calculated as the total number of vascular structures per mm2 of 
viable tumor area. Relative vascular area (RVA) was calculated by dividing the 9F1 
positive area by the viable tumor area. 
For the analysis of proliferation tumor sections were scanned sequentially two 
times at 200x magnification with a 450-490 nm excitation and 520 nm emission filter for 
the FITC and a 365 nm excitation and 420 nm emission filter  for  the  fast  blue signal.  
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A B 
Figure 2  H&E stained tissue sections of C38 murine colon carcinoma (A) and C26a murine colon 
carcinoma  (B) (100x magnification). The scalebars indicate 0.1 mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3  Binary image of a complete tumor section (A) of C38 colon tumor showing the pattern of 
vascular architecture, perfused vessels and hypoxic profile. The scale bar indicates 1 mm. In (B) 
a photomicrograph of a detail showing vasculature and hypoxic areas. In (C) the corresponding 
H&E staining of the photomicrograph in B (100x magnification). The scale bars in (B) and (C) 
indicate 0.1 mm. Vascular structures: red-pink; perfused vessels: blue-purple; hypoxic areas: 
green; the arrow indicates necrotic area. 
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Figure 4  Binary image of a complete section of C26a colon tumor with diameter 6-8 mm (A), showing the 
pattern of vascular architecture, perfusion and hypoxic profile. (B) shows the binary image of a 
complete section of C26a colon tumor with diameter 8-10 mm. The scalebars in (A) and (B) 
indicate 1 mm. In (C) a photomicrograph of a detail of C26a colon tumor with diameter 8-10 mm 
showing vasculature and hypoxic areas. In (D) the corresponding H&E staining of the 
photomicrograph in C. The scalebars in (C) and (D) indicate 0.1 mm. Vascular structures: red-
pink; perfused vessels: blue-purple; hypoxic areas: green (100x magnification). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5  Vascular structures of C38 tumor (A) and C26a tumor (8-10 mm diameter) (B) (100x 
magnification). Scalebars indicate 0.1 mm. 
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Each scan consisted of 64 fields (8 x 8) of 1.2 mm2. Again, from the individual 
microscopic fields one composite image was reconstructed after each scan, one 
showing proliferating nuclei (BrdUrd positive) and one showing all nuclei (fast blue). A 
contour line was drawn to delineate the tumor area and exclude areas of necrosis. The 
labeling index (LI) was calculated as the ratio of the BrdUrd positive surface and the 
total nuclear surface. 
 
STATISTICS AND CALCULATIONS 
To compare differences in hypoxic fraction, perfused fraction, vascular density and 
labeling index between different tumors the t-test for independent samples was used. 
For the analysis of changes in hypoxic fractions within one tumor due to nicotinamide 
administration and/or carbogen breathing, measured by CCI-103F and pimonidazole 
labeling, the t-test for dependent samples was used. Since in general, a mild 
overstaining of pimonidazole relative to CCI-103F is found,49 data were also analyzed 
after correction for this overstaining. Using the hypoxic fractions from the control 
groups the correction factor was calculated by dividing the hypoxic fraction according to 
pimonidazole staining by the hypoxic fraction according to CCI-103F staining. 
Percentual changes in hypoxic fraction, corrected for pimonidazole overstaining, were 
calculated by dividing the difference in hypoxic fraction stained by CCI-103F and 
pimonidazole by the hypoxic fraction stained by CCI-103F, times 100%.  
 
RESULTS 
H&E staining of the C38 tumor showed a corded tumor with cells organized in a 
glandular pattern surrounded with blood vessels in stromal tissue (figure 2A). In 
contrast, the C26a tumor consisted of densely packed tumor cells and stroma without 
clear structural organization (figure 2B). Hypoxic cells in C38 were located at a 
relatively constant distance from blood vessels (figure 3). At a size of 6-8 mm in C26a 
tumors hypoxia was observed in the tumor rim only (figure 4A). At larger sizes, apart 
from the hypoxic rim, centrally located hypoxic areas became more distinct in which a 
relatively constant distance from blood vessels was less obvious (figure 4B-D). The 
pattern of hypoxia in C38 tumor remained the same throughout different tumor sizes. In 
C38 tumors mainly large vessels were found, whereas C26a contained mainly small 
vessels (figure 5). The distribution of proliferative activity in C38 tumors followed the 
well organized vascular structure, whereas proliferation in C26a tumors was distributed 
more randomly throughout the tumor. 
In a quantitative analysis C38 tumors (n = 6) showed a higher hypoxic fraction 
in comparison with C26a tumor with a hypoxic rim only (n = 4), even though the relative  
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Table 1  Comparison of mean tumor area, hypoxic fraction, perfused fraction, relative vascular area, 
vascular density and BrdUrd labeling index in C38 and C26a tumors (± standard error of the 
mean). 1 C versus A: p < .01; C versus B: p < .05; 2 A versus B: p < .01; 3 C versus B: p < .05;    
4 A versus B and C: p < .01 
 
vascular area was higher and the fraction of perfused vessels showed a trend to be 
higher (p = .1). C26a tumors with a hypoxic rim and centre (n = 5) showed a larger 
tumor area than C26a tumors with a hypoxic rim only. Also a larger hypoxic fraction 
was found, while the fraction of perfused vessels and relative vascular area were the 
same (table 1). The relative vascular density showed a trend to decrease in tumors 
with both a hypoxic rim and centre (p < .1). The differences in vascularity and hypoxic 
fraction in C38 and C26a are not associated with differences in overall proliferative 
activity (table 1), despite differences in distribution patterns.  
The changes in hypoxia and vascularity after nicotinamide and/or carbogen 
administration were analyzed in a quantitative way. However, already by microscopic 
observation a striking reduction of hypoxia was noted in C38 tumors after 
administration of nicotinamide (figure 6), carbogen and the combination of carbogen 
and nicotinamide. In C26a tumors the reduction in hypoxia was less obvious and was 
noticed mainly in areas of hypoxia located in the tumor centre. Changes in hypoxia in 
the tumor rim were rarely observed after treatment with carbogen, nicotinamide or the 
combination (figure 7). 
For quantitative analysis of changes in hypoxia and vascularity after 
nicotinamide and/or carbogen administration C26a tumors were included which did not 
only show hypoxia in the tumor rim before administration of nicotinamide and/or 
carbogen, but also in central areas (compare figure 4B).  Figure 8  shows  a summary  
 
A 
C38 
 
 
 
B 
C26a with a 
hypoxic rim 
only 
 
C 
C26a with 
hypoxic rim 
and centre 
number of animals 6 4 5 
tumor area (mm2) 20.08 ± 2.47 20.20 ± 4.15 39.34 ± 5.011 
hypoxic fraction 0.14 ± 0.022 0.03 ± 0.01 0.12 ± 0.033 
perfused fraction 0.68 ± 0.05 0.52 ± 0.07 0.60 ± 0.05 
relative vascular area 0.06 ± 0.014 0.02 ± 0.00 0.02 ± 0.01 
vascular density (no. of vessels/mm2) 42.75 ± 2.53 47.42 ± 3.96 32.37 ± 6.28 
BrdUrd labeling index 0.08 ± 0.02 0.05 ± 0.02 0.06 ± 0.02 
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A 
Figure 6  Binary maps of a complete section C38 colon tumor before (A) and after (B) nicotinamide 
administration. Vascular structures: red-pink; perfused vessels: blue-purple; hypoxic areas: 
green - in (A) determined by CCI-103F injected before nicotinamide administration and in (B) by 
pimonidazole injected 20 min after nicotinamide administration (100x magnification). The scale 
bars indicate 1 mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7  Binary maps of a complete section C26a colon tumor (8-10 mm) before (A) and after (B) 
carbogen breathing. Vascular structures: red-pink; perfused vessels: blue-purple; hypoxic 
areas: green - in (A) determined by CCI-103F injected before carbogen breathing and in (B) by 
pimonidazole injected 5 min after start of carbogen breathing (100x magnification). The scale 
bars indicate 1 mm. 
B 
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of the changes in hypoxic fraction in both C38 and C26a tumors in all four groups of 
mice: air breathing (n = 6 for C38; n = 5 for C26a), administration of nicotinamide (n = 
7, respectively 6), carbogen (n = 6, respectively 7) or the combination of both (n = 6, 
respectively 6). The hypoxic fraction before nicotinamide administration or carbogen 
breathing was measured by CCI-103F, while after treatment changes in hypoxia were 
measured by a second marker, pimonidazole, allowing each tumor to serve as its own 
control. As published for other tumor models49 a slightly larger area was stained by 
pimonidazole relative to CCI-103F. Therefore the results were also analyzed after 
correction for this difference in staining. Statistical analyses were performed on both 
uncorrected and corrected hypoxic fractions.  
C38 showed a decrease in hypoxic fraction in response to nicotinamide, 
carbogen and the combination of both (figure 8). Results were significant both with and 
without correction for the overstaining of pimonidazole relative to CCI-103F. 
Nicotinamide alone showed a 44% reduction in HF, while the combination with 
carbogen resulted in a significant further decrease in HF by 80% (p < .05). Carbogen 
alone decreased HF by 76%, which was not significantly different from the decrease in 
HF after the combination of carbogen with nicotinamide (p > .05). In C26a a trend for a 
decrease in hypoxic fraction in response to all treatment modalities was observed 
compared with the uncorrected data (p ≤ .1). Compared with the data corrected for the 
overstaining of pimonidazole relative to CCI-103F this decrease was statistically 
significant (figure 8; p < .05). The reduction in HF was in the same order of magnitude 
for the different treatment modalities: nicotinamide alone reduced HF by 55%, 
carbogen by 51% and the combination treatment by 58%. Comparing the percentual 
decrease in hypoxia between the C38 and C26a, the C38 line showed a trend for a 
larger decrease in hypoxic fraction upon carbogen breathing (p < .1).  
With respect to the perfused fraction, vascular density and relative vascular 
area of the C38 and C26a tumors no statistically significant changes were observed in 
response to administration of nicotinamide, carbogen or the combination of both. 
However, as indicated in figure 9, the proliferative activity of C38 tumors significantly 
decreased after combination treatment with nicotinamide and carbogen (p < .05). A 
trend for a decrease in proliferation is observed in C26a tumors after nicotinamide (p = 
.1). 
 
DISCUSSION 
Already by microscopic observation the two murine colon tumor lines C38 and C26a 
differed in vascular architecture and in the distribution patterns of both hypoxia and 
BrdUrd positive cells. The location  of  hypoxic  cells  at  a  relatively  constant  distance  
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C26a n = 5 
n = 7  
n = 6 
n = 6 
n = 6 
n = 7  
n = 6  
n = 6 C38 
Figure 8  Quantitative analysis of changes in hypoxic fraction in C38 (left column) and C26a (right 
column) in response to administration of nicotinamide, carbogen and the combination of both. A 
value of p < .05 is indicated by * or *, p < .001 is indicated by ** or **. Hypoxic fraction measured 
by pimonidazole staining is compared with CCI-103F (* or **) and with CCI-103F corrected data 
(* or **) (see Materials and Methods for details on the corrected data). 
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B 
A 
Figure 9  Quantitative analysis of changes in labeling index in C38 (A) and C26a (B) tumors in response 
to administration of nicotinamide, carbogen and the combination of both. A value of p < .05 is 
indicated by * (compared with the control group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
from blood vessels in C38 tumors suggests chronic or diffusion limited hypoxia, 
according to the classical model of Thomlinson and Gray.55 In C26a tumors the relation 
between the location of hypoxia and vasculature is less obvious and local and 
temporary fluctuations of tumor blood perfusion, known as 'acute' or 'transient' 
hypoxia,56 may play a more important role in this tumor. However, it should be noted 
that since pimonidazole requires 20-30 min of hypoxia before it is reduced, it is not an 
optimal marker for acute hypoxia. Also, measurements of the distance from a blood 
vessel in a two-dimensional image can be misleading, because of contribution of out-
of-plane vessels to the oxygenation of the tumor section studied.  
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Quantitatively differences between C38 and C26a were found in hypoxic 
fraction (depending on the size of the C26a) and relative vascular area. C38 tumors 
showed a higher hypoxic fraction in comparison with C26a tumors with an hypoxic rim 
only, even though for the same tumor area the relative vascular area was higher and 
there was a trend to a higher fraction of perfused vessels. Apparently, the more 
extensive vascularity of C38 tumors does not result in a higher oxygenation status, 
compared with C26a tumors of the same size, probably due to inferior functioning of 
the blood vessels. The fact that in C26a tumors a larger hypoxic fraction was found in 
tumors with a larger tumor area, with a trend to a lower vascular density while the 
fraction of perfused vessels was the same, indicated that at increasing tumor size the 
growth of tumor vessels fell short in supplying sufficient oxygen, resulting in an 
increased hypoxic fraction. The consistent finding of a hypoxic rim in the C26a tumors 
and not in the C38 tumors under the same experimental conditions suggests that this 
hypoxic rim is caused by a biological difference between the C26a and C38 tumor lines 
and not by a technical artifact. The hypoxic rim in C26a tumors may be caused by 
pressure of the surrounding tissue on the small C26a tumor vessels, causing 
compression of vasculature which hinders tumor blood perfusion and leads to hypoxia. 
Indeed, perfused vessels were hardly ever observed within the hypoxic rim. It should 
be noted that the present studies were performed in subcutaneously implanted tumors. 
This is not the most optimal model for studying vascular systems of colon carcinoma 
when compared to an orthotopic transplanted site. However, since tumor blood supply 
is not only determined by supplying vessels from the body, but, in fact, predominantly 
by newly formed vessels triggered by intrinsic angiogenic factors within the tumor - as 
is demonstrated by the large and consistent differences in hypoxic profiles of the 
different tumor types C38 and C26a - modification of blood flow by vasoactive 
substances in these tumor models may help to identify basic differences in working 
mechanisms of carbogen and nicotinamide. 
Several methods are available for the determination of tumor oxygenation 
status. For example, the polarographic needle electrodes (EppendorfTM) can measure 
oxygen tension directly.57 Intravascular HbO2 saturation profiles measured 
cryospectrophotometrically provide information about the hemoglobin saturation in 
vessels containing red blood cells.58 Intrinsic markers like carbonic anhydrase 9 (CA-
IX) and glucose transporters (GLUT-1, GLUT-3) may provide qualitative data on the 
distribution of hypoxic cells.59 To determine the changes in tumor cell hypoxia in this 
study a combination of two bioreductive chemical probes was used and a recently 
developed double hypoxic marker technique was applied. With this technique, which 
involves the administration of one bioreductive marker before and one after 
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administration of treatment, each tumor serves as its own control for the analysis of 
microenvironmental parameters at a high spatial resolution.49 The higher hypoxic 
fraction estimated for pimonidazole than for CCI-103F in control tumors has been a 
consistent finding in previous experiments.49 
After administration of nicotinamide and carbogen in C38 and C26a tumors a 
decrease in hypoxic fraction was observed. In fact, a reduction in hypoxic fraction of 
this magnitude after nicotinamide alone has not been observed in experimental tumors 
before. Although both nicotinamide and carbogen were effective in reducing hypoxia in 
C38 and C26a tumors, the response to the treatment modalities differed between the 
two tumor lines, with the C38 tumor line responding best to a carbogen containing 
treatment, while the C26a showed no differences between the treatment modalities. As 
noted previously,60 the observation that even in tumors of the same site and origin 
differences in response to nicotinamide and carbogen may exist, underscores the 
importance of a pre-treatment analysis of response before applying these methods in 
the clinical setting. 
 After nicotinamide and carbogen not only a decrease in hypoxic fraction was 
observed, but also a (trend for a) decrease in proliferative activity, as measured by the 
decrease in BrdUrd labeling index. A decrease in labeling index could be caused by a 
decrease of the number of cells in S-phase or an arrest of the cells in S-phase - in both 
cases no BrdUrd is incorporated in the cells. Since BrdUrd is added at a relatively short 
time interval after start of treatment, it is unlikely that the number of cells moving out of 
S-phase into G2 in this time frame could explain the observed decline in LI. Therefore, 
an arrest of the cells in S-phase due to treatment seems more likely. In the following 
some mechanisms will be discussed which could explain the observed decreases in 
hypoxia and proliferation after nicotinamide and carbogen. 
 For nicotinamide a decrease in hypoxic fraction is usually attributed to improved 
tumor perfusion.33 However, in the current experiments no increase in perfusion was 
noticed. Although this could be due to the experimental set-up in which the perfusion 
marker Hoechst33342 was injected 20 min after administration of nicotinamide, in 
previous experiments a maximum increase in locally measured pO2 has been 
described 20 min after i.p. injection of nicotinamide.61 One would therefore also expect 
changes in perfusion to occur in this time window. However, transient fluctuations in 
microregional blood flow that can be suppressed by nicotinamide treatment62 may not 
have been detected by the current protocol. 
The decrease in hypoxia may be explained by the so-called Crabtree effect, 
which refers to a decrease in cell respiration rate after addition of glucose.63 It has been 
observed in malignant tumors, as well as non-malignant cells with a high proliferation 
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rate and/or a high glycolytic rate,64 such as spermatozoae,65 proliferating thymocytes66 
and intestinal mucosa.67 The induced decrease in cellular oxygen consumption 
consequently decreases the hypoxic fraction in tumors. In fact, it has been suggested 
that reducing oxygen consumption rate may be a more effective method to reduce 
tumor hypoxia than elevating blood flow or oxygen content.68,69 Nicotinamide is known 
to induce glycogen breakdown70,71 and an increase in blood glucose concentration has 
been observed in rats after nicotinamide in a dose of 1000 mg/kg.40 In a different 
experimental set-up, however, with a lower dose of nicotinamide (200 mg/kg) an 
increase in blood glucose after nicotinamide was not observed.72  
The trend for a decrease in proliferative activity after nicotinamide that was 
observed in C26a tumors could be caused by a direct effect of nicotinamide on 
proliferation, as has been described for hepatocytes and hepatoma cells,73,74 
insuloma75 and smooth muscle cells in vitro.76 The mechanism by which this ‘direct’ 
inhibition of proliferative activity is exerted still remains unclear. A conversion of 
metabolism from oxidative phosphorylation towards enhanced glycolysis due to the 
Crabtree effect may also explain the observed decrease in proliferative activity, since it 
is likely to increase lactate concentrations in the tumor. Overproduction of lactic acid 
can be detrimental for tumor development.77  
For carbogen an increased oxygen content of the blood28 could explain the 
observed decrease in hypoxic fraction. In near infrared spectroscopic studies in human 
glioma xenografts an increase in [O2Hb] in tumor blood was observed after carbogen 
breathing, which was not observed after 100% O2 breathing, suggesting that changes 
in oxygen tension in the tumor during carbogen breathing are mediated by the CO2 
component of carbogen.78 The decrease in hypoxic fraction may also be explained by a 
so-called vascular steal effect.79 If tumor vasculature lacks responsive smooth 
musculature and is in parallel with the host vasculature, tumor blood perfusion will be 
reduced upon carbogen breathing, due to the vasodilating effect of the CO2 component 
of carbogen on host vessels. The reduction in tumor perfusion and hence the reduction 
in supply of nutrients would reduce the O2 consumption rate of cells.78 This steal effect 
has been observed by Van der Sanden et al.78 after 5 min of carbogen breathing, using 
fast dynamic 1H-MRI measurements of Gadolinium-DTPA uptake in human glioma 
xenografts (line E49), and by Bussink et al.80 after 60 min of carbogen breathing, using 
the perfusion marker Hoechst33342 in the human laryngeal squamous cell carcinoma 
xenograft SCCNij3. However, in the human laryngeal squamous cell carcinoma 
xenograft SCCNij19 there were no changes in the perfusion fraction after carbogen 
breathing. In the current experiments after 30 min of carbogen breathing no in 
perfusion was observed, as assessed by Hoechst33342 staining.  
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In contrast with a reduction in supply of nutrients also an increase in nutrient 
(viz. glucose) supply could explain the observed decrease in hypoxic fraction, as 
discussed above. Indeed, increased blood glucose levels have been described after 
carbogen breathing.40 Richardson and Dewhirst72 found an increase in blood glucose 
levels after carbogen breathing, which was not significantly different from the increase 
observed after 100% oxygen breathing, suggesting that the increase in blood glucose 
levels after carbogen breathing is caused by the oxygen component of carbogen.  
Although treatment with nicotinamide only or carbogen only did not result in a 
significant decrease in BrdUrd labeling index in C38 tumors, from the observation that 
a significant decrease was reached after combination treatment it may be inferred that 
single treatment also has some effect on proliferation. In fact, a decrease after 
carbogen breathing has also been described by Bussink et al.80 for both the human 
laryngeal squamous cell carcinoma line SCCNij3 and SCCNij19. This decrease in 
proliferation could result from the CO2 component of carbogen, causing a decrease in 
tissue pH which leads to decreased tumor cell proliferation.81 Carbogen breathing, in 
contrast with breathing of hyperoxic hypercapnic gas mixtures with a lower percentage 
of CO2, indeed significantly decreases blood pH,82 which could lead to a decrease in 
tissue pH. Just as the decrease in hypoxic fraction after carbogen breathing, also a 
decrease in proliferation after carbogen breathing could be explained both by a 
vascular steal effect and by the Crabtree effect. In the first case the reduction in tumor 
perfusion and hence the reduction in supply of nutrients, would explain the decreased 
proliferative activity. In the second case increased lactate concentrations in the tumor 
due to increased glycolysis would decrease proliferative activity. In Morris hepatoma 
increased glucose levels after carbogen breathing were accompanied by a decrease in 
lactate production,83 suggesting the absence of a Crabtree effect. However, it should 
be noted that the magnitude of the Crabtree effect is dependent on baseline pO2 and 
that some cell lines are not susceptible to the Crabtree effect.69 Apparently, in some 
tumor lines (for example SCCNij3) a vascular steal effect is the predominant 
mechanism that could explain the observed decrease in both hypoxia and proliferation 
after carbogen breathing, whereas in other tumor lines (for example SCCNij19, C38, 
C26a) a vascular steal effect is not observed and the Crabtree effect may be a more 
appropriate explanation.  
In conclusion, in this study a decrease in hypoxic fraction in two different murine 
colon carcinoma lines was observed in response to nicotinamide, carbogen or its 
combination and a (trend for a) decrease in proliferative activity in response to 
nicotinamide and combination treatment, without changes in tumor perfusion. The 
mechanism that can explain all these observations simultaneously may be the 
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conversion of metabolism from oxidative phosphorylation towards more glycolysis due 
to increased glucose levels (Crabtree effect), although other mechanisms of actions 
cannot be excluded.  
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ABSTRACT 
For the systemic treatment of colorectal cancer 5-fluorouracil (FU)-based 
chemotherapy is standard. However, only a subset of patients responds to 
chemotherapy. Breathing of carbogen (95% O2; 5% CO2) may increase uptake of FU 
by changes in tumor physiology. The aim of this study was to monitor in vivo in animal 
models the effect of carbogen breathing on tumor blood plasma volume, pH and 
energy status, as well as the effect on FU uptake and metabolism in two colon tumor 
models that differ in their vascular structure. Phosporus-31 magnetic resonance 
spectroscopy (MRS) was used to assess tumor pH and energy status and fluorine-19 
MRS to follow FU uptake and metabolism. Advanced MR imaging methods using ultra 
small particles of iron oxide were performed to assess blood plasma volume. The 
results showed that carbogen breathing significantly decreased extracellular pH and 
increased tumor blood plasma volume and FU uptake in the tumors. These effects 
were most significant in the tumor line with the largest relative vascular area. Carbogen 
breathing also enhanced systemic toxicity by FU.  
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INTRODUCTION 
Colorectal cancer is one of the most frequently occurring cancers in the western world. 
For almost two decades 5-fluorouracil (FU) in combination with leucovorin has been 
regarded as the standard adjuvant and palliative treatment of primary colon cancer and 
advanced colorectal cancer, respectively. FU is used as a radiosensitizer in 
combination with radiation therapy of rectal cancer. Although new classes of drugs 
have become available, FU and other fluoropyrimidines remain part of the treatment of 
colorectal cancer.1 
 A critical factor in the success of systemic treatment of advanced colorectal 
cancer may be adequate drug delivery to metastases by the vascular network. Tumor 
hypoxia, which results from poor vascularization or which may even be a constitutive 
characteristic of solid tumors,2,3 contributes to drug resistance.4 Recently, it was 
demonstrated that a substantial amount of hypoxia is present in liver metastases of 
patients with colorectal cancer (cf. chapter 6). 
 Breathing carbogen, a gas mixture of 95% O2 and 5% CO2, has been shown to 
increase the uptake of anticancer drugs like ifosfamide5,6 and FU7-9 in murine solid 
tumors. Carbogen breathing may induce several physiological changes - a decrease in 
tumor hypoxia, an increase in tumor blood flow, a decrease in extracellular pH and an 
increase in tumor energy status - which may all contribute to the improved uptake of 
chemotherapeutic drugs. However, these physiological changes do not occur in all 
experimental tumor lines10 and the response to carbogen breathing may be 
heterogeneous within a tumor.11 Also, it has been hypothesized that an increase in 
tumor blood flow may in itself be insufficient for an increased uptake of FU in solid 
tumors, since not only drug delivery but also drug clearance will be increased.9 
Therefore, for carbogen to increase FU uptake a secondary mechanism may be 
necessary, apart from an increase in tumor blood flow. 
 The murine colon carcinoma lines C38 and C26a are known as well-
differentiated and poorly differentiated colon carcinoma,12 respectively, with a 
differently structured vascular network.13 Previously, it has been shown that both C38 
and C26a tumors respond to carbogen breathing by a decrease in tumor hypoxia.13 
Changes in other key physiological parameters caused by carbogen breathing, which 
may alter FU response, have not been studied in these nor in other colon tumor 
models. Therefore, the aim of this study was to monitor the effect of carbogen 
breathing on tumor blood plasma volume, pH and energy status, as well as the effect 
on FU uptake and metabolism in C38 and C26a colon tumors. Since these effects are 
monitored best in the in vivo situation phosporus-31 magnetic resonance spectroscopy 
(31P MRS) was used to assess tumor pH and energy status14 and fluorine-19 (19F) MRS 
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to follow FU uptake and metabolism.15 Advanced MR imaging (MRI) methods using 
ultra small particles of iron oxide (USPIO) were applied to study blood plasma 
volume.16 The results show that carbogen breathing can significantly increase FU 
uptake in murine colon tumors, most likely through an increase in tumor blood plasma 
volume, but that systemic toxicity is also enhanced. 
 
MATERIALS AND METHODS 
TUMORS 
The C38 and C26a murine colon tumors were acquired from Dr. G.J. Peters of the Vrije 
Universiteit (Amsterdam, the Netherlands). Viable C38 and C26a tumor tissue 
fragments with a diameter of 1-3 mm were implanted subcutaneously in the right flank 
of C57BL/6 and BalbC mice, respectively. The vascular structure and hypoxic profile of 
three untreated C38 and C26a tumors were studied by immunofluorescent staining 
after intravenous injection of the perfusion marker Hoechst33342 and the hypoxic 
marker CCI-103F, as described previously.13 Animals were kept according to 
institutional guidelines for animal care. Experiments were performed when tumors had 
reached a diameter of approximately 10 mm. All experiments were approved by the 
institutional ethical committee for animal use. 
 
HARDWARE FOR MR EXAMINATIONS 
All MR experiments were performed on a S.M.I.S. 7 T horizontal bore animal system. A 
homemade 31P/19F double tuned 10 mm surface RF coil, also tunable to 1H, was used 
as a transmitter/receiver.17 After mice were anesthetized with isoflurane (1.5-2%), 
oxygen (30%) and nitrous oxide (68%) the tumor was positioned in the centre of the 
coil. During the measurements, the body temperature was monitored with a rectal 
fluoroptic probe (Luxtron 712, Luxtron Corporation, California, USA) and maintained at 
constant body temperature with a warm water pad.  
 
31P/19F MR MEASUREMENTS 
An unlocalized 31P/19F interleaved pulse-acquire sequence with a 90° rectangular RF 
pulse of 20 µs was used in all experiments. Each 31P scan was alternated with six 19F 
scans. The repetition time (TR) for 31P MR acquisition was three seconds and for 19F 
430 ms, with a total measurement time of 4 min. In total 31 sequential measurements 
were performed.  
As a marker of extracellular pH 3-aminopropylphosphonate (3-APP, Sigma-
Aldrich, Zwijndrecht, the Netherlands) was injected intraperitoneally (i.p.) via a catheter 
CHAPTER 4 
 
  115
approximately 10 min before start of carbogen breathing (figure 1A). In ten mice with a 
C38 tumor and 12 mice with a C26a tumor the breathing gas was switched to carbogen 
5 min before start of the 31P/19F MRS measurements and continued with carbogen 
during 28 min, i.e. during the first seven measurements. Then FU (Teva, Mijdrecht, the 
Netherlands) was administered (150 mg/kg) i.p. within ten seconds before start of the 
first 31P/19F MRS measurement. Twelve mice with a C38 tumor and ten mice with a 
C26a tumor did not undergo carbogen breathing and served as a control.  
MR data were processed using jMRUI version 2.0.18 The intracellular and 
extracellular pH were calculated using the chemical shift difference between inorganic 
phosphate (Pi) and phosphocreatine (PCr) and between 3-APP and PCr, 
respectively.19 The energy status of the tumor at each time point was represented by 
the ratio of β-nucleoside triphosphate (βNTP) over Pi signal (βNTP/Pi). Using 
Graphpad Prism (version 4) quantitative changes in integrals of FU resonances were 
fitted to a biexponential equation for each mouse, according to: Y = CFU · {[1-exp(-
0.693x/tuptake)] · exp[-0.693x/t½]}, in which CFU refers to the maximum concentration 
(a.u.) of FU, tuptake to the time (min) to 50% of maximum FU resonance amplitude in the 
tumor, t½ to the half life (min) of FU in the tumor and x to the measurement time (min). 
If the data fitting to this equation would not converge, a monoexponential equation was 
used, according to: Y = C · exp(-0.693x/t½). Quantitative changes in the resonances of 
the anabolites, which are the active metabolites of FU, and of the catabolites α-fluoro-
β-ureidopropionic acid (FUPA) and α-fluoro-β-alanine (FBAL) were fitted to a 
monoexponential equation, according to: Y = Canab, FUPA, FBAL · {1-exp[-(0.693/tuptake) · (x-
B)]}, in which Canab, FUPA, FBAL refers to the maximum concentration (a.u.) of anabolites, 
FUPA or FBAL and B to the time interval (min) between start of the measurement and 
appearance of resonances of anabolites, FUPA or FBAL. 19F MRS data of individual 
mice were included for further calculations and comparisons if R2 of the fit was ≥ 0.8. 
 
MRI MEASUREMENTS 
As a measure of relative blood plasma volume, quantitative measurements of the 
changes in T1 relaxation rate of water proton spins were used, after administration of a 
contrast agent which consisted of ultra small superparamagnetic particles of iron oxide 
(USPIO).16,20 
After three gradient echo scout MR images for anatomical localization of the 
tumor, high resolution multislice gradient echo images were acquired to identify one 
slice of interest through the centre of the tumor. Inversion recovery snapshot fast low-
angle shot (IR-FLASH) was performed to measure the water T1 relaxation time (image 
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matrix size 64 x 64, field of view (FoV) 3 cm x 3 cm, slice thickness (SLT) 1.6 mm, TR 
5 ms, echo time (TE) 2.7 ms, inversion times (TI) 52 + n*320 ms, where n = 0,1,2,…15. 
T1 relaxation times were measured during 1 h after administration of USPIO at five time 
points (figure 1B). The USPIO blood-pool contrast agent sinerem (Guerbet, France 
150 µmol Fe/Kg) was injected intravenously (i.v.) via a catheter inserted in the tail vein 
in all mice. In six mice with a C38 tumor and six mice with a C26a tumor carbogen 
breathing was started 13 min after injection of sinerem, during 30 min. Three mice with 
a C38 tumor and four mice with a C26a tumor did not undergo carbogen breathing and 
served as a control. 
 The Levenberg Marquardt non-linear least squares algorithm was used to 
analyze the T1 data. The algorithm was implemented in MatLab (Mathworks, Natick, 
MA, USA). For each tumor, pixel-by-pixel maps of the apparent T1 (T1*) were generated 
from a three-parameter fit of the image intensities according to the equation S = A + B 
exp(-nTI/T1*). The value of the corrected T1 was calculated from the formula: T1 = 
T1*(B/A –1)). For each tumor, R1 (R1 = 1/ T1) maps were obtained at all time points. 
From each map, the mean R1 was calculated by drawing a region of interest (ROI) - 
which included the whole tumor - on the R1 map and averaging the values of all pixels. 
The values of the mean R1 at all time points were normalized to the value of the first 
time point. The mean R1 relaxation rate in the controls was then compared with the 
mean R1 in the treated tumors, at each time point.  
 
TUMOR GROWTH AND FU TOXICITY 
Separate groups of mice were followed for tumor volume after treatment with FU as a 
single treatment or combined with carbogen breathing, using caliper measurements 
(control C38: n = 6; control C26: n = 8; carbogen C38: n = 7; carbogen C26a: n = 8 ). 
To each group four to five mice were added to monitor systemic toxicity. Carbogen 
breathing was started 5 min before i.p. administration of FU (150 mg/kg) and continued 
for 25 min after FU injection. Since several mice which underwent carbogen breathing 
were found to be severely ill after approximately ten days, pathological analysis was 
performed on paraffin embedded biopsies of heart, lungs, intestine, muscle, kidney, 
spleen, pancreas and long bone, using H&E staining of the material. The experiment 
was repeated at a dose of 100 mg/kg FU (controls: n = 5 for C38 and n = 8 for C26a; 
carbogen breathing: n = 5 for C38 and n = 8 for C26a). Tumor volumes were 
normalized to one at the day of treatment (day 0). 
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Figure 1  Experimental design of MRS (A) and MRI (B) experiments.  
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Figure 2  Binary image of complete tumor sections of C38 (A) and C26a (B) colon tumor showing the 
pattern of vascular architecture, perfused vessels and hypoxic profile. Vascular structures: red-
pink; perfused vessels: blue-purple; hypoxic areas: green (100x magnification). The scale bar 
indicates 1 mm.  
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RESULTS 
TUMORS 
Figure 2 illustrates the difference in vascular structure and distribution of hypoxia in 
C38 and C26a tumors. C38 tumors are well-organized tumors with cells in a glandular 
pattern, surrounded by blood vessels. Blood vessels are relatively large and hypoxic 
cells are located at a rather constant distance from the vasculature. In contrast, C26a 
tumors consist of densely packed tumor cells without a clear organization of the 
stroma. The blood vessels in C26a tumors are small compared with C38 tumors. Apart 
from a hypoxic rim due to pressure from the skin on the small vessels, hypoxia is 
mostly centrally located.  
 
31P MRS MEASUREMENTS  
To monitor changes in pH and energy status during and after carbogen breathing 31P 
MRS was performed on C38 and C26a tumors. A typical 31P MR spectrum from a C26a 
tumor is shown in figure 3. The intracellular pH (pHi) and extracellular pH (pHe) were 
calculated from the chemical shift difference between the resonances of Pi and PCr 
and between 3-APP and PCr, respectively. The energy status of the tumors was 
assessed by βNTP/Pi. Table 1 summarizes the mean values of pH and energy status 
throughout the measurement in the control groups of the C38 and C26a tumors. A 
higher pHi and pHe was found in C38 tumors compared to C26a, but a lower delta pH 
(∆pH = pHe - pHi). In both tumor lines ∆pH was positive. The energy status βNTP/Pi of 
C38 tumors was more than one and a half times higher than that of C26a tumors. 
The pH and energy status of C38 and C26a tumors during two hours after 
injection of FU as a single treatment or combined with carbogen breathing is shown in 
figure 4. Both in C38 and C26a tumors pHi remained constant throughout the 
measurement. In contrast, pHe decreased significantly in C38 tumors 15 min after start 
of carbogen breathing compared with the control group and remained significantly 
lower during 32 min. In C26a tumors a similar but less pronounced pattern was 
observed. In C38 tumors the decrease in pHe was large enough to result in a decrease 
in ∆pH. The energy status of both tumor lines as assessed from the ratio βNTP/Pi 
remained constant throughout the experiment. 
 
19F MRS MEASUREMENTS 
19F MRS was used to monitor the uptake and metabolism of FU in C38 and C26a 
tumors. Figure 5 shows a typical 19F MR spectrum from a C26a tumor. In most of the 
tumors not only a  resonance  of  FU,  but also resonances of the anabolites and of  the  
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ppm 
Figure 3  31P MR spectrum of a C26a tumor. Resonances of 3-APP as a marker of extracellular pH, 
phosphomonoesters (PME), inorganic phosphate (Pi), phosphodiesters (PDE), phosphocreatine 
(PCr) and high energy phosphates (NTP) are shown. The acquisition started 12 min after 
injection of FU. No carbogen breathing was applied. 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 1  pH and energy status of C38 and C26a tumors. Mean pH and energy status ± standard error of 
the mean are shown for of C38 and C26a tumors from the control groups. *** indicates 
statistically significant differences between C38 and C26a tumors (p < .001).  
 
catabolite FUPA were detected. A resonance of FBAL was present in a minority of 
tumors. Due to movement artifacts in two tumors from the C26a groups, two tumors 
from the C38 control group and one tumor from the C38 carbogen breathing group the 
changes in 19F MR resonance integrals could not be fitted to a monoexponential or 
biexponential equation with an R2 of the fit ≥ 0.80. The data of these tumors were 
excluded from the analysis. Since in most mice the signal-to-noise ratio (SNR) of the 
resonances of the anabolites and of the catabolite FBAL was too low to provide an 
adequate fit to a monoexponential or biexponential equation, further analyses were 
performed on pharmacokinetics of FU and FUPA. 
The uptake and clearance of FU in C38 and C26a tumors is shown in figure 6. 
C38 tumors had a significantly larger amount of FU and faster uptake of FU compared 
to C26a tumors (table 2). The half life of FU in C38 tumors was significantly longer than 
in C26a tumors and the total amount of FU that was present in C38 tumors (as measured 
by  the  average  resonance  integral  of  FU)  was higher.  After carbogen breathing CFU 
 pHi pHe ∆pH βNTP/Pi 
C38 7.05 ± 0.0030 *** 7.22 ± 0.0030 *** 0.18 ± 0.0039 *** 2.20 ± 0.018 *** 
C26a 6.89 ± 0.0041 7.11 ± 0.0029 0.22 ± 0.0036 1.33 ± 0.020  
3-APP
PCr
βNTP αNTP  γNTP  
PDE  
Pi 
PME  
30 20 10 0 -10 -20 
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Figure 4  Intracellular pH (pHi), extracellular pH (pHe), delta pH (pHe - pHi) and energy status (beta 
NTP/Pi) for C38 (left) and C26a (right) tumors of the control and carbogen breathing groups. 
The error bar indicates the standard error of the mean. A significant difference between control 
and carbogen breathing group is indicated by * p < .05; ^ p < .01; ♦ p < .001. Carbogen 
breathing is started at t = -5 min and terminated at t = 28 min; FU is injected at t = 0. 
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* * * * * * *  
* * 
control 
carbogen 
CHAPTER 4 
 
  122
ppm 
Figure 5  19F MR spectrum of a C26a tumor. Resonances of anabolites, FU and the catabolites FUPA 
and FBAL are shown. The acquisition of this spectrum started 60 min after injection of FU at t = 
0. Carbogen breathing was applied from t = -5 to t = 28 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6  FU uptake in and clearance from all C38 and C26a tumors of the control and carbogen 
breathing groups. The error bar indicates the standard error of the mean. * indicates a 
significant difference (p < .05 ) between control and carbogen breathing group. 
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Table 2  Pharmacokinetics of FU in C38 and C26a tumors. Mean of maximum concentration of FU (CFU), 
doubling time of FU resonance integral increase in the tumor (tuptake), half life of FU in the tumor 
(t½) and the average of all resonance integrals (average FU resonance integral) ± standard error 
of the mean are shown for C38 and C26a tumors. Values are calculated from a fit of the mean 
resonance integral of all mice per group to a biexponential equation (see Materials & Methods). 
1 p < .0001 compared with the C26a control group; 2 p < .001 compared with the C38 control 
group; 3 p < .05 compared with the C26a control group; 4 p < .01 compared with the C26a 
control group; 5 p < .01 compared with the C26a control group; 6 p < .0001 compared with the 
C26a control group; 7 p < .001 compared with the C38 control group. 
 
 
Figure 7  FUPA uptake in all C38 (A) and C26a (B) tumors of the control and carbogen breathing groups. 
The error bar indicates the standard error of the mean.  
 
 
 
 
 
 
 
 
 CFU (a.u.) tuptake (min) t½ (min) average of all measured 
FU resonance integrals 
in time (a.u.) 
C38 control 
(n = 10) 
1603 ± 96.91 
 
0.94 ± 0.353 
 
72.99 ± 8.695 929.0 ± 55.36 
C38 carbogen 
(n = 9) 
2223 ± 85.52 
 
0.71 ± 0.20 
 
65.16 ± 4.63 1223 ± 82.27 
C26a control 
(n = 7) 
581.2 ± 37.6 
 
2.30 ± 0.48 
 
33.17 ± 2.56 192.9 ± 23.6 
 
C26a carbogen 
(n = 10) 
665.3 ± 31.3 
 
0.54 ± 0.224 
 
33.00 ± 2.12 231.6 ± 31.2 
C26a 
control 
carbogen 
control 
carbogen 
C38 
A B 
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increased in both tumor lines, but the increase was significant for C38 tumors only. In 
both tumor lines tuptake decreased - i.e. FU was taken up faster - which was significant 
for the C26a tumors. A significant decrease in t½ was observed in C38 tumors - i.e. FU 
was eliminated from the tumors more quickly. In both tumor lines the average of all 
measured resonance integrals in time increased upon carbogen breathing, which was 
significant for the C38 tumors.  
The appearance of FUPA in C38 and C26a tumors was also monitored (figure 
7). In C38 tumors the resonance integral of FUPA increased throughout the 
measurement period, whereas in C26a tumors a plateau was reached. The average of 
all measured resonance integrals in time of FUPA was significantly higher in C38 
tumors (table 3). However, the average resonance integral of FUPA in C38 tumors 
divided by the average resonance integral of FU was significantly lower compared to 
C26a tumors. After carbogen breathing the average resonance integral of FUPA 
divided by the average resonance integral of FU significantly decreased in C38 tumors 
compared with control tumors.  
 
MRI MEASUREMENTS 
To assess the changes in blood plasma volume the relaxation rate R1 was determined 
for each tumor at five different time points. In figure 8 the fractional change in relaxation 
rate R1 is shown before, during and after carbogen breathing for the C38 and C26a 
tumors. In both tumor lines a significant increase in R1 was observed during carbogen 
breathing, which corresponds to an increase in tumor blood plasma volume. The 
fractional increase in relative tumor blood plasma volume during carbogen breathing 
was larger in C38 than in C26a tumors, which was statistically significant when taking 
the two time points during carbogen breathing together (p = .03). After terminating 
carbogen breathing R1 quickly returned to control values in C38 tumors, whereas in 
C26a tumors R1 remained significantly higher compared to the control group. 
 
TUMOR GROWTH AND FU TOXICITY 
To determine whether carbogen breathing increased FU efficacy the growth of C38 and 
C26a tumors was measured after FU (150 mg/kg) as a single agent or in combination 
with carbogen breathing. However, approximately ten days after the start of treatment 
several mice in the groups which received carbogen breathing had already died or 
were severely ill - as indicated by hair loss, shivering and loss of mobility - and the mice 
were sacrificed because of bioethical reasons. Mortality at 13 days was significantly 
higher after carbogen breathing combined with FU compared to FU only (figure 9).  
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Table 3  Uptake of FUPA in C38 and C26a tumors. Mean of the total FUPA resonance amplitude and 
mean of the total FUPA resonance amplitude divided by the total FU resonance amplitude ± 
standard error of the mean are shown for of C38 and C26a tumors. 1  p < .001 compared with 
the C26a control group; 2  p < .001 compared with the C26a carbogen group; 3 p < .05 
compared with the C26a control group; 4 p < .01 compared with the C26a carbogen group; 5 p < 
.0001 compared with the C38 carbogen group.  
  
 
Figure 8  Fractional change in the longitudinal relaxation rate R1 for C38 and C26a tumors 3 min before 
start carbogen breathing, during carbogen breathing and after terminating carbogen breathing.  
* indicates a significant difference (p < .05 ) between control and carbogen breathing group;     
** indicates a significant difference (p < .01) between control and carbogen breathing group;      
¤ indicates a significant difference (p < .01 ) between C38 and C26a tumors. The error bars 
indicate the standard error of the mean.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 mean of all measured FUPA 
resonance integrals in time (a.u.) 
mean of the total FUPA resonance 
amplitude divided by the total FU 
resonance amplitude 
C38 control 
(n = 5) 
 306.2 ± 36.01 
 
 1.1 ± 0.23 
C38 carbogen 
(n = 5) 
 278.2 ± 33.82 
 
    0.3 ± 0.14,5 
C26a control 
(n = 4) 
154.6 ± 16.7 
 
3.3 ± 0.8 
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(n = 8) 
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Figure 9  13-day survival of C57BL/6 (A) and a BalbC mice (B) after FU (150 mg/kg) as a single treatment 
or in combination with carbogen breathing. Day 0 is the day of treatment. * indicates a 
significant difference (p < .05 ) between control and carbogen breathing group; ** indicates a 
significant difference (p < .01) between control and carbogen breathing group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adequate comparison of growth curves from carbogen breathing and control 
groups was not possible due to mortality in the carbogen breathing group before tumor 
doubling time was reached. After decreasing the FU dose to 100 mg/kg toxicity was 
absent in both groups. At this reduced dose no difference in tumor growth was 
observed between the two groups. 
 Pathological analysis of biopsies of heart muscle of mice which were ill, showed 
increased hypercontraction and eosinophily of muscle fibers indicative of acute 
ischemic infarction. In the bone marrow of long bones of diseased mice a marked 
increase in megakaryocytes, which were also considerably variable in size, was 
observed compared with healthy mice. This may be considered as a sign of 
thrombocythemia. The lungs, intestine, muscle, kidney, spleen and pancreas did not 
show abnormalities, except for pulmonary edema in one mouse. 
A 
control 
carbogen 
control 
carbogen 
B 
** 
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DISCUSSION 
The key observation of this study was that carbogen breathing had significant but 
different effects on the physiology and FU uptake of two murine colon carcinoma lines. 
However, carbogen breathing also enhanced systemic toxicity of FU.  
 A consistent effect of carbogen breathing on tumor physiology in different 
experimental tumor lines is a decrease in tumor hypoxia,9,10,13,21,22 although the 
magnitude of this effect varied in different tumor lines.11,23 As tumor hypoxia may 
contribute to drug resistance,4 carbogen breathing could improve the efficacy of 
chemotherapy. The classical explanation for a decrease in tumor hypoxia by carbogen 
breathing is an increase in oxygen transport by the blood plasma.24 However, several 
other changes in tumor physiology have been described after carbogen breathing, such 
as changes in (blood) pH, energy status and blood flow. These changes may not only 
have an impact on tumor hypoxia, but may also directly influence uptake and 
metabolism of chemotherapeutic agents. 
 
PH 
In this study a decrease in extracellular pH was observed in C38 and C26a tumors due 
to carbogen breathing. A similar effect has been described in, for example, RIF-1 
tumors,8 GH3 xenografts9 and hepatomas.25 In C38 tumors the decrease in 
extracellular pH resulted in a decrease in ∆pH. Previously, it has been shown that 
uptake of FU in isolated tumor cells may be pH dependent14,26 and a decrease in ∆pH 
has been associated with an increased half life of FU in subcutaneous tumors.27 Like in 
other tumors,28 ∆pH was negative in those experiments - i.e. the extracellular 
microenvironment was more acidic than the intracellular space. This negative ∆pH 
could result in co-transport of FU with protons into the cell.26 However, in C38 and 
C26a tumors ∆pH was positive and even after carbogen breathing ∆pH did not 
decrease below zero. Therefore, the change in extracellular pH may not have been 
sufficient to affect FU retention in these tumors. In fact, no increase in FU half life was 
observed after carbogen breathing. 
 
ENERGY STATUS 
The pre-treatment energy status (NTP/Pi) of chemically induced primary rat mammary 
tumors has been shown to be a predictor for tumor response.29,30 It has been 
hypothesized that an elevated energy status may reflect a well-vascularized tumor 
which has more capacity for energy-dependent FU uptake and anabolism.29 In this 
study a large difference in energy status was observed between C38 and C26a tumors 
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which corresponds well to the difference in relative blood plasma volume16 and relative 
vascular area13 in these tumor lines, as well as the difference in chemotherapy 
sensitivity.12  
In subcutaneous hepatomas an increase in NTP/Pi has been observed during 
carbogen breathing, whereas energy status in GH3 xenografts remained constant.9 For 
human gliomas implanted subcutaneously in mice a decrease in energy status upon 
carbogen breathing has been observed,10 which was likely due to the so-called steal-
effect (as described by Jirtle,31 see below). In subcutaneous C38 and C26a tumors no 
difference in energy status between the control and carbogen breathing groups was 
observed. 
 
BLOOD PLASMA VOLUME 
In C38 tumors a larger blood plasma volume16 and relative vascular area has been 
observed13 compared to C26a tumors. This could explain the higher maximum 
concentration of FU and the higher average resonance integral of FU and FUPA in C38 
tumors. The higher maximum concentration and average resonance integral of FU in 
C38 tumors, as well as the longer half life of FU, may contribute to the higher 
chemosensitivity of C38 tumors compared to C26a tumors which has been described 
before.12 
The effects of carbogen on tumor vasculature are usually measured in terms of 
tumor blood flow and/or vascular diameter. O2 has been shown to have a 
vasoconstrictive effect on both immature and mature tumor vessels.32 In theory the CO2 
component of carbogen (95% O2, 5% CO2) may overcome the vasoconstrictive effects 
of O2. However, in this respect variable effects of carbogen breathing have been 
reported. In subcutaneously or intramuscularly implanted R3230Ac tumors carbogen 
had no consistent effect on tumor blood flow measured by Doppler flowmetry.23 In 
another study with the same tumor model carbogen breathing resulted in a transient 
reduction in tumor arteriolar diameter measured by intravital microscopy and a 
reduction in tumor blood flow measured by Doppler flowmetry.33 In subcutaneous 
human glioblastomas a decrease in tumor blood flow after carbogen breathing was 
observed by fast dynamic 1H-MR imaging of Gd-DTPA uptake,10 possibly due to a steal 
effect.31 The steal effect refers to a situation where tumor vasculature lacks responsive 
smooth musculature and is in parallel with the host vasculature. Tumor blood perfusion 
could then be reduced during carbogen breathing due to a vasodilating effect of the 
CO2 component of carbogen on host vessels. In this study tumor blood plasma volume 
was assessed using MR methods with ultra small particles of iron oxide as a contrast 
agent. In both C38 and C26a tumors a significant increase was observed in the 
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relaxation rate R1 which is proportional to an increase in relative tumor blood plasma 
volume. Therefore, these results suggest a vasodilating effect of carbogen breathing 
rather than a vasoconstrictive or steal effect in C38 and C26a tumors. This is the first 
study showing an increased relative tumor blood plasma volume after carbogen 
breathing using this MR approach. The advantage of this technique, in contrast with 
measurements of vascular diameter, is that it could not only be applied in 
subcutaneous (window chamber) models, but also in orthotopic models. Moreover, the 
interpretation of the data is more straight forward than, for example, for blood 
oxygenation dependent (BOLD) MRI measurements which reflect a combination of 
blood oxygenation, flow and volume responses.34 
Since MRI techniques using blood pool agents measure the volume of plasma 
perfused vessels and are not sensitive to hematocrit, i.e. potential oxygen carrying 
erythrocytes, they may overestimate oxygen delivery.34 For delivery of chemotherapy 
plasma perfused vascular volume rather than vascular volume occupied by 
erythrocytes is of primary importance, although tumor hypoxia may be related to 
chemotherapy resistance.35 The observed increase in relative tumor blood plasma 
volume after carbogen breathing implies that the vascular surface area in the tumor is 
increased which could lead to an improved tumor uptake of FU. In both C38 and C26a 
tumors CFU and the average of all measured FU resonance integrals in time were 
increased in the carbogen breathing group compared to the control group, although this 
was significant for C38 tumors only. In fact, the blood plasma volume response to 
carbogen breathing was also larger in C38 than in C26a tumors. Previously, similar 19F 
MRS results were reported for C38 tumors when carbogen breathing was initiated 1 
min before and maintained 8.5 min after FU (150 mg/kg) bolus injection.7 In that study 
increased levels of FU were found, as well as increased levels of anabolites and 
catabolites, without enhanced FU retention in the tumor. In the present study, after 
terminating carbogen breathing the relative blood plasma volume in C38 tumors 
returned to control values more quickly than in C26a tumors. This indicates a difference 
in responsive tumor vasculature in C38 and C26a tumors. In fact, on a microscopic 
level the tumor vasculature of C38 and C26a tumors is rather different: C38 tumors 
mainly show large vessels in a corded structure, whereas in C26a the tumor 
vasculature consists of smaller vessels.13  
 
TUMOR GROWTH AND TOXICITY 
Although the effects of carbogen breathing on tumor physiology and FU 
pharmacokinetics are stronger in C38 than in C26a tumors, the direction of the 
changes in both tumor lines favor an increased efficacy of FU when combined with 
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carbogen breathing. Unfortunately, at the dose of FU used in the MRS experiments 
(150 mg/kg), enhanced toxicity and early deaths were observed in the group which 
underwent carbogen breathing. Consequently, tumor growth curves at this dose were 
inconclusive. After decreasing the dose of FU to 100 mg/kg no difference in tumor 
growth was observed between the carbogen and control groups. Apparently, at a lower 
dose of FU the physiological changes induced by carbogen breathing, if any, were 
insufficient to increase FU efficacy.  
 This is the first report of carbogen induced toxicity in combination with FU 
therapy. In patients cardiac toxicity has been observed after high dose continuous 
infusion of FU36 and megakaryocytosis is a well-described effect of FU on the bone 
marrow.37 Thus, the pathological anatomical observations in this experiment (ischemic 
necrosis of the heart muscle, cardiac failure and thrombocytosis) may be related to FU 
induced systemic toxicity and high levels of catabolites have been associated with 
cardiotoxicity.38-40 In this study no increase in catabolite levels in the group of mice 
which underwent carbogen breathing was observed. However, since catabolites are 
mainly produced in the liver and are taken up in the tumor via the blood circulation,41-44 
the level of catabolites in the tumor is not necessarily correlated with catabolite levels in 
other organs, like heart muscle. 
In previous studies no toxicity has been described after the combination of FU 
treatment with carbogen breathing. In fact, Griffiths et al.45 showed that there were no 
significant effects of carbogen breathing on the levels of FU and its metabolites in 
normal rat tissues, nor on the histology of the tissues. In that study FU was 
administered at a dose of 50 mg/kg and carbogen was applied for 10 min. Not only the 
administered dose of FU, but also the duration of carbogen breathing may be crucial 
for the occurrence of systemic toxicity. In a recent study, increased clearance of FU 
from the plasma was observed after 30 min of carbogen breathing compared to 20 min 
of carbogen breathing.9 If this increased clearance of FU is caused by an increased 
uptake of FU in vital organs like heart muscle, this may well explain the observed 
toxicity. 
 
In conclusion, these results show that even within one tumor type, namely colon 
carcinoma, the effect of carbogen breathing on tumor physiology and FU uptake and 
metabolism differs, which may be caused by differences in tumor vasculature. For 
clinical applications this underscores the importance of an early analysis of response to 
carbogen breathing (for example by 19F MRS) in individual patients. In the murine 
models C38 and C26a an increase in FU uptake in the tumors was observed after 
carbogen breathing, but systemic toxicity was also enhanced. Thus, a clinical study 
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evaluating the effect of carbogen breathing on FU efficacy should be preceded by a 
phase I trial monitoring the effect of carbogen breathing on FU toxicity. 
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ABSTRACT  
There is increasing evidence that modulation of tumor hypoxia may improve therapy 
outcome. However, most of the pre-clinical data are derived from subcutaneous rather 
than orthotopic tumor models. This study investigated the effect of the hypoxia 
modulating agents nicotinamide and carbogen on tumor hypoxia, tumor blood perfusion 
and proliferative activity in liver metastases of the murine colon carcinoma line C26a. In 
untreated C26a liver metastases a considerable amount of hypoxia was observed, 
similar to the amount of hypoxia in liver metastases of patients with colorectal cancer. 
The hypoxic fraction in the liver metastases of mice treated with nicotinamide and 
carbogen breathing as single treatments or in combination was significantly smaller 
compared to untreated mice. In the group of mice which underwent carbogen breathing 
a significantly lower perfusion was observed compared to the untreated group, but the 
decrease was only marginal The proliferative activity was similar in all groups. 
Recently, in subcutaneous C26a tumors a similar effect on hypoxia has been observed, 
which, however, was combined with a decrease in proliferative activity. The different 
effects of nicotinamide and carbogen on parameters of the tumor microenvironment in 
liver metastases and subcutaneous tumors suggest that the host tissue influences the 
mechanism by which nicotinamide and carbogen exert their effects. Since tumor 
hypoxia may be a clinical problem in colorectal liver metastases, these results open 
possibilities for further research on the effect of hypoxic modifiers on colorectal liver 
metastases in order to improve therapy outcome. 
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INTRODUCTION 
It is well-known that tumor hypoxia may decrease the efficacy of both radiotherapy and 
chemotherapy1 and there is growing evidence that modulation of tumor hypoxia may 
improve treatment outcome.2 Pre-clinical studies on modulation of tumor hypoxia and 
other parameters of the tumor microenvironment, like vascularization, perfusion and 
proliferative activity, have been performed mostly on subcutaneous tumors. However, 
several studies, particularly on angiogenesis, have shown that the characteristics of the 
host tissue may influence the tumor microenvironment.3 Therefore, modulation of the 
microenvironment by nicotinamide and carbogen may have different effects in 
subcutaneous tumors and at metastatic sites. Recently, it was shown that tumor 
hypoxia in subcutaneous murine colon carcinomas can be modified by administration 
of nicotinamide and/or breathing of carbogen.4 The liver is the most common site for 
metastases of colorectal cancer and extensive hypoxia is present in these colorectal 
liver metastases (cf. chapter 6). Modulation of the tumor microenvironment of liver 
metastases may therefore have important clinical consequences. To assess the 
prospects of modulating the tumor microenvironment this study investigated the effect 
of nicotinamide and carbogen in liver metastases of a murine colon carcinoma line.  
 
MATERIALS AND METHODS 
MURINE LIVER METASTASIS MODEL 
C26a cells were acquired from Dr. G.J. Peters of the Vrije Universiteit (Amsterdam, the 
Netherlands) and grown in Dulbecco’s Modified Eagle Media (D-MEM) with 10%  fetal 
calf sera (FCS). 100.000 cells were injected in the spleen of female BalbC mice and 
after one day the spleen was removed to avoid local tumor growth. Animals were kept 
according to institutional guidelines for animal care. Experiments were performed 15 
days after injection of the cells. Pilot experiments had shown that at that time multiple 
metastases had developed in the liver. All experiments were approved by the 
institutional ethical committee for animal use. 
 
NICOTINAMIDE AND CARBOGEN  
Nicotinamide (Sigma-Aldrich, Zwijndrecht, the Netherlands) (20 mg/ml) was injected 
intra-peritoneally (i.p.) at a concentration of 500 mg/kg. For carbogen (95% O2, 5% 
CO2, Hoek Loos, Schiedam, the Netherlands) breathing, the mice were put in a 
perspex box with a continuous carbogen flow of 5 l/min. Nicotinamide was 
administered 20 min before the start of carbogen breathing. Carbogen breathing 
continued for 30 min before killing the animals. The mice were treated with 
nicotinamide alone (n = 4), carbogen alone (n = 5) or the combination of both (n = 5). 
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The effects on tumor hypoxia, perfusion and proliferation were analyzed and compared 
with a control group of animals kept under normal air breathing (n = 4).  
 
MARKERS OF HYPOXIA, PERFUSION AND PROLIFERATION  
Pimonidazole (1-((2-hydroxy-3-piperidinyl)propyl)-2-nitroimidazole hydrochloride, Natural 
Pharmacia International, Belmont, USA),5-7 which is a bioreductive chemical probe with 
an immuno-recognizable side chain, was used as a marker of hypoxia. Pimonidazole 
(20 mg/ml) was combined with the perfusion marker Hoechst33342 (Serva, Heidelberg, 
Germany) (3.75 mg/ml) and 0.1 ml of this solution was injected intravenously in the tail 
vein of each mouse. As a marker of proliferation the S-phase marker 
bromodeoxyuridine (BrdUrd) (Sigma-Aldrich, Zwijndrecht, the Netherlands) (2.5 mg/ml) 
was injected i.p. at a dose of 0.5 ml. Pimonidazole/Hoechst33342 and BrdUrd were 
injected 25 min before the animals were sacrificed by cervical dislocation. This time 
point was chosen because for nicotinamide a maximum effect on the blood perfusion 
pO2 has been described 20 min after i.p. injection of nicotinamide8 and for carbogen 
the maximum effect has been observed after 5 min of carbogen breathing.9 Livers were 
removed immediately, cut in fragments of approximately 6 mm and stored in liquid 
nitrogen. Frozen sections 5 µm thick were cut for staining and further analysis. 
 
IMMUNOHISTOCHEMICAL STAINING OF MURINE LIVER METASTASES 
After thawing, the sections were fixed in cold (4 °C) acetone for 10 min. Then slides 
were scanned (see below) for the Hoechst33342 signal before immunohistochemical 
staining of the other markers. After scanning of the Hoechst33342 signal and between 
all consecutive steps of the staining procedure sections were rinsed three times for 2 
min in PBS. Sections stained for pimonidazole were mounted in fluorostab (Organon, 
Boxtel, the Netherlands) and the sections stained for BrdUrd were mounted in 
phosphate buffered saline (PBS). The first tissue section was stained for endothelium 
plus the hypoxic marker pimonidazole. The second consecutive tissue section was 
stained for endothelium and the S-phase marker BrdUrd. 
 
Endothelial structures and pimonidazole  
After rehydration for 20 min in PBS, sections were incubated with rabbit-anti-
pimonidazole (J.A. Raleigh), diluted 1:800 in polyclonal liquid diluent (PLD, Euro-DPC, 
Breda, the Netherlands), during 45 min at 37 °C. After incubation with donkey-anti-
rabbitF(ab’)2-Alexa488 (Molecular Probes, Leiden, the Netherlands), diluted 1:400 in 
PLD during 45 min at 37 °C, sections were incubated with undiluted 9F1, a rat 
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monoclonal to mouse endothelium, during 60 min at room temperature (Department of 
Pathology, Radboud University Nijmegen Medical Center, the Netherlands10). Finally, 
sections were incubated for 30 min at 37 °C with chicken-anti-rat-Alexa647 (Molecular 
Probes) diluted 1:200 in PLD.  
 
Endothelial structures and BrdUrd  
DNA was denatured by incubation for 10 min at room temperature in 2 M hydrochloric 
acid. pH was neutralized by rinsing the sections for 10 min in 0.1 M borax. Next, 
sections were incubated for 60 min at 37 °C with sheep-anti-BrdUrd (Abcam Ltd, 
Cambridge, UK) diluted 1:50 in PLD overnight at 4 °C. Then, sections were incubated 
with donkey-anti-sheep-Cy3 (Jackson Immuno Research Laboratories), diluted 1:400 in 
PLD for 30 min at 37 °C. After incubation with 9F1 during for 60 min at room 
temperature, sections were incubated 30 min at 37 °C with chicken-anti-rat-Alexa647 
(Molecular Probes) diluted 1:200 in PLD. Finally, sections were incubated with fast blue 
(Sigma-Aldrich), diluted 1:1000 in PBS during 5 min at room temperature. 
 
Image analysis  
To analyze tumor hypoxia, perfusion and proliferation quantitatively a semiautomatic 
method based on a computerized digital image analysis system was used, which has 
been described previously and has been shown to be an accurate and reproducible 
technique.11-13 A high-resolution intensified solid-state camera on a fluorescence 
microscope (Axioskop, Zeiss, Weesp, the Netherlands) was used with a computer-
controlled motorized stepping stage to scan whole tumor cross-sections sequentially, 
with different filters for the detection of the fluorescent signals. Analysis of hypoxia and 
vascular structures was performed with 100x magnification and analysis of proliferation 
was performed with 200x magnification. Depending on the size of the tumor section 
each scan consisted of 36-144 fields of 1.2 mm2. One composite image was 
reconstructed from the individual microscopic fields. A contour line was drawn to 
delineate the tumor area thereby excluding non-tumor tissue (such as normal liver 
tissue and necrosis) from the analyses, using consecutive H&E stained tumor sections. 
The hypoxic fraction (HF) of the tumor section was computed as the tumor area stained 
by the hypoxic marker relative to the total viable tumor area. The perfused fraction (PF) 
of the tumor was defined as the area which was stained both by Hoechst33342 and 
9F1 (i.e. perfused vascular area) relative to the total vascular area. The relative 
vascular area (RVA) was computed by dividing the 9F1 positive area by the total viable 
tumor area. The BrdUrd labeling index (LI) was defined as the ratio of the BrdUrd 
positive area and the total nuclear area. 
CHAPTER 5 
 
 
142
Figure 1  H&E scan of part of the liver of one mouse from the control group, containing three liver 
metastases of C26a tumor (A). In (B) the corresponding liver metastases stained for hypoxia as 
indicated by pimonidazole binding: green; perfusion: blue-purple; vasculature: red-pink (100x 
magnification). The scalebar indicates 1 mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
A 
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Figure 2  Binary maps of complete sections of C26a colon liver metastases without treatment (A) and 
after nicotinamide administration combined with carbogen breathing (B). Vascular structures: 
red-pink; perfused vessels: blue-purple; hypoxic areas: green (100x magnification). The 
scalebars indicate 100 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1  Average hypoxic fraction (HF), perfused fraction (PF), relative vascular area (RVA) and BrdUrd 
labeling index (LI) ± standard deviation for all liver fragments of the control and treatment 
groups. Multiple (two to three) sections from different locations in the liver per mouse (four to 
five mice) were used. * p < .05 compared with the control group ; ** p < .01 compared with the 
control group. 
 
 
 
 
 
 
treatment HF PF RVA LI 
control 0.12 ± 0.11 0.89 ± 0.05 0.05 ± 0.02 0.06 ± 0.02 
nicotinamide 0.01 ± 0.01** 0.89 ± 0.07 0.04 ± 0.02 0.13 ± 0.07 
carbogen 0.03 ± 0.03* 0.83 ± 0.07* 0.05 ± 0.02 0.09 ± 0.06 
nicotinamide + carbogen 0.02 ± 0.04** 0.87 ± 0.10 0.04 ± 0.02 0.09 ± 0.04 
B 
A 
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Statistics and calculations 
The t-test for independent samples was used to compare differences in HF, PF, RVA 
and LI between different groups of mice.  
 
RESULTS 
In all mice several metastases of about 2 mm were observed in the liver. Figure 1 
shows a small part of the liver containing three metastases. No preference for a 
specific lobe of the liver was noted and no metastases were seen in other organs. The 
metastases consisted of densely packed tumor cells and stroma without clear structural 
organization (figure 1A). In untreated mice areas of hypoxia were found throughout the 
whole metastases (figure 1B).  
  Microscopic examination showed that compared to the control group less 
hypoxia was present in the liver metastases which were treated with nicotinamide, 
carbogen or the combination of nicotinamide and carbogen (figure 2). For a quantitative 
analysis of hypoxia and vasculature, two to three fragments of the liver per mouse were 
analyzed separately; for a quantitative analysis of the BrdUrd labeling index one 
fragment of the liver per mouse was used. Results of the quantitative analysis are 
shown in table 1. A significant decrease in hypoxic fraction was observed after 
treatment with nicotinamide, carbogen and the combination of nicotinamide and 
carbogen (p < .05; figure 3). Although in the group of mice which underwent carbogen 
breathing a significantly lower perfused fraction was observed compared to the control 
group (p < .05), the decrease in perfused fraction was only marginal from 0.89 in 
control animals to 0.83 in carbogen treated animals. The relative vascular area and 
BrdUrd labeling index were not statistically different in the treatment groups compared 
to the control group. 
 
DISCUSSION 
In untreated C26a liver metastases a hypoxic fraction of 0.12 was observed, which is 
similar to the amount of hypoxia in liver metastases of patients with colorectal cancer 
(cf. chapter 6). A recent study described hypoxia, vascularity and proliferative activity of 
subcutaneous C26a tumors implanted in the flank of BalbC mice and the response to 
nicotinamide and carbogen.4 Quantitative data for hypoxia and proliferative activity 
were similar for the liver metastases and subcutaneous tumors of the same tumor line. 
However, a higher relative vascular area and a higher perfused fraction were observed 
in the liver metastases compared to subcutaneous tumors (RVA: 0.05 versus 0.02 and 
PF: 0.89 versus 0.56 respectively, p < .05). The time interval between the 
administration of Hoechst33342 and freezing of the tumors was relatively long (25 min) 
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Figure 3  Quantitative assessment of the hypoxic fraction per liver fragment in C26a liver metastases. 
Values are shown for control tumors, and for tumors after administration of nicotinamide, 
carbogen and the combination of both. The horizontal line indicates the mean for each group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
and diffusion of Hoechst33342 from perfused to non-perfused vessels could have 
taken place, resulting in an artificially high perfused fraction. This time interval was 
chosen to monitor the distribution of pimonidazole which needs to be administrated 25 
min before animals are sacrificed to allow for binding to hypoxic cells. Since this time 
interval was used both in liver metastases and subcutaneous tumors it cannot explain 
the high perfused fraction in liver metastases compared to subcutaneous tumors. Since 
liver metastases were smaller than subcutaneous tumors, it could be hypothesized that 
when tumor growth is faster than growth of (functional) vasculature, the perfused 
fraction decreases at larger tumor sizes. Alternatively, the host vasculature may play a 
role in the difference in perfused fraction between liver metastases and subcutaneous 
tumors. The vasculature of primary tumors and metastases may consist of 
neoangiogenic vessels or of host vessels that have been co-opted by the tumor.14 If 
C26a tumors mainly depend on co-option for their vascularization, this would explain 
the higher perfused fraction in liver metastases compared to subcutaneous tumors, 
since the liver is an extremely well-perfused organ compared to subcutaneous tissue. 
In the subcutaneous tumors a hypoxic rim was observed, possibly caused by pressure 
of the surrounding tissue on the small C26a tumor vessels, resulting in compression of 
vasculature thereby hindering tumor blood perfusion and leading to hypoxia. In the liver 
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metastases model used in this study no hypoxic rim was present, which is probably 
due to reduced tissue pressure in the liver compared with overlying skin. 
  To assess the feasibility of modulating tumor hypoxia the effect of nicotinamide 
and carbogen in C26a liver metastases was investigated. A significant decrease in 
hypoxic fraction was observed after nicotinamide and carbogen as single agents, as 
well as after the combination treatment, similar to the previous findings for 
subcutaneously implanted C26a tumors.4 It should be noted that except for the murine 
C26a and C38 colon carcinoma lines a reduction in hypoxic fraction of this magnitude 
after nicotinamide as a single agent has not been observed in experimental tumors 
before.  
  Several mechanisms could play a role in the observed decrease of hypoxia in 
liver metastases. For nicotinamide the classical hypothesis is that a decrease in 
hypoxic fraction can be attributed to an improved tumor perfusion15 by suppression of 
transient fluctuations in microregional blood flow.16 Although in the current experiments 
no increase in perfusion of the liver metastases was observed, these transient 
fluctuations may not have been picked up by the current protocol, where an interval of 
25 min was chosen between nicotinamide and Hoechst33342 administration. 
Previously, it has been suggested that nicotinamide may decrease hypoxia in C26a 
tumors by increasing blood glucose,4 possibly by induction of glycogen breakdown.17,18 
This so-called Crabtree effect,19 which refers to a decrease in cell respiration rate after 
addition of glucose, would be accompanied by a decrease in proliferative activity, due 
to enhanced anaerobic glycolysis, leading to an overproduction of lactic acid which 
may disrupt tumor development. However, in liver metastases no decrease in BrdUrd 
labeling index was observed and therefore the Crabtree effect does not seem to occur. 
This suggests that the host tissue may have some influence on the mechanism by 
which nicotinamide exerts its effects. 
  For carbogen it is supposed that increased oxygen transport by the plasma 
causes a decrease in tumor hypoxia.20 This decrease in tumor hypoxia has also been 
described as a result of the so-called vascular steal effect.21 In tumor vasculature, 
which lacks responsive smooth musculature and which is ordered in parallel with the 
host vasculature of surrounding normal tissue, carbogen breathing can cause a 
reduction in tumor blood perfusion. This is due to the vasodilating effect of the CO2 
component of carbogen on host vessels in the surrounding normal tissues, ‘stealing’ 
blood from the tumor. Hence, the reduced supply of nutrients would decrease the O2 
consumption rate of tumor cells and decrease the hypoxic fraction.9 However, in liver 
metastases tumor vasculature, especially when consisting of co-opted host vessels, 
will be in series with host vasculature rather than in parallel. Therefore, it is unlikely that 
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a vascular steal effect plays a role of importance in the observed decrease in hypoxic 
fraction.  
 Although in liver metastases the reduction in hypoxic fraction by nicotinamide 
and carbogen seems to occur via different mechanisms (suppression of fluctuations in 
blood flow and increased plasma oxygen transport, respectively) the magnitude of the 
effect was similar.  
 Since tumor hypoxia has been related to poor prognosis due to progression to a 
more malignant phenotype and increased therapy resistance,22 it has become a central 
issue in cancer treatment. Clinical studies in several tumor types23-26 have shown 
promising results with the combination of hypoxia modulation with radiation therapy. 
For advanced colorectal cancer chemotherapy is often the treatment of choice. A 
variety of direct and indirect mechanisms have been described by which hypoxia can 
decrease chemotherapy efficacy.27 For example, shut down of blood vessels (acute 
hypoxia) and increased diffusion distances (chronic hypoxia) diminish the distribution of 
chemotherapy. Other mechanisms include an increased activity of DNA repair 
enzymes and increased invasiveness and angiogenic potential. This study described 
the presence of hypoxia in an orthotopic murine model of liver metastases of colon 
carcinoma and the reduction in hypoxia by the use of nicotinamide and carbogen. 
Further experiments will show whether the combination of these hypoxic modifiers with 
chemotherapy can improve treatment outcome of advanced colon cancer. 
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ABSTRACT  
The purpose of this study was to investigate hypoxia measured by pimonidazole 
binding, glucose transporter 1 (GLUT-1) and carbonic anhydrase IX (CA-IX) 
expression, proliferation and vascularity in liver metastases of colorectal cancer and to 
compare GLUT-1 and CA-IX expression in corresponding primary tumors.  
Twenty-five patients with liver metastases of colorectal cancer, planned for 
metastasectomy, were included. The hypoxia marker pimonidazole and proliferation 
marker iododeoxyuridine were administered before surgery. After immunofluorescent 
staining of the frozen metastases, pimonidazole binding, vascularity and proliferation 
were analyzed quantitatively. Thirteen paraffin embedded primary tumors were stained 
immunohistochemically for GLUT-1 and CA-IX expression, which was analyzed semi-
quantitatively in primary tumors and corresponding liver metastases.  
In liver metastases pimonidazole binding showed a pattern consistent with 
diffusion limited hypoxia. The mean pimonidazole positive fraction was 0.146; the mean 
distance from vessels to pimonidazole positive areas was 80 µm. When GLUT-1 and 
CA-IX were expressed, often co-localization was observed between pimonidazole 
binding and GLUT-1 or CA-IX expression, but microregional areas of mismatch were 
also observed. There was no correlation between the level of pimonidazole binding and 
GLUT-1 or CA-IX expression. In some patients a large fraction (up to 30%) of 
proliferating cells was present in pimonidazole stained areas. CA-IX expression in 
primary tumors and metastases showed a significant correlation, which was absent for 
GLUT-1 expression.  
In conclusion, compared to other tumor types, liver metastases of colorectal 
cancer contain large amounts of hypoxic cells. The lack of correlation with 
pimonidazole binding questions the value of GLUT-1 and CA-IX as endogenous 
markers of hypoxia.  
 
KEYWORDS  
CA-IX, GLUT, hypoxia, liver metastases, pimonidazole,  
HYPOXIA IN LIVER METASTASES OF COLORECTAL CANCER                                  
 
 
153
INTRODUCTION 
Colorectal cancer is one of the leading causes of cancer death in the western world. 
Once metastasized prognosis is often poor, despite advances in surgery and 
chemotherapy.1 After surgical resection of liver metastases in selected cases, five-year 
survival rates are approximately 35%.2 For patients treated with palliative 
chemotherapy a median overall survival of 21 months may currently be achieved.3 
There is an increasing awareness that elements of the tumor microenvironment such 
as the vascular bed, tumor cell proliferation and tumor hypoxia can play an important 
role in therapy resistance. This has been demonstrated most clearly in clinical studies 
of squamous cell carcinoma of the cervix4-6 and of the head and neck region.7-9 
Information about the extent and microregional distribution of tumor hypoxia can 
be provided by the use of nitroimidazole markers, for example pimonidazole which is a 
bioreductive chemical probe with an immuno-recognizable side chain.10 The 
disadvantage of pimonidazole as a marker of hypoxia is the need to administer the 
drug intravenously several hours prior to biopsy or surgery. Similar information on the 
amount and the distribution of hypoxic cells may be obtained by intrinsic markers. In 
this respect glucose transporters (GLUT-1, GLUT-3) and carbonic anhydrase IX (CA-
IX) have recently received much attention. GLUT and CA-IX are upregulated by 
microenvironmental hypoxia through activation of the hypoxia inducible factor-1 (HIF-1) 
pathway.6,8,11-13 In ovarian and lung carcinoma cells hypoxic conditions induced 
increased GLUT-1 expression compared to cells exposed to normoxic conditions.14,15 
Also increased GLUT-1 mRNA levels16 and increased transcription of a GLUT-1 
reporter gene17 were observed after induction of hypoxia. Strong GLUT-1 
immunostaining has been shown in hypoxic regions surrounding necrotic foci in breast 
tumors and colorectal cancer xenografts.18,19 Similar observations have been made for 
CA-IX. In vitro data suggest a strong induction of CA-IX mRNA and CA-IX protein 
accumulation by chronic hypoxia.20 In tumor sections CA-IX showed a perinecrotic 
labeling pattern.20-22  
 Although therapy resistance is a problem in metastasized colorectal cancer, 
clinical studies on the tumor microenvironment of metastases have not been published 
thusfar. This study analyzed tumor hypoxia by pimonidazole binding, GLUT-1 and CA-
IX expression, tumor cell proliferation and tumor vascularity in patients with liver 
metastases of colorectal cancer. In a subset of patients GLUT-1 and CA-IX expression 
in the liver metastases were compared with GLUT-1 and CA-IX expression in the 
primary tumors. A remarkable observation in this study is the large amount of hypoxia 
in liver metastases of  colorectal cancer  when compared to carcinomas of the uterine 
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Figure 1 Binary images of complete sections of liver metastases of two patients stained for both 
pimonidazole binding (green) and vasculature (PAL-E, red) (100x magnification) (A, B). In C 
and D the corresponding H&E images. The scale bars indicate 1 mm. 
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Figure 2  Hypoxic fraction calculated per subarea for all metastasis sections per patient, sorted from a low 
median hypoxic fraction to a high median hypoxic fraction. The bold horizontal lines indicate the 
median value for each patient and the columns indicate the 25th to the 75th percentiles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3  Photomicrograph of a liver metastasis triple-stained for both GLUT-1 (green), CA-IX (red), and 
vasculature (PAL-E, blue-purple); overlap between GLUT-1 and CA-IX in yellow. The scale bar 
indicates 100 µm.  
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cervix and the head and neck. This may be very relevant information in the search for 
new treatment strategies for this tumor type. 
 
MATERIALS AND METHODS 
PATIENTS 
Patients with liver metastases of histologically proven colorectal cancer who underwent 
laparotomy for liver resection were eligible for the study. Material of the liver metastases 
was obtained during laparotomy specifically for this study (see below). Paraffin 
embedded material from the primary tumors was obtained from the clinical archives of 
the departments of pathology of the hospitals where the patients had been treated for 
their primary tumor. All patients gave written informed consent and the study was 
approved by the institutional review board of the Radboud University Nijmegen Medical 
Centre, the Netherlands.  
 
EXTERNAL MARKERS OF HYPOXIA AND PROLIFERATION IN HUMAN LIVER METASTASES 
As a marker of hypoxia pimonidazole (1-((2-hydroxy-3-piperidinyl)propyl)-2-
nitroimidazole hydrochloride, Natural Pharmacia International, Belmont, USA)10,23,24 
was injected intravenously (i.v.) in 20 min in a dose of 500 mg/m2, the day before the 
surgery, at least 12 h before start of general anaesthesia. The S-phase marker 
iododeoxyuridine (IdUrd, Centre Hospitalier Universitaire Vaudois, Lausanne, 
Switzerland) was injected i.v. in 5 min in a dose of 200 mg on the day of the surgery, at 
least half an hour before start of general anaesthesia. Immediately after surgical 
resection a 3 mm slice of the whole liver metastasis was cut by the pathologist. In case 
of relatively small metastases (approximately 2 cm) this whole slice was taken for 
further analysis. In case of larger metastases maximally five biopsies of approximately 
5 x 5 mm were taken from the slice (four biopsies from the rim and one from the 
center). The material was snap-frozen in isopentane (BDH, Dagenham, United 
Kingdom) precooled in liquid nitrogen and stored at -80 °C until further use. The 
differentiation grade and largest size of the metastases was recorded from the 
pathology report. 
 
IMMUNOFLUORESCENT STAINING OF LIVER METASTASES  
Frozen sections of 5 µm thickness were cut from the metastases for 
immunofluorescent staining and analysis of pimonidazole binding, GLUT-1 and CA-IX 
expression, vascularity and proliferation. All biopsies of the metastases of each patient 
were analyzed and stained, except for the combined analysis of pimonidazole binding, 
IdUrd and vasculature, which was performed in one representative biopsy per patient. 
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After thawing, the sections were fixed in cold (4 °C) acetone for 10 min and rehydrated 
in phosphate buffered saline (PBS) during 30 min. Between the consecutive steps of 
the staining procedure sections were rinsed three times for 2 min in PBS. As a final 
step, sections were mounted in fluorostab (Organon, Boxtel, the Netherlands), except 
for the sections stained with fast blue which were mounted in PBS. Consecutive 
sections were used to stain for the various combinations of markers. Negative controls 
were included for pimonidazole, GLUT-1 and CA-IX staining.  
 
Endothelial structures and pimonidazole 
To stain the vasculature and pimonidazole, sections were incubated with Pathologie 
Anatomie Leiden-Endotheel (PAL-E, mouse-antibody, Department of Pathology, 
Leiden University, Leiden, the Netherlands), which is a marker of endothelium, diluted 
1:15 and rabbit-anti-pimonidazole (gift J.A. Raleigh)25,26 diluted 1:200 in polyclonal 
liquid diluent (PLD, Euro-DPC, Breda, the Netherlands) during 30 min at 37 °C. 
Sections were then incubated with goat-anti-mouse-Texas-red (Jackson Immuno 
Research Laboratories, West Grove, PA, USA) and donkey-anti-rabbit-Alexa488 
(Molecular Probes, Leiden, the Netherlands), both diluted 1:200 in PLD during 30 min 
at 37 °C.  
 
Endothelial structures, GLUT-1 and CA-IX 
Sections were incubated overnight at 4 °C with mouse-anti-CA-IX (E. Oosterwijk, 
Department of Urology, Radboud University Nijmegen Medical Centre, the 
Netherlands) diluted 1:100 and rabbit-anti-GLUT-1 (Santa Cruz Biotechnology, Santa 
Cruz, California, USA) diluted 1:50 in PLD. Then, sections were incubated in goat-anti-
mouse[Fab]-Cy3 (Jackson Immuno Research Laboratories) and donkey-anti-rabbit-Cy2 
(Jackson Immuno Research Laboratories) diluted 1:200 in PLD. After incubation with 
donkey-anti-goat-TRITC (Molecular Probes), diluted 1:200 in PLD for 30 min at 37 °C, 
sections were incubated with donkey-anti-mouse-Fab (Molecular Probes) diluted 1:100 
in PLD for 30 min at 37 °C. Finally, sections were incubated with PAL-E diluted 1:15 in 
PLD for 30 min at 37 °C, followed by incubation with chicken-anti-mouse-Alexa647, 
diluted 1:200 in PLD for 30 min at 37 °C. 
 
Endothelial structures, pimonidazole and GLUT-1 or CA-IX  
To assess the co-localization between pimonidazole binding and GLUT-1 or CA-IX 
expression  sections with the highest GLUT-1 or CA-IX expression were triple-stained  
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Figure 4  Panels (A) and (B): section of a liver metastasis triple-stained for pimonidazole binding (green), 
GLUT-1 expression (red) and vasculature (PAL-E, blue-purple) in the same section. To show all 
areas with pimonidazole binding and GLUT-1 expression these two markers are shown in 
separate panels (A, B). Panels (C) and (D): section of a liver metastasis triple-stained for 
pimonidazole binding (green), CA-IX expression (red) and vasculature (PAL-E, blue-purple) in 
the same section. Again pimonidazole binding and CA-IX expression are shown in separate 
panels (C, D). Areas of mismatch are indicated with an arrow. The scale bars indicate 100 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5  Two liver metastases triple-stained for pimonidazole binding (green), IdUrd (red) and 
vasculature (PAL-E, blue-purple) (200x magnification). In (A) a detail from a section in which 
4.9% of proliferating cells was located in pimonidazole stained areas; in (B) a detail from a 
section in which 25.8% of proliferating cells was located in pimonidazole-stained areas. The 
scale bars indicate 100 µm.  
 
 
A B 
A 
D C 
B 
HYPOXIA IN LIVER METASTASES OF COLORECTAL CANCER                                  
 
 
159
A B 
Figure 6  Relation between IdUrd labeling index (‘labeling index’) and size of the metastases (‘tumor 
size’) after resection (A) and relation between labeling index and amount of GLUT-1 expression 
(B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7  Examples of differences in expression between GLUT-1 and CA-IX in primary tumors. The 
tumor at the top shows paucity of GLUT-1 staining (A) and extensive CA-IX staining (B), 
whereas the tumor at the bottom shows extensive GLUT-1 staining (C) and paucity of CA-IX 
staining (D) (200x magnification). The scale bar indicates 100 µm.  
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for endothelial structures (using PAL-E), pimonidazole (using monoclonal anti-
pimonidazole when combined with GLUT-1 and rabbit-anti-pimonidazole when combined 
with CA-IX) and GLUT-1 (using rabbit-anti-GLUT-1) or CA-IX (using mouse-anti-CA-
IX). 
 
IdUrd 
DNA was denatured by incubation for 10 min at room temperature in 2 M hydrochloric 
acid. pH was neutralized by rinsing the sections for 10 min in 0.1 M borax. Next, 
sections were incubated for 30 min at 37 °C with mouse-anti-IdUrd (Caltag 
Laboratories, San Francisco, USA) diluted 1:200 in monoclonal liquid diluent (MLD, 
Euro-DPC). Then, sections were incubated with donkey-anti-mouse-biotin (Jackson 
Immuno Research Laboratories) for 30 min at 37 °C and with strep-Alexa488 
(Molecular Probes), diluted 1:200 in PLD for 30 min at 37 °C. Finally, sections were 
incubated with fast blue (Sigma-Aldrich, Zwijndrecht, the Netherlands), diluted 1:1000 
in PBS during 15 min at room temperature. 
 
Endothelial structures, IdUrd and pimonidazole 
To analyze the overlap between IdUrd positive nuclei and pimonidazole stained areas 
one section per patient was stained for endothelial structures, IdUrd and pimonidazole. 
As described above, DNA was denatured by incubation for 10 min at room temperature 
in 2 M hydrochloric acid and then pH was neutralized by rinsing the sections for 10 min 
in 0.1 M borax. Next, sections were incubated for 30 min at 37 °C with mouse-anti-
IdUrd diluted 1:200 and rabbit-anti-pimonidazole diluted 1:200 in PLD. Then, sections 
were incubated for 30 min at 37 °C with goat-anti-mouse[Fab]-Cy3 and donkey-anti-
rabbit-Alexa488 diluted 1:200 in PLD. Sections were then incubated with donkey-anti-
goat-TRITC diluted 1:200 in PLD for 30 min at 37 °C, followed by incubation with 
rabbit-anti-mouse-Fab (Jackson Immuno Research), diluted 1:50 in PLD for 30 min at 
37 °C. Finally, sections were incubated with PAL-E diluted 1:15 in for 30 min at 37 °C, 
followed by incubation with chicken-anti-mouse-Alexa647, diluted 1:200 in PLD for 30 
min at 37 °C. 
 
IMMUNOHISTOCHEMICAL STAINING OF PRIMARY COLORECTAL TUMORS 
Paraffin embedded tumor sections of 5 µm were cut for light microscopy analysis. 
Sections were mounted on poly-L-lysine coated slides. After deparaffinization and 
rehydration sections were steamed in 10 mM citrate buffer for 30 min at 90 °C, cooled 
down to room temperature (30 min) and rinsed in PBS, followed by an incubation with 
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normal donkey serum 5% (Jackson Immuno Research Laboratories) in MLD for 30 min 
at room temperature. Consecutive sections were then further prepared for staining of 
endothelial structures and GLUT-1 or endothelial structures and CA-IX. 
 
Endothelial structures and GLUT-1  
Sections were incubated with mouse-anti-human-CD34 (Coulter Immunotech, 
Mijdrecht, the Netherlands) which is a marker of endothelium diluted 1:20 and rabbit-
anti-human-GLUT-1 (Chemicon International, Temecula, CA, USA) diluted 1:1500 in 
PLD for 2 h at room temperature. After rinsing with PBS, sections were incubated in 
3% H2O2 in methanol for 10 min at room temperature and rinsed again with PBS. Then, 
sections were incubated with donkey-anti-mouse-AF (Jackson Immuno Research 
Laboratories) diluted 1:100 and donkey-anti-rabbit-biotin (Jackson Immuno Research 
Laboratories) diluted 1:500 in PLD for 1 h at room temperature. After rinsing with PBS 
and tris buffered saline sections were incubated with Vector-red alkaline phosphatase 
substrate (Vector laboratories, Burlingame, UK) for 30 min at room temperature. After 
rinsing with tap-water and PBS, sections were incubated with ABC-reagent (Vector 
Laboratories) for 30 min at room temperature and rinsed with PBS and demi-water. 
Then sections were incubated with DAB-chromogen (ZYMED Laboratories, San 
Francisco, CA, USA) for 3 min at room temperature, rinsed with demi-water and 
incubated in hematoxylin (Klinipath, Duiven, the Netherlands) for 30 seconds at room 
temperature. Finally, sections were rinsed with tap-water, dehydrated and mounted in 
KP-mountingmedium (Klinipath). 
 
Endothelial structures and CA-IX 
Sections were incubated with mouse-anti-human-CD34 diluted 1:20 in MLD for 60 min 
at 37 °C. After rinsing with PBS, sections were incubated in donkey-anti-mouse-IgG-AF 
diluted 1:100 in PLD for 60 min at room temperature and rinsed with PBS and TBS. 
After incubation with Vector-red alkaline phosphatase substrate (Vector laboratories) 
for 30 min at room temperature, sections were rinsed with tap-water and PBS. Next, 
the sections were incubated in MOM-block (Vector laboratories) overnight at 4 °C. 
Then sections were incubated in mouse-anti-CA-IX (Department of Urology, Radboud 
University Nijmegen Medical Centre, the Netherlands) diluted 1:25 in MLD for 45 min at 
37 °C. After rinsing with PBS, sections were incubated in 3% H2O2 in methanol for 10 
min at room temperature and rinsed again with PBS. Then, sections were incubated 
with donkey-anti-mouse-biotin (Jackson Immuno Research Laboratories) diluted 1:500 
in PLD for 1 h at room temperature. After rinsing with PBS, sections were incubated 
with ABC-reagent during 30 min at room temperature and rinsed with PBS and demi-
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water. Then sections were incubated with DAB-chromogen for 3 min at room 
temperature, rinsed with tap-water and incubated in hematoxylin for 30 seconds at 
room temperature. Finally, sections were rinsed with tap-water, dehydrated and 
mounted in KP-mountingmedium (Klinipath). 
 
IMAGE ANALYSIS  
Quantitative data for hypoxia, vascularity and proliferation of the liver metastases were 
acquired with a semiautomatic method based on a computerized digital image analysis 
system, which has been shown to be a reproducible method.27,28 A high-resolution 
intensified solid-state camera mounted on a fluorescence microscope (Axioskop, Zeiss, 
Weesp, the Netherlands) with a computer-controlled motorized stepping stage was 
used to scan each metastasis cross-section using different filters. Whole metastases 
sections were scanned sequentially, one time for each fluorescent signal, with different 
filters for the detection of the fluorescent signals. Analysis of the hypoxic marker and 
vascular structures was performed with 100x magnification, whereas analysis of the 
proliferation marker was performed with 200x magnification. Each scan consisted of 
36-144 fields of 1.2 mm2, depending on the size of the section. From the individual 
microscopic fields one composite image was reconstructed after each scan. As a final 
step a contour line was drawn to delineate the area of the metastases thereby 
excluding non-tumor tissue (such as normal liver tissue and necrosis) from the 
analyses, using consecutive H&E stained sections. For each biopsy from the liver 
metastases the hypoxic fraction (HF) of a whole section was computed as the tissue 
surface area stained by pimonidazole relative to the viable tumor surface area. For 
each section HF was also calculated in subareas of 0.3 mm2 for the analysis of intra-
metastasis variability. In each section the distances from the vessels to the nearest 
hypoxic regions were analyzed in 1-22 randomly selected regions of interest 
(depending on the size of the metastases), as described previously.29 The vascular 
density (VD) was calculated as total number of vascular structures per mm2 of viable 
tumor area. Relative vascular area (RVA) was calculated by dividing the PAL-E positive 
area by the viable tumor area. The IdUrd labeling index (LI) was calculated as the ratio 
of the IdUrd positive surface and the total nuclear surface (fast blue stain). 
Since computerized analysis of GLUT-1 and CA-IX expression was not possible 
under light microscopy, the expression in the liver metastases and the primary tumors 
relative to the viable tumor area was scored on a five-point scale (0 = 0-5%, 1 = 6-15%, 
2 = 16-30%, 3 = 31-50%, 4 > 50% expression) at 100x magnification by two 
independent reviewers (H.W.M.v.L. and J.H.A.M.K.). Since biologically active GLUT-1 
is located on the outer part of the cell membrane the score was based on membrane 
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staining only. Sections of which the score between the two reviewers differed more 
than one point were re-analyzed and a consensus score per section was determined. 
For the liver metastases a mean score per liver metastasis was calculated, averaging 
the scores of all sections.  
 
STATISTICS AND CALCULATIONS 
Pearson’s r was calculated to assess correlations between all parameters. To compare 
the mean HF of all biopsies of the metastases with the mean HF of the central biopsy a 
paired t-test was used. These analyses were all performed with the statistical package 
SPSS (version 12.0.1). Median values and percentiles of HF of the arbitrary subareas 
and of the distances from the vessels to the nearest hypoxic regions were calculated 
using Statistica (version 4.0). 
 
RESULTS 
Between July 2001 and September 2003 25 patients were included of whom 12 were 
male and 13 were female. The mean age was 59.6 ± 8.5 years (range 43-74 years). 
Liver metastases were metachronous in 13 cases and synchronous in 12 cases. All 
patients underwent a resection of the liver metastases, in some cases combined with 
radiofrequent ablation, except for two patients. In these two patients resection nor 
radiofrequent ablation was possible and biopsies were taken from the liver metastases 
during surgery. The mean size of the fully resected metastases was 43.9 ± 25.3 mm 
(range 10-100 mm) and they were all moderately well differentiated, except for one 
metastasis which was well differentiated and one metastasis which was poorly to 
moderately differentiated. One patient refused administration of pimonidazole. In five 
patients no IdUrd was administered because of logistical reasons. Material from the 
primary tumor of 13 patients was available for analysis of GLUT-1 and CA-IX 
expression.  
 
QUANTITATIVE ANALYSIS OF PIMONIDAZOLE BINDING, GLUT-1 AND CA-IX EXPRESSION, 
PROLIFERATION AND VASCULARITY IN HUMAN LIVER METASTASES 
Pimonidazole staining was present in all biopsies of the liver metastases of all patients. 
Pimonidazole binding was typically observed at a certain distance from vessels with 
different distribution patterns throughout the tumor tissue, as is illustrated in figure 1. 
The mean pimonidazole positive fraction (HF) of the liver metastases was 0.146 ± 
0.069 (range 0.001-0.307). HF showed a considerable intra-metastasis variation, but 
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the amount of variation was quite different between patients. The standard deviation as 
a percentage of the mean of all biopsies per patient ranged from 9% to 58%. To further  
characterize the intra-metastasis variability HF was calculated for small subareas in all 
biopsies of each patient. The results of this are summarized in figure 2. The mean 
distance from the vessels to the nearest pimonidazole stained areas ranged from 49 
µm to 156 µm (mean for all metastases: 80 µm).  
The majority of biopsies from the liver metastases showed some degree of 
GLUT-1 and CA-IX staining; in one of 25 patients no GLUT-1 staining was observed 
and in three of 25 patients there was no CA-IX staining. The mean GLUT-1 score was 
1.7 ± 1.1 (range 0-4) and the mean CA-IX score was 1.5 ± 1.3 (range 0-4). Co-
localization of GLUT-1 and CA-IX was present, but there were also areas of mismatch 
(figure 3). No correlations were found between the level of GLUT-1 expression and CA-
IX expression. If GLUT-1 or CA-IX were expressed co-localization between 
pimonidazole binding and GLUT-1 or CA-IX expression was generally observed, but 
microregional areas of mismatch were also observed (figure 4). No correlation between 
the level of pimonidazole binding and GLUT-1 or CA-IX expression was observed. 
The mean LI of all biopsies was 0.105 ± 0.057 (range 0.019-0.230). In some 
patients a relatively large overlap between proliferating cells and pimonidazole stained 
areas was observed, with active proliferation within the inner layers of the hypoxic 
compartment (figure 5). On average 7.9 ± 8.4% of proliferating cells was located in 
pimonidazole stained areas (range 0.0-30.0%). A significant positive correlation was 
found between LI and the size of the metastasis as determined by the pathologist after 
resection (r = .563; p = .015) and a negative correlation between LI and GLUT-1 
expression (r = -.516; p = .020) (figure 6A and 6B). No correlation with pimonidazole 
binding or CA-IX expression was found.  
The mean RVA was 0.018 ± 0.007 (range 0.004-0.030) and the mean VD was 
25.4 ± 8.8 mm-2 (range 7.3-40.1 mm-2). RVA and VD were correlated (r = .915; p < 
.000). No correlations between RVA or VD and pimonidazole binding, GLUT-1 and CA-
IX expression or LI were found.  
  No significant differences in pimonidazole binding, GLUT-1 and CA-IX 
expression, vascular density and labeling index between synchronous and 
metachronous liver metastases were found. 
 
GLUT-1 AND CA-IX EXPRESSION IN PRIMARY TUMORS AND LIVER METASTASES 
In eight of 12 primary tumors GLUT-1 expression was observed and in eight of 13 
tumors CA-IX expression.  Due to staining artifacts one case could not be analyzed for  
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Figure 8  Relation between GLUT-1 expression in primary tumors and liver metastases (A) and CA-IX 
expression in primary tumors and liver metastases (B). The solid line indicates the regression 
line.  
 
 
 
GLUT-1. There was no correlation between GLUT-1 and CA-IX expression in primary 
tumors, as is illustrated in figure 7. No correlation was observed between GLUT-1 
expression of the primary tumors and the liver metastases, but a significant correlation 
was noted between CA-IX expression of the primary tumors and the liver metastases 
(r = .752, p = .003; figure 8). T-stage and differentiation grade of the primary tumor 
were not correlated with GLUT-1 or CA-IX expression. 
 
DISCUSSION 
PIMONIDAZOLE BINDING AND VASCULATURE IN LIVER METASTASES 
This study showed for the first time the presence of extensive tumor hypoxia in liver 
metastases of colorectal cancer. Since the hypoxic status of solid tumors has been 
related with poor prognosis due to progression to a more malignant phenotype and 
increased resistance to therapy,30 it has become a central issue in cancer 
pathophysiology and treatment. Externally administered 2-nitroimidazoles, such as   
EF-5 and pimonidazole, are validated10 and widely accepted as markers of cellular 
hypoxia,31 although some studies comparing pimonidazole binding directly with pO2 
values measured by microelectrodes have not shown significant correlations.32-34 
Several explanations have been suggested for this discrepancy.32 One important factor 
may be tumor necrosis which is usually excluded in immunohistochemical analyses but 
included in microelectrode readings. Moreover, the spatial resolution of 
immunohistochemical methods and polarographic methods differ. Pimonidazole 
binding measures hypoxia at the level of individual cells, while the polarographic 
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oxygen electrodes measure regional oxygenation status averaged over 50 to 500 cells 
or more.  
Tumor types that show a strong correlation between the presence of hypoxia 
and treatment outcome include carcinomas of the head and neck and of the uterine 
cervix. The pimonidazole assay shows average hypoxic fractions of 0.06 (range 0.003-
0.172) for head and neck cancers, when pimonidazole was injected 2 h before biopsy 
taking under general anaesthesia.8 In cervical cancers the mean hypoxic fraction 
measured by pimonidazole binding without use of anaesthesia was 0.044 (range 
0.011-0.136).35 Comparisons of hypoxic fractions between studies that have used 
different protocols with respect to the use of anaesthesia and the time interval between 
pimonidazole should be interpreted with caution. It should be noted that pimonidazole 
binding occurs predominantly within 20-30 min after injection. When tissue samples are 
taken after longer intervals, either or not under anaesthesia, the pimonidazole binding 
found in these samples will reflect the oxygenation status at the time of injection.36 With 
a plasma half life of 5-6 h and the anaesthesia given more than 12 h after pimonidazole 
injection, it is very unlikely that possible effects of the anaesthesia on tumor 
oxygenation would have significantly affected pimonidazole binding in this study. 
Acknowledging the differences in protocols between studies, the average HF of 0.146 
(range 0.001-0.307) in the liver metastases compares high relative to cancers of the 
head and neck and uterine cervix for which the clinical relevance of tumor hypoxia has 
been proven. This suggests that in liver metastases of colorectal cancer and possibly 
also in the primary tumors, hypoxia may well be an important factor determining 
treatment outcome.  
In this study hypoxia was observed mainly at a certain distance (on average 80 
µm) from the vasculature, which has also been observed in other tumor types, for 
example head and neck tumors.37,38 This typically represents chronic hypoxia which 
occurs due to the limited diffusion distance of oxygen.39 This oxygen diffusion distance 
depends on the balance between oxygen supply (blood perfusion and oxygen carrying 
capacity of blood) and oxygen consumption in the cell layers surrounding the vessels. 
The observation that active proliferation was present in the inner layers of the hypoxic 
compartment may suggest that, at least in some of the liver metastases, a large 
oxygen consumption rather than a limited oxygen supply contributes to tumor hypoxia. 
In the head and neck tumors also other hypoxic patterns were observed, like 
large areas of hypoxia at a greater distance (> 200 µm) from vessels, indicating a much 
larger oxygen diffusion distance, and a more diffuse type of hypoxia occurring at very 
short distance from vessels, which might be explained by acute hypoxia caused by a 
temporary occlusion of blood vessels.40 These other hypoxic patterns were not 
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observed in the liver metastases which suggests less variability in the balance between 
oxygen supply and oxygen consumption compared with head and neck tumors.  
 
PIMONIDAZOLE BINDING, GLUT-1 AND CA-IX EXPRESSION IN LIVER METASTASES 
Recently much attention has been given to endogenous markers of hypoxia. Significant 
correlations have been observed between pimonidazole binding, GLUT-1 and CA-IX 
expression in cervical cancer12 and bladder cancer.41 Studies in cervical cancer have 
shown a weak correlation between GLUT-1 and pO2 values6, although another study 
showed no correlation between CA-IX and pO2 values measured by microelectrodes.42 
In head and neck cancer a weak but significant correlation was observed between CA-
IX expression and pimonidazole binding.8 In the present study, co-localization was 
observed between pimonidazole binding and GLUT-1 or CA-IX expression, but 
microregional areas of mismatch were also observed and no correlation between the 
level of pimonidazole binding and GLUT-1 expression or CA-IX expression was 
observed in liver metastases of colorectal cancer. The areas of mismatch and the lack 
of correlation may be influenced by the fact that pimonidazole was administered 
approximately 12 h before start of surgery and thus reflects the hypoxic status of the 
metastases before surgery, whereas GLUT-1 and CA-IX expression may still undergo 
changes in this period before and during surgery. However, it should be noted that 
GLUT-1 and CA-IX expression will also be determined by several other factors, apart 
from hypoxia. For example, GLUT-1 and CA-IX are target genes of HIF-1, which may 
be over-expressed in tumors as a result of gene mutations, irrespective of tumor 
hypoxia.43 It has been shown that GLUT-1 expression may be subject to other 
regulatory mechanisms, like the presence of estrogen or progesterone,44 alkaline pH,45 
and the supply of glucose.46 For CA-IX it has been shown that it plays a role in the 
maintenance of neutral intracellular pH which may result in an acidic extracellular pH. 
The latter is a characteristic of the malignant phenotype47 and tumor pH may influence 
CA-IX expression.42 Although tumor pH is partly determined by lactic acid production 
due to anaerobic glycolysis under hypoxic conditions, tumors may also demonstrate 
glycolysis under normoxic conditions, the so-called Warburg effect.48 Also, tumor pH is 
not only determined by lactic acid production, but also by carbonic acid production.49 In 
short, the exact biological relationship between GLUT-1 and CA-IX expression and 
hypoxia remains to be elucidated. For liver metastases of colorectal cancer GLUT-1 
and CA-IX expression do not seem to be robust markers of tumor hypoxia. 
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PROLIFERATION AND PIMONIDAZOLE BINDING IN HUMAN LIVER METASTASES 
In colorectal liver metastases proliferation, measured by IdUrd labeling, increased with 
increasing size of the metastases. This suggests that an actively proliferating cell 
population results in a more extended tumor. Recently, a similar observation has been 
made for head and neck cancer in which IdUrd labeling increased with T-stage.50  
In several liver metastases a considerable percentage of proliferating cells was 
observed in hypoxic areas. In the study in head and neck cancer by Hoogsteen et al. 50 
the co-localization of IdUrd labeling and CA-IX expression ranged from 0-53%. In that 
study CA-IX was interpreted as a marker of intermediate hypoxia (pO2 less than 20 
mmHg), in contrast with the hypoxic marker pimonidazole which labels cells with pO2 of 
less than 10 mmHg. A large percentage of co-localization between IdUrd labeling and 
CA-IX expression was correlated with a worse disease-free survival, suggesting that the 
presence of a population of tumor cells under hypoxic conditions that still has 
proliferative capacity may be indicative of tumor aggressiveness and treatment 
resistance.  
   
GLUT-1 AND CA-IX EXPRESSION IN PRIMARY TUMORS AND LIVER METASTASES 
Since tumor progression is not only influenced by intrinsic characteristics of the tumor 
cells, but also by paracrine interactions between tumor cells and the surrounding 
stroma, metastases do not necessarily exhibit the same biological behavior as their 
primary tumors.  
In a study of primary colorectal carcinoma, using formalin fixed, paraffin 
embedded specimens, 90% of the cases showed GLUT-1 immunostaining; 45% of the 
cases had less than 10% GLUT-1 positive cells and 38% had 10-50% GLUT-1 positive 
cells,51 which is similar to the results reported in this study. In another study of primary 
rectal carcinoma 30% of the cases had less than 10% GLUT-1 positive cells and 63% 
had 10-50% GLUT-1 positive cells.52 In the present study no correlation between the 
level of expression in the primary tumors and the liver metastases was observed. 
Although these results could be due to the relatively small number of patients, the lack 
of correlation may suggest that GLUT-1 expression in primary tumors with metastatic 
potential and in the corresponding metastases is influenced by the host tissue rather 
than by intrinsic characteristics of the malignant tumor cells. Alternatively, it may be 
hypothesized that the metastases originated from a subpopulation of cells in the 
primary tumor that was independent of GLUT-1 expression. It should be noted that 
frozen liver metastases were studied by fluorescence microscopy while paraffin 
embedded primary tumors were studied by light microscopy, and both were scored on 
a five-point scale. Although these scores cannot directly be compared, they can be 
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used to provide a ranking of the data (from high to low expression), in the present study 
showing a lack of correlation between the levels of expression. 
 In a study of 21 primary colorectal carcinomas 24% showed no CA-IX 
expression, 29% showed a weak positive reaction and 47% showed a moderate to 
strong reaction.53 In the present study a slightly higher number of cases without CA-IX 
expression were found and less cases with a moderate to strong reaction, but this may 
well be due to the fairly small study population. Saarnio et al.53 observed in four out of 
seven metastases (six lymph nodes, one liver metastasis) a similar staining intensity 
compared to the corresponding primary tumor. In another study comparing normal 
intestinal mucosa and colorectal cancer it was observed that CA-IX staining was low in 
normal mucosa, but high in tumor tissue.54 In the present study CA-IX expression in 
primary tumors was correlated to CA-IX expression in the liver metastases. Although 
the number of primary tumors and corresponding liver metastases is small, these 
results suggest that in colorectal tissue CA-IX expression accompanies progression to 
malignant transformation, but once metastases are present CA-IX expression remains 
the intrinsic characteristic of the malignant tumor cells. 
 Unfortunately, in this study no pimonidazole was administered prior to surgery 
of the primary tumor. Therefore, a direct comparison of hypoxia in primary colorectal 
tumors and liver metastases could not be made. In a previous study in head and neck 
tumors a correlation was found between polarographic measurement of oxygenation in 
primary tumors and their regional lymph node metastases, suggesting that the level of 
oxygenation in metastatic deposits resembles that of the primary tumor.55 Whether 
primary colorectal carcinomas express the same level of pimonidazole binding as the 
liver metastases is a subject of further study. 
 
In conclusion, in colorectal liver metastases the hypoxic fraction as assessed by 
pimonidazole binding was high relative to other tumor types with proven clinical 
relevance of hypoxia, such as carcinomas of the head and neck and the uterine cervix. 
This may have important implications for new therapeutic approaches for metastasized 
colorectal cancer. Pimonidazole binding was observed at a certain distance from the 
blood vessels, suggesting that this mainly represents diffusion limited hypoxia. The 
limited diffusion capacity of oxygen may in part be caused by high oxygen consumption 
close to the vessels due to active proliferation in these areas. In view of the areas of 
mismatch between pimonidazole binding and GLUT-1 expression or CA-IX expression 
and the lack of correlation between the level of pimonidazole binding, GLUT-1 
expression and CA-IX expression, the suitability of GLUT-1 and CA-IX as endogenous 
markers of hypoxia seems questionable in this tumor type.  
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ABSTRACT  
The purpose of this study was to investigate the reproducibility of dynamic contrast 
enhanced MRI (DCE-MRI) in colorectal liver metastases using a vascular normalization 
function (VNF) from pixels in the spleen, and to compare this with a technique using an 
arterial input function (AIF) from pixels in the aorta. 
DCE-MRI with Gadolinium-DTPA (Gd-DTPA) was performed in patients with 
colorectal liver metastases. The VNF and AIF were determined with an automated 
algorithm. Using a physiological pharmacokinetic model the average Gd-DTPA uptake 
rate (kep) was calculated for the metastases. To calculate the repeatability coefficient of 
the measurements of kep the protocol was repeated on a second day. 
Using the VNF from the spleen the overall mean kep of the two sessions for 
eleven patients was 0.033 s-1 and the repeatability coefficient 0.009 s-1. Using the AIF 
from the aorta these values were 0.031 s-1 and 0.028 s-1, respectively.  
The mean Gd-DTPA uptake rate using a vascular normalization function taken 
from the spleen can be determined with adequate reproducibility in colorectal liver 
metastases. The use of a VNF from pixels in the spleen is better than an AIF from 
pixels in the aorta in terms of reproducibility, and is recommended when this DCE-MRI 
technique is used for prediction and monitoring of therapy outcome in colorectal liver 
metastases. 
 
KEYWORDS 
arterial input function, colorectal cancer, dynamic contrast enhanced MRI, 
reproducibility, vascular normalization function  
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INTRODUCTION 
Colorectal cancer is one of the most common cancers in the western world and 
approximately half of the patients will develop distant metastases. Chemotherapy is 
effective in a subgroup of patients and prolongs median survival with several months.1 
Therefore, early selection of patients who could benefit from chemotherapy is 
desirable. Dynamic contrast enhanced MRI (DCE-MRI) is becoming increasingly 
widespread for tumor identification and its kinetic parameters may provide a useful 
noninvasive measure for the prediction of treatment outcome and the follow-up of 
therapy.2 The predictive value of DCE-MRI parameters has been reported for primary 
tumors like sarcoma,3 cervical carcinoma,4 rectal cancer,5,6 head and neck cancer,7 and 
glioma.8 DCE-MRI has been used to monitor the effects of a variety of treatments and 
may detect effects of therapy in an earlier stage than conventional imaging.9-11 
In order to predict treatment outcome or monitor therapy, differences in DCE-
MRI outcome parameters should reflect true differences in tumor biology and not 
differences induced by variations in the MR protocol or body physiology.12-14 This issue 
is relevant, since differences in for example cardiac output between different 
measurements may lead to changes in systemic blood contrast agent concentration as 
a function of time, which has a direct impact on the tracer uptake kinetics.15 
Furthermore, a large interindividual variation of systemic pharmacokinetics of the 
contrast agent Gadolinium-DTPA (Gd-DTPA) has been described.16 Therefore, to be 
able to assess inter- and intrapatient variability normalization  of DCE-MRI data should 
be applied to minimize these variations.  
In physiological models for the analysis of DCE-MRI data, as described by Tofts 
and Kermode17 and Larsson et al.18 the concentration of contrast agent in plasma of a 
capillary as a function of time (Cp(t)) is used in the analysis of the Gd-DTPA uptake in a 
tissue of interest, according to: Ct(t) = Ktrans · e-kep · (t) * Cp(t), in which Ct = tissue 
concentration of Gd-DTPA; kep = rate constant (s-1) between extravascular extracellular 
space and blood plasma; Ktrans = volume transfer constant (s-1); * denotes a convolution 
operation.19 Thus,  Cp(t) enables normalization of a variable systemic blood flow and 
quantification of physiological parameters from DCE-MRI data. In practice, the change 
in contrast concentration of the capillaries in the tissue of interest is approximated by 
imaging of more remotely located arterial vessels, i.e. by a so called arterial input 
function (AIF).20 
In colorectal cancer the liver is the most common site for metastases. To 
assess the use of DCE-MRI in the prediction and follow up of therapy outcome in 
metastasized colorectal cancer, the reproducibility of DCE-MRI in liver metastases has 
to be determined. The aorta, the most obvious arterial vessel to determine the AIF in 
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transversal MRI slices of the upper abdomen, may show large flow and pulsation 
artifacts in comparison with other arteries, complicating reproducibility. Other 
approaches to approximate the change in concentration of contrast agent over time in 
capillary vessels of liver metastases may overcome this. The spleen is a highly 
vascularized organ, located in the field of view of transversal MRI slices of the upper 
abdomen. Therefore, the change in concentration of contrast agent as a function of 
time in (arterial) vessels in the spleen, a so-called vascular normalization function 
(VNF), may provide such an approach. 
The objective of this study is to determine the reproducibility of DCE-MRI in 
colorectal liver metastases using a vascular normalization function taken from pixels in 
the spleen and to compare this technique with the use of an arterial input function from 
pixels in the aorta.  
 
MATERIALS AND METHODS 
Patients with liver metastases of histologically confirmed colorectal carcinoma were 
included in this study. Patients did not receive anticancer therapy during a period of at 
least ten days prior to the MRI examination. All patients gave written informed consent 
and the study was approved by the institutional review board of the Radboud University 
Nijmegen Medical Centre, the Netherlands.   
DCE-MRI was performed on a 1.5 T Siemens Vision MR system, using a body 
phased array coil. After conventional T1 and T2 weighted imaging, 15 ml 0.5 M 
Gadolinium-DTPA (Gd-DTPA, Magnevist, Schering, Berlin, Germany) was 
administered intravenously in six seconds by a SpectrisTM MR injection system (Medrad, 
Inc., Maastricht, the Netherlands). Using a T1 weighted fast low-angle shot (FLASH) 
sequence with a time resolution of two seconds Gd-DTPA uptake in the tumor and the 
bolus passage in the aorta and vessels in the spleen was monitored. Sequence 
parameters were: repetition time (TR) 50 ms, echo time 4.4 ms, flip angle 90°, slice 
thickness 7 mm, four slices, matrix 160x256, field of view 263x350. A saturation band 
was used to reduce inflow artifacts in the aorta. DCE-MRI data were acquired for 90 
seconds.  
 Before Gd-DTPA injection proton density weighted images were recorded with 
the same sequence parameters as the DCE-MRI except for the flip angle 8° and TR 200 
ms. Data from these images were combined with the DCE-MRI data to calculate the 
concentration of Gd-DTPA in arbitrary units, using the method described by Hittmair et 
al.21 
The measurement protocol was repeated with an interval of minimally 24 h and 
maximally four days. This interval was chosen to allow for Gd-DTPA clearance and to 
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prevent physiological changes in the tumor which may influence contrast enhancement 
characteristics. Slice positions in the second session were matched with the first 
session using the spine as a reference. 
The analysis of the DCE-MRI data was adapted from Rijpkema et al.22 In brief, 
the VNF was obtained from pixels in the spleen using an algorithm based on the 
concentration of Gd-DTPA (high in blood vessels) and time to bolus passage (short in 
arteries). In one DCE-MRI slice a region of interest was drawn around the spleen. An 
automatic threshold to the maximum Gd-DTPA concentration during bolus passage was 
applied to select pixels containing (large) blood vessels from this region of interest. 
Then a threshold was set at the time of Gd-DTPA injection. This level was stepwise 
increased with one interimage interval to select pixels with the shortest time to bolus 
passage until at least ten pixels were selected by the algorithm. Using a physiological 
pharmacokinetic model18 the Gd-DTPA concentration versus time curves of  the pixels 
in all MRI slices containing tumor tissue were analyzed, using a home-made algorithm 
to deconvolute the tumor data. Since the concentration of Gd-DTPA was measured in 
arbitrary units and neither T1 before administration of Gd-DTPA nor tissue relaxivity 
were determined, the only physiological parameter in the model of Tofts and Larsson 
which can be absolutely quantified is kep.20 Therefore, values of kep were calculated 
rather than Ktrans. The spatial distribution of the values of kep was represented in a map. 
On a T1 weighted MR image recorded directly before Gd-DTPA injection a region of 
interest was drawn containing the metastases. This region of interest was applied to the 
map of the Gd-DTPA uptake rate  in order to select the single values of kep for all tumor 
pixels. The  mean of the Gd-DTPA uptake rate of these pixels was calculated after log 
transformation,  averaged over all slices containing tumor tissue. Back transformation of 
this average log transformed value  resulted in an average kep value for the whole 
tumor. The same method of analysis was repeated for each patient using pixels from 
the aorta as an AIF to compare the Gd-DTPA uptake rate calculated with a vascular 
normalization function taken from pixels in the spleen with an arterial input function from 
the aorta. 
One way analysis of variance was used to estimate the within patient standard 
deviation and the between patient standard deviation of the repeated tumor kep values 
using a VNF from the spleen (kep(spleen)) and an AIF from the aorta (kep(aorta)). The 
dependent variable was kep(spleen) and kep(aorta) respectively, and the independent class 
variable was patient.23 Data of the duplo kep measurements were visualized according to 
the method of Bland and Altman24 and the coefficients of repeatability  were 
calculated.24 The repeatability is defined as twice the standard deviation of the 
differences between the duplo values of kep. It implies that for 95% of pairs of 
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observations the absolute difference between two measurements on the same patient is 
expected to lie below this threshold. Therefore, the repeatability coefficient is a 
statistical measure, providing direct insight into the probability that differences between 
two measurements are due to real differences in for example tumor biology and not due 
to the measurement protocol. 
 
RESULTS 
DCE-MRI was performed in eight female and four male patients with liver metastases 
of colorectal cancer (mean age 58 years, range 33-70 years). Both a VNF from pixels 
in the spleen and an AIF from pixels in the aorta were determined for each patient. An 
example is shown in figure 1. In one case the algorithm could not select a VNF from 
the spleen, probably due to breathing and motion artifacts. This patient was excluded 
from further analysis. 
On the T1 weighted MR image recorded just before Gd-DTPA administration the 
metastases could easily be detected in all patients. In figure 2A a T1 weighted MR 
image is shown for one patient. On this image a region of interest is drawn to delineate 
the tumor, which is then applied to the kep-map (figure 2B). Average values of kep for 
the whole tumor, using the AIF from pixels in the aorta and the VNF from pixels in the 
spleen, are shown in figure 3 for measurements 1 and 2. 
Figure 4 shows for all patients the difference d in kep between session 1 and 2 
versus the mean kep of session 1 and 2 using the VNF from pixels in the spleen and the 
AIF from pixels in the aorta, respectively. Using the VNF there was no significant 
correlation between the absolute values of d and the mean kep values of the two 
sessions per patient (p > .05). However, using the AIF there was a significant positive 
correlation between the absolute values of d and the mean kep values of the two 
measurements per patient (p < .05). It is obvious that the extreme values (figure 4B) 
highly contribute to this correlation. No patient characteristics (age, weight, body 
surface area, medication, tumor diameter) were identified that could explain the 
extreme values. In the log transformed data24 a less pronounced but still similar pattern 
was recognized. Therefore the further analysis was performed using untransformed 
data. 
Comparison of figure 4A and 4B suggests a larger variability of the differences 
in kep using pixels from the aorta as arterial input function. Table 1 shows that the 
repeatability coefficient of kep(aorta) is higher than of kep(spleen) (0.028 s-1 and 0.009 s-1, 
respectively). Likewise, the within patient standard deviation of  kep(aorta) is larger than 
the within patient standard deviation of  kep(spleen) (table 1: 0.010 versus 0.003) and the   
QUANTITATION OF DCE-MRI IN COLORECTAL LIVERMETASTASES 
 
  181
B A 
Figure 1  Arterial input function taken from pixels in the aorta and vascular normalization function taken 
from pixels in the spleen of a patient with colorectal liver metastases, selected by an automated 
algorithm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Transversal T1 weighted MR image (A) and map of Gd-DTPA uptake rate kep (B) of a patient 
with a liver metastasis of colon carcinoma. On the T1 weighted image a region of interest is 
drawn around the metastasis, which is then applied to the map of kep. 
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Figure 3  Average values of Gd-DTPA uptake rate kep for the whole tumor, using the AIF from pixels in 
the aorta and the VNF from pixels in the spleen for measurements 1 and 2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4  Difference d in Gd-DTPA uptake rate kep between measurement 1 and 2 versus mean kep of 
measurement 1 and 2 using selected pixels from the spleen as a vascular normalization 
function (A) and selected pixels from the aorta as an arterial input function (B). The mean 
difference and the mean plus and minus two times the standard deviation (st. dev.) are indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1  Measures of reproducibility of values of kep. R = percentage of the between variance to the sum 
of within variance and between variance; 100% is ideal. r = twice the standard deviation of the 
differences between the repeated values of kep. kep(spleen) = kep using the vascular normalization 
function from pixels in the spleen. kep(aorta) = kep using the arterial input function from pixels in the 
aorta. 
 
  within patient  
standard deviation  
between patient 
standard deviation 
R (%) mean repeatability r 
kep(spleen)  0.003 s-1 0.010 s-1 91 0.033 0.009 
kep(aorta)  0.010 s-1 0.010 s-1 50 0.031 0.028 
A B 
mean ± 2 ⋅ st. dev.
mean difference 
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proportion of the total variance related to the within patient variance is higher using 
kep(aorta) compared to the kep(spleen), 50% and 9% respectively (table 1:  R = 50% and 91%  
respectively). The analysis of variance also showed that the mean kep(aorta) (0.031 s-1) 
and the mean kep(spleen) (0.033 s-1) were not significantly different (p > .05).  
 
DISCUSSION 
Reproducibility of DCE-MRI is of utmost importance for the application of DCE-MRI in 
the prediction of therapy outcome and follow-up of therapy. In this study the 
reproducibility of DCE-MRI in colorectal liver metastases was determined using a VNF 
from selected pixels in the spleen and an AIF from selected pixels in the aorta.  
Comparing the methods using the VNF from the spleen and the AIF from the 
aorta, the analysis of variance showed that the mean kep(aorta) and the mean kep(spleen) 
were not significantly different, indicating that the mean of two measurements, using an 
AIF from pixels in the aorta or a VNF from pixels in the spleen, performed equally well. 
However, a smaller within patient standard deviation and a smaller repeatability 
coefficient was found for the method using the VNF, indicating a better reproducibility. 
From the data of Rijpkema et al.22 using an AIF from a carotid artery or internal iliac 
artery a repeatability coefficient of 0.006 s-1 could be calculated, which is smaller than 
the repeatability found using the AIF from the aorta. The larger within patient standard 
deviation and repeatability coefficient using a AIF from the aorta may be caused by 
artifacts due to pulsation and flow or due to T2* effects in regions of high Gd-DTPA 
concentration, especially at the top of the bolus passage. These artifacts will be larger 
in the aorta than in other arterial vessels. As can be seen from figure 3 these artifacts 
lead to a poor reproducibility mainly in three patients. Patient 1, 7 and 11 (figure 3) 
show a major difference in values of kep between measurement 1 and 2. Leaving out 
these patients in the analysis of reproducibility, the repeatability factor becomes 0.011 
s-1. However, no patient characteristics could be identified that would predict whether 
results will be compromised by possible artifacts in the aorta. Therefore, when using 
this MRI method the acquisition of a normalization function from vessels other than the 
aorta is recommended. 
For the determination of repeatability, the differences between measurements 1 
and 2 are assumed not to vary in a systematic way over the range of the measurement. 
If this is not the case, a log transformation has to be applied.24 In the data set with kep 
values using the AIF from the aorta one log transformation was insufficient to remove 
this relation. Although a second log transformation might improve the distribution, the 
results would be hard to interpret. Therefore, the calculations of repeatability were 
performed with untransformed data, knowing that the limits of agreement will be wider 
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apart than necessary for small values of kep and narrower than they should be for larger 
value of kep.24 
 The repeatability coefficient of 0.009 s-1  for the Gd-DTPA uptake rate kep with a 
VNF from the spleen implies that for 95% of pairs of observations the absolute 
difference between two measurements on the same patient is expected to lie below 
this threshold. It can be compared directly to repeatability coefficients as determined for 
other measurement protocols or tumor types.25 In view of the range of kep values 
observed in the patients (0.016-0.058 s-1, figure 3) and the between patient standard 
deviation (0.010 s-1, table 1) the presented method for quantitation of contrast agent 
uptake in colorectal liver metastases may be of clinical value in therapy monitoring or 
the prediction of response to therapy in patients. The presented repeatability coefficient 
compares well with the literature on reproducibility of  kep values in tumor tissue. 
Galbraith et al.12 reported mean kep values of 0.022 s-1 and 0.023 s-1 with repeatability 
coefficients of 0.013 s-1 and 0.015 s-1, respectively. The larger repeatability coefficients 
in their study may be due to the use of a biexponential function as an approximation of 
the arterial input function rather than a coregistered AIF. The mean kep value reported 
by Rijpkema et al.22 is 0.030 s-1 in brain, head and neck and prostate tumors using a 
coregistered AIF per patient, with a  smaller repeatability coefficient of 0.006 s-1. In 
comparison with the upper abdominal region, DCE-MRI data from especially the brain 
and head and neck region will be less compromised by motion artifacts. Perfusion and 
permeability mapping of hepatic malignancies with DCE-MRI could significantly be 
improved by a breath-hold technique. Jackson et al.14 have described a technique 
which would allow detection of changes in mean values of  Ktrans in the order of 15-
20%. However, for this method a breath-hold of 41 seconds is required, which may be 
difficult for patients to perform. Data-analysis in this breath-hold technique was based 
on actual breath-hold component of the data, discarding the data of the time period that 
the patients had not been able to hold their breath. This implies that the actual data-
analysis is based on a time period less than 41 seconds, which significantly reduces 
the number of datapoints available for an accurate estimation of kep. Comparing 
reproducibility of DCE-MRI parameters with other imaging modalities like positron 
emission tomography (PET) and computer tomography (CT) similar results are 
reported.26-29 
According to the physiological models of Tofts and Kermode17 and of Larsson et 
al.,18 the quantification of Gd-DTPA uptake rate in tumor tissue requires knowledge of 
the concentration of the contrast agent in plasma at the capillary level over time. In 
practice, this is approximated by measuring a concentration Gd-DTPA versus time 
curve in a large artery, the so called arterial input function (AIF).  In fact, the term 
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arterial normalization function would have been more appropriate for this 
approximation. In this study, it was assumed that the bolus passage of contrast agent 
in vessels in the spleen is representative for bolus passage in the capillaries in liver 
metastases. Although the algorithm used to determine the VNF was designed to select 
pixels mainly from arterial vessels, a possible contribution from large veins in the 
spleen cannot be excluded. However, like normal liver tissue, liver metastases may 
also derive part of their blood supply from the portal system.30-32 Therefore, for liver 
metastases a VNF from the spleen that is composed of pixels from both large arteries 
and veins, may actually be a better representative for the changes in plasma 
concentration of Gd-DTPA at the capillary level than an AIF from the aorta. As can be 
seen from figure 3 the choice for the use of either a VNF or an AIF may not be trivial for 
the values of Gd-DTPA uptake rate. Obtaining a VNF from pixels in the normal liver, as 
proposed by Su et al.33 would not be adequate in this study, since the liver may contain 
diffuse metastases, not visible on MRI, which would impinge on the correct estimation 
of DCE-MRI parameters in tumor tissue. Although diffuse metastases could also be 
present in the spleen, splenic metastases (solitary, multiple or diffuse) of colorectal 
carcinoma are very rare (incidence < 5%) and usually a sign of extensive end stage 
disease.34 Moreover, in a series of 92 patients with spleen metastases of various 
primary tumors only eight showed diffuse spleen metastases.35 In the present study 
there was no radiological evidence of splenic metastases. Hence, in daily clinical 
practice this will most probably not be a significant problem. Kovar et al.36 have 
described a method for analysis of DCE-MRI data using a capillary input function 
estimated from the rate of contrast agent uptake in healthy reference tissue such as 
muscle, based on literature values for perfusion rate, extraction fraction and 
extracellular volume. This method can be useful, particularly when first-pass methods 
cannot be applied. 
In conclusion, determination of the Gd-DTPA uptake rate kep using a vascular 
normalization function taken from pixels in the spleen can be performed with adequate 
reproducibility in patients with colorectal liver metastases. Using an AIF from pixels in 
the aorta decreases reproducibility compared with the use of an VNF from pixels in the 
spleen, which may be due to flow and pulsation artifacts. The presented method 
enables reproducible acquisition and analysis of DCE-MRI data, which is a necessary 
prerequisite for prediction and monitoring of therapy outcome. 
 
ACKNOWLEDGEMENTS 
The authors thank J.J. van Asten for software development and the technicians of the 
Department of Radiology for their assistance. 
CHAPTER 7 
 
 
186
 REFERENCES 
 
 1.  Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and 
meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000;321:531-535. 
 2.  Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis 
on quantification, validation and human studies. Clin Radiol 2001;56:607-620. 
 3.  Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone 
sarcoma. J Magn Reson Imaging 1999;10:277-285. 
 4.  Mayr NA, Hawighorst H, Yuh WT, Essig M, Magnotta VA, Knopp MV. MR microcirculation 
assessment in cervical cancer: correlations with histomorphological tumor markers and clinical 
outcome. J Magn Reson Imaging 1999;10:267-276. 
 5.  De Vries AF, Griebel J, Kremser C, Judmaier W, Gneiting T, Kreczy A, Ofner D, Pfeiffer KP, Brix 
G, Lukas P. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts 
therapy outcome for primary rectal carcinoma. Cancer Res 2001;61:2513-2516. 
 6.  George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA, Swift RI. Non-invasive 
methods of assessing angiogenesis and their value in predicting response to treatment in 
colorectal cancer. Br J Surg 2001;88:1628-1636. 
 7.  Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H. Dynamic contrast 
enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy 
for advanced head and neck cancer. Br J Radiol 1999;72:1093-1098. 
 8.  Hawighorst H, Knopp MV, Debus J, Hoffmann U, Grandy M, Griebel J, Zuna I, Essig M, 
Schoenberg SO, de Vries AF, Brix G, van Kaick G. Pharmacokinetic MRI for assessment of 
malignant glioma response to stereotactic radiotherapy: initial results. J Magn Reson Imaging 
1998;8:783-788. 
 9.  Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, Leach MO, 
Husband JE. Effects of androgen deprivation on prostatic morphology and vascular permeability 
evaluated with MR imaging. Radiology 2001;218:365-374. 
 10.  Burn PR, McCall JM, Chinn RJ, Vashisht A, Smith JR, Healy JC. Uterine fibroleiomyoma: MR 
imaging appearances before and after embolization of uterine arteries. Radiology 2000;214:729-
734. 
 11.  Barentsz JO, Berger-Hartog O, Witjes JA, Hulsbergen-van der Kaa C, Oosterhof GO, van der 
Laak JA, Kondacki H, Ruijs SH. Evaluation of chemotherapy in advanced urinary bladder cancer 
with fast dynamic contrast-enhanced MR imaging. Radiology 1998;207:791-797. 
 12.  Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, Padhani AR. 
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of 
quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-142. 
 13.  Padhani AR, Hayes C, Landau S, Leach MO. Reproducibility of quantitative dynamic MRI of 
normal human tissues. NMR Biomed 2002;15:143-153. 
QUANTITATION OF DCE-MRI IN COLORECTAL LIVERMETASTASES 
 
  187
 14.  Jackson A, Haroon H, Zhu XP, Li KL, Thacker NA, Jayson G. Breath-hold perfusion and 
permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass 
leakage profile model. NMR Biomed 2002;15:164-173. 
 15.  Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson 
Imaging 1999;10:254-259. 
 16.  Port RE, Knopp MV, Hoffmann U, Milker-Zabel S, Brix G. Multicompartment analysis of 
gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic 
MR imaging. J Magn Reson Imaging 1999;10:233-241. 
 17.  Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space 
using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-367. 
 18.  Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of 
blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with 
multiple sclerosis and brain tumors. Magn Reson Med 1990;16:117-131. 
 19.  Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr 
NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic 
contrast-enhanced T(1)- weighted MRI of a diffusable tracer: standardized quantities and 
symbols. J Magn Reson Imaging 1999;10:223-232. 
 20.  Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 
1997;7:91-101. 
 21.  Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J. Method for the 
quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn 
Reson Med 1994;31:567-571. 
 22.  Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative 
mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 
2001;14:457-463. 
 23.  Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley & Sons, 1986. 
 24.  Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of 
clinical measurement. Lancet 1986;327:307-310. 
 25.  Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. 
Statistician 1983;32:307-317. 
 26.  Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic 
measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-1777. 
 27.  Hermans R, van der GA, Baert AL. Image interpretation in CT of laryngeal carcinoma: a study on 
intra- and interobserver reproducibility. Eur Radiol 1997;7:1086-1090. 
 28.  Van Hoe L, van Cutsem E, Vergote I, Baert AL, Bellon E, Dupont P, Marchal G. Size 
quantification of liver metastases in patients undergoing cancer treatment: reproducibility of one-, 
two-, and three-dimensional measurements determined with spiral CT. Radiology 1997;202:671-
675. 
CHAPTER 7 
 
 
188
 29.  Mahaley MS, Jr., Gillespie GY, Hammett R. Computerized tomography brain scan tumor volume 
determinations. Sensitivity as an objective criterion of response to therapy. J Neurosurg 
1990;72:872-878. 
 30.  Paku S. Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 1998;4:62-75. 
 31.  Kan Z, Ivancev K, Lunderquist A, McCuskey PA, Wright KC, Wallace S, McCuskey RS. In vivo 
microscopy of hepatic tumors in animal models: a dynamic investigation of blood supply to 
hepatic metastases. Radiology 1993;187:621-626. 
 32.  Taniguchi H, Daidoh T, Shioaki Y, Takahashi T. Blood supply and drug delivery to primary and 
secondary human liver cancers studied with in vivo bromodeoxyuridine labeling. Cancer 
1993;71:50-55. 
 33.  Su MY, Muhler A, Lao X, Nalcioglu O. Tumor characterization with dynamic contrast-enhanced 
MRI using MR contrast agents of various molecular weights. Magn Reson Med 1998;39:259-269. 
 34.  Berge T. Splenic metastases. Frequencies and patterns. Acta Pathol Microbiol Scand [A] 
1974;82:499-506. 
 35.  Lam KY, Tang V. Metastatic tumors to the spleen: a 25-year clinicopathologic study. Arch Pathol 
Lab Med 2000;124:526-530. 
 36.  Kovar DA, Lewis MZ, River JN, Lipton MJ, Karczmar GS. In vivo imaging of extraction fraction of 
low molecular weight MR contrast agents and perfusion rate in rodent tumors. Magn Reson Med 
1997;38:259-268. 
 
 
 
 
 
Chapter 8 
 
 
 
Relation between Gadolinium-DTPA and FDG uptake in liver metastases 
of colorectal carcinoma as determined by MRI and PET 
 
 
Hanneke W.M. van Laarhoven, Lioe-Fee de Geus-Oei, Bastiaan Wiering, Jasper Lok, 
Mark Rijpkema, Johannes H.A.M. Kaanders, Paul F.M. Krabbe, Theo J.M. Ruers, 
Cornelis J.A. Punt, Albert J. van der Kogel, Wim J.G. Oyen, Arend Heerschap 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on: 
Van Laarhoven HW, de Geus-Oei L-F, Wiering B, Lok J, Rijpkema M, Kaanders JH, Krabbe PF, 
Ruers TJ, Punt CJ, van der Kogel AJ, Oyen WJ, Heerschap A. Relation between Gadolinium-
DTPA and FDG uptake in liver metastases of colorectal carcinoma as determined by MRI and 
PET. Radiology 2005; in press. 
CHAPTER 8 
 
 
190
ABSTRACT  
The purpose of this study was to examine the in vivo relationship between FDG uptake 
as measured by PET, and functional tumor vasculature as measured by DCE-MRI in 
patients with liver metastases of colorectal cancer. 
All patients gave written informed consent and the study was approved by the 
institutional review board of the Radboud University Nijmegen Medical Centre, the 
Netherlands. Twenty-six patients, 12 male and 14 female patients with a mean age of 
59 years, with suspected liver metastases of histologically proven colorectal cancer 
who underwent a work-up for liver metastasectomy were included. Patients underwent 
whole body FDG-PET and tumor to non-tumor ratios of FDG uptake (T/NT) in the 
metastases were calculated. DCE-MRI was performed and the rate constant kep (s-1) of 
Gadolinium-DTPA uptake in the metastases was determined. Using the hypoxic marker 
pimonidazole, tumor hypoxia and vascular density (VD) of the metastases were 
determined immunohistochemically. To assess the relations between FDG uptake, rate 
constant kep of Gd-DTPA uptake, HF and VD the Pearson’s correlation coefficient r was 
calculated. 
A negative correlation between T/NT and kep was observed (r = -.421; p = .082). 
No correlation between tumor hypoxia and T/NT or kep was found. A positive correlation 
was observed between VD and kep (r = .458;p = .037), but not with T/NT.  
In conclusion, the negative correlation between T/NT and kep suggests that 
lower values of Gd-DTPA uptake rate imply an acutely reduced supply of oxygen which 
necessitates a higher uptake of glucose to maintain tumor energy levels. The positive 
correlation of VD with kep, but not with T/NT, emphasizes the potential of DCE-MRI to 
measure tumor vascularity in vivo and its additional value compared to ex vivo 
methods.  
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INTRODUCTION 
The current management of metastatic colorectal cancer is based on imaging methods 
which are generally anatomical in nature. An exception is positron emission 
tomography with 2-deoxy-2-18F-fluoro-D-glucose (FDG-PET). FDG-PET is based on 
the elevated glucose utilization in malignant cells compared to normal tissue.1 FDG-
PET has been proven useful in the follow-up of patients with colorectal malignancies to 
differentiate between recurrent colorectal tumor and scar tissue.2 In a small series of 
patients FDG-PET was more accurate compared to computer tomography (CT) in the 
determination of response to preoperative radiation and chemotherapy in rectal 
cancer.3 Furthermore, FDG-PET may substantially improve the preoperative staging 
procedure for resection of liver metastases by sensitive detection of extra-hepatic 
disease.4,5 Previous results suggest that FDG-PET can predict response to 
chemotherapy in patients with hepatic metastases.6  
 Although in general FDG uptake is increased in malignant tumors, the 
underlying mechanism for increased glucose uptake, and thus for the increased FDG-
PET signal, is still a matter of debate. For glucose to be taken up and used by a cancer 
cell, an adequate vascular supply (and thus angiogenesis or vascular co-option) is 
necessary, as well as the presence of several membrane bound glucose transport 
proteins (GLUT) which facilitates transport of glucose over the cell membrane. The 
intracellular hexokinase (HK) isoforms are necessary for subsequent phosphorylation 
into glucose-6-phosphate which may then be further converted via the glycolytic 
pathway. All these factors - vascularity, transmembrane transport, phosphorylation, 
glycolysis - are known to be upregulated in cancer cells7 which may be due to 
overexpression of the hypoxia inducible factor 1 (HIF-1) protein. HIF-1 can be 
overexpressed in tumors in response to tumor hypoxia resulting from an inefficient 
tumor vascular network and constitutively as a result of gene mutations.8 In fact, 
(constitutive) overexpression of HIF-1 induces VEGF expression, which may lead to an 
inefficient tumor vascular network, resulting in insufficient tumor oxygenation. 
Therefore, tumor hypoxia seems to play a pivotal role in the metabolic status of tumors.  
 To improve the understanding of PET scans, several studies have focused on 
the link between FDG uptake and biomarkers like GLUT, HK and vascular density 
(VD). Some studies have reported positive correlations between these biomarkers and 
FDG uptake,9,10 but other studies have been negative.11-15 Divergent results may be 
explained by differences in tumor biology, immunohistochemical staining methods and 
PET procedures. However, one usually does not account for the fact that FDG uptake 
is measured in vivo, whereas from immunohistochemical analysis ex vivo data are 
obtained. This may be particularly important for the relationship between FDG uptake 
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and VD, since it is not so much the presence of tumor vasculature, but the presence of 
functional tumor vasculature that may determine FDG uptake.  
Functionality of tumor vasculature can be monitored in vivo by dynamic contrast 
enhanced magnetic resonance imaging (DCE-MRI), using the contrast agent 
Gadolinium-DTPA (Gd-DTPA). From physiological models for the analysis of DCE-MRI 
data parameters for vascularity, for example blood flow and permeability of blood 
vessels, can be determined.16,17 DCE-MRI is currently used for tumor identification in 
the clinic. For example, in breast cancer DCE-MRI has proven to be an accurate 
method to differentiate benign and malignant lesions.18 DCE-MRI parameters may 
provide a useful noninvasive measure for the prediction of treatment outcome and the 
follow-up of therapy19 and have been shown to have predictive value for the response 
to treatment of several primary tumors.20-25  
The purpose of this study was to examine the in vivo relationship between FDG 
uptake as measured by PET, and functional tumor vasculature as measured by DCE-
MRI in patients with liver metastases of colorectal cancer.  
 
MATERIALS AND METHODS 
PATIENTS 
Patients with suspected liver metastases of histologically proven colorectal carcinoma 
who underwent a work-up for liver resection were eligible for this study. Patient data 
were included in the analysis of the present study when data of at least two of the three 
functional imaging modalities were available (i.e. PET and DCE-MRI, PET and 
immunohistochemistry or DCE-MRI and immunohistochemistry). All patients gave 
written informed consent and the study was approved by the institutional review board 
of the Radboud University Nijmegen Medical Centre, the Netherlands. Between May 
2001 and September 2003 data from 26 patients were available for analysis (12 male 
and 14 female patients with a mean age of 60 years; range 43-74 years) 
 
FDG-PET 
Whole body FDG-PET was performed as part of the work-up for liver metastasectomy 
when clinically indicated according to the treating surgeon. Imaging was performed with 
a dedicated PET-scanner (ECAT-EXACT full ring PET-scanner, Siemens/CTI, 
Knoxville, TN, USA). Prior to FDG-injection, patients fasted for at least 6 h. Intake of 
sugar-free liquids was permitted. Immediately prior to the procedure, the patients were 
hydrated with 500 ml of water. One hour after intravenous injection of 200-220 MBq 
FDG (Mallinckrodt Medical, Petten, the Netherlands) and 12 mg furosemide, emission 
and transmission images of the area between proximal femora and the base of the 
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skull were acquired (10 min per bed position). The images were corrected for 
attenuation and reconstructed using the ordered-subsets expectation maximization  
algorithm.  
 
FDG-PET IMAGE ANALYSIS  
Tumor metabolism was evaluated semi-quantitatively by calculation of the tumor to 
non-tumor (T/NT) ratio of FDG uptake, using a semi-automated method with normal 
liver adjacent to the lesions as a reference. A volume of interest (VOI) in liver 
metastases was defined using a 50% threshold of maximum intensity. Central 
photopenic areas in the metastases, which may be regarded as areas of gross tumor 
necrosis, were excluded from the VOI. The scans were analyzed by two independent 
observers (W.J.G.O. seven years of PET experience, L.F.d.G.O. four years of PET 
experience) who were blinded for quantitative MRI and histological results. 
Disagreements between the two observers were resolved by consensus. The normal 
liver VOI was placed adjacent to the measured lesion. The boundaries of the VOIs 
were just within the apparent hypermetabolic zone of the tumor. VOIs of identical 
configuration were placed on normal liver tissue to serve as a reference for 
normalization.  
 
DCE-MRI 
DCE-MRI was performed in all patients who underwent a work-up for liver 
metastasectomy as part of a wider research program to validate the use of DCE-MRI in 
patients with liver metastases. The study was approved by the institutional review board 
of the Radboud University Nijmegen Medical Centre, the Netherlands, and informed 
consent was obtained from all patients. Three researchers (H.W.M.v.L., M.R. and A.H.) 
were involved in DCE-MRI procedures and data collection (all had at least four years 
experience with liver MR). There was no randomization as to which test (MRI or PET) 
was done first; the clinical order was followed. In practice, patients had their PET scan 
before or on the same day as the MRI scan.  
Measurements were performed on a 1.5 T Siemens Vision MR system, using a 
body phased array coil. After conventional T1 and T2 weighted imaging in axial, coronal 
and saggital direction, 15 ml 0.5 M Gd-DTPA (Magnevist, Schering, Berlin, Germany) 
was administered intravenously with an injection rate of 2.5 ml/s by a SpectrisTM MR 
injection system (Medrad, Inc., Maastricht, the Netherlands). Using a T1 weighted fast 
low-angle shot (FLASH) sequence with a time resolution of two seconds Gd-DTPA 
uptake in the tumor and the bolus passage in vessels in the spleen was monitored. 
Sequence parameters were: repetition time (TR) 50 ms, echo time 4.4 ms, flip angle 
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90°, slice thickness 7 mm, four slices, matrix 160x256, FoV 263x350 mm. DCE-MRI 
data were acquired for 90 seconds. If the four slices did not fully cover the tumor in the 
head-foot direction, slices were positioned in such a way that the largest diameter of 
the tumor (measured left to right on the coronal view) was covered.  
  Just before Gd-DTPA injection proton density weighted images were recorded 
with the same sequence parameters as the DCE-MRI except for the flip angle 8° and 
TR 200 ms. Data from these images were combined with the DCE-MRI data to 
calculate the concentration of Gd-DTPA in arbitrary units, using the method described 
by Hittmair et al.26 
 For the analysis of the DCE-MRI data, which was blinded for the PET data 
analysis, a previously described method was used.27 In brief, a vascular normalization 
function (VNF) was obtained from pixels in the spleen using an algorithm based on the 
concentration of Gd-DTPA (high in blood vessels) and time to bolus passage (short in 
arteries). Using a physiological pharmacokinetic model17 the Gd-DTPA concentration 
versus time curves of the pixels in all MRI slices containing tumor tissue were analyzed 
and values of the rate constant kep (s-1) of Gd-DTPA uptake were calculated according 
to the formula: Ct(t) = Ktrans · e-kep · t * Cp(t), in which Ct = tissue concentration of Gd-
DTPA; kep = rate constant (s-1) between extra vascular extra cellular space and blood 
plasma; Ktrans = volume transfer constant (s-1); Cp = the concentration of contrast agent 
in plasma of a capillary; * denotes a convolution operation.28 In Larsson’s model,17 the 
Gd-DTPA uptake rate constant kep is directly related to tumor blood flow, the product of 
the permeability of perfused capillaries and the total surface area of perfused 
capillaries, according to: kep = (1 – exp(-PS/TBF)) · TBF/ve, in which ve = volume of 
contrast extra vascular extra cellular space per unit volume of tissue; P = permeability of 
capillaries (cm s-1); S = total surface area of vessels (cm2); PS = permeability surface 
area product (ml s-1); TBF = tumor blood flow (ml s-1).   
  The spatial distribution of the values of kep was represented in a map. On a T1 
weighted MR image recorded directly before Gd-DTPA injection a region of interest was 
drawn which comprised the metastases. This region of interest was applied to the map 
of the rate constant kep of Gd-DTPA uptake in order to select the single values of kep for 
all tumor pixels. The mean of the rate constant kep of these pixels was calculated after 
log transformation and averaged over all slices containing tumor tissue. Log 
transformation excludes all values of kep equals zero. These tumor pixels may be 
regarded as necrotic tumor parts. Back transformation of this average log transformed 
value resulted in an average kep value for the whole tumor.27  
 In 12 patients for whom sufficient time was left before surgery was planned, the 
measurement protocol was repeated with an interval of 24 h to four days as part of a 
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reproducibility study. The DCE-MRI results of ten of these 12 patients have been 
published elsewhere.27 For these patients the average kep value for the whole tumor 
was calculated from the mean of the two measurements and for further calculations this 
mean kep value was used.  
 
TUMOR HYPOXIA AND VASCULAR DENSITY 
As a marker of hypoxia pimonidazole (1-((2-hydroxy-3-piperidinyl)propyl)-2-
nitroimidazole hydrochloride, Natural Pharmacia International, Belmont, Massachusets, 
USA)29-31 was injected intravenously in 20 min in a dose of 500 mg/kg, at least 12 h 
before start of surgery. Pimonidazole is a bioreductive chemical probe with an immuno-
recognizable side chain. Complete inhibition of bioreductive activation occurs at a pO2 
below 10 mmHg.31  
Immediately after surgical resection, the metastasis for which DCE-MRI data 
were available was identified in the pathology specimen using the T1 and T2 weighted 
MR images in axial, coronal and saggital direction. On the T1 weighted MRI images the 
distance in cranio-caudal direction was measured from the edge of the metastasis to 
the centre of the region where the slices for DCE-MRI were taken. In the pathology 
specimen the same distance was measured and at this level a 3 mm transversal slice 
of the liver metastasis was cut by a pathologist. In case of relatively small metastases 
(approximately 2 cm) the whole slice was taken for further analysis. In case of larger 
metastases maximally five sections of approximately 5 x 5 mm were cut from the slice 
(four sections from the rim and one from the center). The sections from the rim were 
evenly distributed, i.e. one from the dorsal part, one from the ventral part, one from the 
lateral and one from the medial part of the tumor. Sections were snap-frozen in 
isopentane (BDH, Dagenham, United Kingdom) precooled in liquid nitrogen and stored 
at -80 °C until further use. The differentiation grade and largest size of the metastases 
was recorded from the clinical pathology report. 
Frozen tumor sections of 5 µm thickness were cut for immunohistochemical 
staining and analysis of hypoxia and VD. After thawing, the sections were fixed in cold 
(4 °C) acetone for 10 min, rehydrated in phosphate buffered saline (PBS) during 30 
min. Between the consecutive steps of the staining procedure sections were rinsed 
three times for two minutes in PBS. To stain the hypoxic marker and the vasculature, 
sections were incubated with Pathologie Anatomie Leiden-Endotheel (PAL-E, mouse-
antibody, Department of Pathology, Leiden University, Leiden, the Netherlands) diluted 
1:15 and rabbit-anti-pimonidazole (J. A. Raleigh)30,32 diluted 1:200 in polyclonal liquid 
dilutant (PLD, Euro-DPC, Breda, the Netherlands) during 30 min at 37 °C. Sections 
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were then incubated with goat-anti-mouse-Texas-red (Jackson Immuno Research 
Laboratories, West Grove, PA, USA) and donkey-anti-rabbit-Alexa488 (Molecular 
Probes, Leiden, the Netherlands), both diluted 1:200 in PLD during 30 min at 37 °C. 
Finally, sections were mounted in fluorostab (Organon, Boxtel, the Netherlands).  
Quantitative data for hypoxia and tumor vasculature were acquired using a 
semi-automatic method based on a computerized digital image analysis system, as 
described previously.33,34 In brief, a high-resolution intensified solid-state camera on a 
fluorescence microscope (Axioskop, Zeiss, Weesp, the Netherlands) with a computer-
controlled motorized stepping stage was used to scan each tumor cross-section. Whole 
tumor sections were scanned at 100x magnification with different filters for the 
detection of the fluorescent signals. Each scan consisted of 36-144 fields of 1.2 mm2, 
depending on the size of the tumor section. From the individual microscopic fields one 
composite image was reconstructed after each scan. As a final step a contour line was 
drawn to delineate the viable tumor area, using consecutive H&E stained tumor 
sections to distinguish tumor from non-tumor tissue. The hypoxic fraction (HF) of the 
tumor section was computed as the tissue surface area stained by the hypoxic marker 
relative to the viable tumor surface area and VD was calculated as total number of 
vessels per mm2 of viable tumor area. The average HF and VD for each liver 
metastasis were calculated, averaging the scores of all tumor sections per liver 
metastasis. 
 
STATISTICAL ANALYSIS 
The mean and range of T/NT, kep, HF and VD for the whole population were calculated, 
and to assess the relations between FDG uptake, rate constant kep of Gd-DTPA 
uptake, HF and VD Pearson’s correlation coefficients were calculated with SPSS 
(version 12.0.1). To calculate the 95% regression and prediction intervals for the 
relation between FDG T/NT and kep SigmaPlot (version 9) was used. Values of p < .05 
were regarded as statistically significant, whereas values of p < .1 were interpreted as 
a trend. 
 
RESULTS 
STUDIES PERFORMED 
FDG-PET data were available for 19 of 26 patients, DCE-MRI data for 25 patients and 
immunohistochemistry data for 22 patients (table 1). In six patients (no. 4, 6, 8, 19, 21, 
24)  FDG-PET was not clinically indicated according to the attending surgeon and in  
one patient (no. 7) no liver metastases were detected by FDG-PET. In one patient (no. 
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Table 1  Patient characteristics and assessment modalities. (+) indicates that data are available for this 
patient, (-) indicates that data are not available.  
 
14) there was no spleen in the field of view of the MRI scan. Data of this patient were 
excluded from the analysis of Gd-DTPA uptake. In two patients no tumor material was 
available since surgery was canceled because of irresectable liver metastases (no. 11) 
or metastases outside the liver (no. 12). In one patient no tumor material was available 
because the metastasis was treated with radiofrequent ablation (no. 21). For one of the 
patients (no. 17) no data on tumor hypoxia were available, since this patient refused 
the administration of pimonidazole. In two patients (no. 8 and 24) the liver metastases 
could not be resected,  but a biopsy was taken.  Direct comparison of FDG-PET and 
DCE-MRI data could be made for 18 patients,  comparison of FDG-PET and immuno- 
number gender age PET MRI 
immunohisto- 
chemistry 
TNM stage at time of diagnosis of 
primary tumor 
1 female 62 + + + T3 N1 M1 
2 female 51 + + + T3 N0 M1 
3 male 64 + + + T1 N0 Mx 
4 male 44 - + + T3 N1 Mx 
5 female 69 + + + T3 N1 M1 
6 female 63 - + + T3 N0 M1 
7 male 67 - + + T3 N0 Mx 
8 female 55 - + + T3 N2 M1 
9 female 67 + + + T3 N1 Mx 
10 female 55 + + + T3 N0 M0 
11 male 70 + + - T3 N0 Mx 
12 female 54 + + - T3 N1 Mx 
13 female 58 + + + T3 N1 Mx 
14 male 74 + - + T3 N1 Mx 
15 male 58 + + + T3 N1 M1 
16 female 52 + + + T3 N1 M1 
17 male 72 + + - T3 N0 M1 
18 female 57 + + + T3 N1 Mx 
19 male 70 + + + T4 N0 M0 
20 male 65 - + + T3 N1 M1 
21 male 66 + + - T3 N1 M1 
22 male 50 - + + T3 N1 M1 
23 female 50 + + + T2 N0 M0 
24 female 61 + + + T3 N1 M1 
25 male 43 - + + T3 N1 M1 
26 female 52 + + + T4 N1 Mx 
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A B C 
Figure 1  In (A) a transversal FDG-PET image is shown for one patient. In (B) the T1 weighted MR image 
(TR 50 ms, TE 4. 4 ms, flip angle 90°, slice thickness 7 mm, matrix 160x256, FoV 263x350 mm) 
shows the same liver metastasis (indicated by the arrow) to allow direct comparison of FDG 
T/NT and kep for the individual metastases. On this image a region of interest was drawn to 
delineate the metastasis, which was then applied to the map of the rate constant kep of Gd-
DTPA uptake (C) to select the single values of kep for all tumor pixels. 
 
 
 
 
 
 
 
 
 
 
Figure 2 Relation between the tumor to non-tumor ratio (T/NT) of 18FDG uptake and the rate constant kep 
of Gd-DTPA uptake. The regression line (black line), 95% confidence interval (black curved 
lines) for means and the 95% prediction interval (dotted lines) for individuals are indicated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
r = -.421 
p = .082
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Figure 3  Binary image of a complete tumor section stained for both hypoxia (green) and vasculature (red) 
in A; corresponding H&E section in (B) (100x magnification). The arrows indicate viable tumor 
tissue. The scalebar indicates 100 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4  Relation between the rate constant kep of Gd-DTPA uptake and vascular density. The 
regression line (black line), 95% confidence interval (black curved lines) for means and the 95% 
prediction interval (dotted lines) for individuals are indicated.  
 
 
 
 
 
 
 
 
 
 
 
r  = .458 
p = .037 
A B 
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histochemistry data for 15 patients and comparison of DCE-MRI and 
immunohistochemistry data for 21 patients. The mean time interval between the 
performance of FDG-PET and DCE-MRI was 35 days (s.e.m. eight days), between 
FDG-PET and surgery 50 days (s.e.m. ten days) and between DCE-MRI and surgery 
12 days (s.e.m. two days). Patients did not receive anticancer therapy between FDG-
PET, DCE-MRI and surgery, except for patient no. 1 who received two cycles of 5-
fluorouracil (FU) and leukovorin (LV) between FDG-PET and DCE-MRI and patient no. 
16 who received one cycle of FU, LV and oxaliplatin between FDG-PET and DCE-MRI. 
 
COMPARISON OF T/NT AND KEP 
From the FDG-PET images (figure1 A) the T/NT values were calculated for all patients 
for whom FDG-PET data were available (19/26 patients). The mean T/NT of these 
patients was 2.021 (s.e.m. 0.187). On the T1 weighted MR image recorded just before 
Gd-DTPA administration the metastases could easily be detected in all patients for 
whom DCE-MRI data were available (25/26 patients) (figure 1B). The mean kep of 
these patients was 0.031 (s.e.m. < 0.001). Comparison of the T/NT ratios and kep 
showed a trend for higher T/NT values at lower kep values (p = .082; figure 2). 
Excluding one observation with a relatively high T/NT ratio (upper point in figure 2) from 
the analysis, resulted in a significant correlation between T/NT and kep (p = .049). The 
omitted patient did not differ from the whole population with respect to age, co-
morbidity, medication, differentiation grade of the metastasis or tumor diameter as 
measured after resection.  
 
COMPARISON OF HF, VD, T/NT AND KEP 
The mean HF for all liver metastases, computed as the tissue surface area stained by 
the hypoxic marker relative to the viable tumor surface area, was 0.134 (s.e.m. 0.013; 
figure 3). No significant correlations were found between HF and FDG T/NT (p = .783), 
nor with kep (p = .442) and VD (p = .641).  
The mean VD for all liver metastases, measured as the number of vessels per 
mm2 of viable tumor area, was 25.4 mm-2 (s.e.m. 1.97). A statistically significant 
positive correlation between vascular density and values of kep was found (figure 4), but 
there was no correlation between vascular density and FDG T/NT ratios (p = .944). 
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DISCUSSION 
RELATION BETWEEN FDG T/NT AND KEP 
Both FDG-PET and DCE-MRI are in vivo methods which can provide functional 
information about tumor tissue. DCE-MRI allows to obtain information on the tumor 
vascular system, which mediates the supply of glucose and oxygen. Other factors 
which may be of importance for FDG uptake, i.e. upregulation of GLUT, HK and 
glycolysis, cannot be assessed by this method and should be investigated in future 
studies.  
The results showed a negative correlation between T/NT ratios of FDG uptake 
and Gd-DTPA uptake rate constants kep in liver metastases. When the tumor blood flow 
(TBF) is much larger than the permeability surface area product (PS), lower values of 
kep may indicate lower PS (see formula for kep in Materials and Methods). When TBF is 
much smaller than PS, lower values of kep may indicate lower TBF. A lower blood flow, 
lower permeability or smaller surface area of tumor blood vessels may all result in a 
reduced supply of nutrients like FDG and oxygen to the tumor. A reduced supply of 
nutrients could lead to lower FDG T/NT ratios in the tumor, as was shown in an 
experimental study in which substrate availability modulated glucose metabolism,35 and 
would result in a positive correlation between T/NT ratios and kep. However, the poorer 
vascular function, reflected by lower values of kep, could not only lead to a reduced 
supply of nutrients, but also to a reduced supply of oxygen. A reduced supply of 
oxygen would necessitate a higher uptake of glucose in order to maintain tumor energy 
levels. This would lead to higher FDG T/NT ratios in the tumor, thus resulting in a 
negative correlation between kep and FDG T/NT ratios. Therefore, the observed 
negative correlation between kep and FDG T/NT ratios suggests that differences in 
tumor oxygenation rather than differences in FDG delivery are a driving force for FDG 
uptake in colorectal liver metastases.  
Whether FDG delivery or tumor oxygenation are the driving force for FDG 
uptake may be tumor and even stage dependent. For example, a positive correlation 
between FDG uptake and the permeability surface area product as determined by 
DCE-MRI was found in patients with lung cancer36 and between the metabolic rate of 
FDG and blood flow determined by 15O-water measurements in patients with advanced 
breast cancer.37 Brix et al.38 did not observe a correlation between FDG-PET and DCE-
MRI parameters in a group of patients with suspicious breast lesions. Clearly, this 
group consisted of different stages of breast cancer, which might explain the lack of 
correlation between FDG-PET and DCE-MRI parameters.  
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RELATION BETWEEN HF, FDG T/NT AND KEP  
The hypothesis that tumor hypoxia is a driving force for FDG uptake in colorectal liver 
metastases seems to contradict the observed lack of correlation between FDG uptake 
and HF in liver metastases as measured by pimonidazole binding. In this respect the 
difference between ‘chronic’ or ‘diffusion limited’ hypoxia, according to the classical 
model of Thomlinson and Gray39 and ‘acute’ or ‘transient’ hypoxia,40 due to local and 
temporary fluctuations of tumor blood perfusion may be relevant. Experimental tumor 
cells in an acutely hypoxic environment may increase their FDG uptake more than 
twofold41,42 in order to survive the temporary decrease in oxygen supply. A decreased 
cell proliferation has been shown in chronically hypoxic regions.43 This may be 
interpreted as an energy saving method to adapt to a reduced supply of oxygen and 
nutrients. Alternatively, it may be argued that an important part of the chronically 
hypoxic cell population is becoming necrotic or apoptotic and is therefore less 
metabolically active. In these chronically hypoxic regions FDG uptake will actually 
decrease. Thus, depending on whether acute or chronic hypoxia plays a major role, 
hypoxic tumors can be highly metabolic or may have modest glucose metabolism.44 
The discordance of FDG uptake and tumor hypoxia can be tumor type specific44 and 
may even be heterogeneous within one tumor.45 Both chronically and acutely hypoxic 
cell regions contribute to the measured hypoxic fraction as measured by pimonidazole. 
This may explain the lack of correlation between FDG uptake and hypoxia in liver 
metastases in this study.  
 
RELATION BETWEEN VD, FDG T/NT AND KEP 
A positive correlation between VD and the Gd-DTPA uptake rate constant kep was 
observed, but not between VD and FDG uptake. A positive correlation between 
microvascular density and DCE-MRI vascular parameters has been reported by 
Hawighorst et al.25 for cervical carcinoma, but Su et al.46 did not observe such a 
correlation in breast cancer. As explained above, kep is defined by (the product of) 
permeability of perfused capillaries and surface area of perfused capillaries and by 
tumor blood flow. From this definition, the relation between the Gd-DTPA uptake rate 
constant kep and the vascular density is obvious. However, it should be noted that in 
VD, both perfused and non-perfused vessels are included. Since mainly the acute 
closure of the former seems to determine uptake of FDG in colorectal liver metastases, 
this may explain the lack of correlation between VD and FDG uptake and underscores 
the importance of functional in vivo data on the tumor vascular system.  
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LIMITATIONS OF THE STUDY 
The mean time interval between FDG-PET and DCE-MRI and FDG-PET and surgery 
was relatively long in this study. It may be suggested that the lack of correlation 
between FDG-PET and immunohistochemical results was caused by this long time 
interval. However, since it seems unlikely that the correlation between FDG-PET and 
DCE-MRI data is caused by the long time interval between the two scans, the lack of 
correlation between FDG-PET and immunohistochemical results should be explained 
by biological factors, rather than the long time interval. Nevertheless, its influence 
cannot be excluded. Two patients received anticancer therapy between FDG-PET and 
DCE-MRI. Although this may have influenced the results, it only regards a small 
number of patients. 
  The mean value of kep indicates the value of this parameter over the region of 
interest, but does not reflect the heterogeneity of a tumor. Currently, statistical 
analyses, like a functional principal component analysis, are under investigation, to 
further characterize spatial heterogeneity (see for example O’Connor et al.47). Although 
in the present analysis tumor heterogeneity was not taken into account, all data are 
corrected for (gross) necrosis. 
  It should be noted that an exact one-to-one correlation between FDG-PET or 
DCE-MRI and immunohistochemistry was not fully possible, since tissue sections had 
a size of approximately 5 µm x 5 mm x 5 mm, whereas the PET and MRI data were 
obtained from the whole or a large part of the tumor. Also, in two patients the 
metastases were not fully removed and a biopsy was taken during surgery. It was 
assumed that the acquired material was a sufficient representation for the whole tumor. 
Since the sample size of this study was small, it should be expanded in a future follow-
up. 
 
CONCLUSION 
For colorectal liver metastases a negative relationship was found between the rate 
constant kep of Gd-DTPA uptake as determined from DCE-MRI and FDG T/NT ratios as 
measured by PET. This suggests that in liver metastases differences in acute tumor 
hypoxia which are caused by differences in functional tumor vasculature constitute a 
driving force for FDG uptake. The observed correlation between vascular density and 
the rate constant kep of Gd-DTPA uptake, but not with T/NT ratios, emphasizes the 
potential of DCE-MRI to measure tumor vascularity in vivo and its additional value 
compared to ex vivo methods.  
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ABSTRACT  
In metastatic colorectal cancer the oral 5-fluorouracil (FU) prodrug capecitabine is used 
with increasing frequency as an alternative to intravenous FU administration. The rate 
of  conversion of capecitabine into 5′deoxy-5-fluorouridine (5′DFUR) has been related 
to tumor response and FU catabolites have been associated with FU-related systemic 
toxicity. In this study it is demonstrated for the first time that capecitabine, its 
metabolites 5′deoxy-5-fluorocytidine and 5′DFUR and its catabolites α-fluoro-β-
ureidopropionic acid, α-fluoro-β-alanine (FBAL) and FBAL-bile acid conjugate can be 
monitored in vivo by fluorine-19 magnetic resonance spectroscopy (19F MRS) in the 
liver of patients with metastatic colorectal cancer. Moreover, an improved signal-to-
noise ratio and spectral resolution of the 19F MRS spectra is demonstrated when 
measurements are performed at 3 Tesla (T) field strength as compared to 
measurements at the common clinical field strength of 1.5 T. In conclusion, 
assessment of capecitabine metabolism in patients by 19F MRS is a promising 
noninvasive tool for the prediction of its efficacy and toxicity, especially at the now 
currently available clinical field strength of 3 T. 
 
KEYWORDS 
capecitabine metabolism; colorectal carcinoma; 19F magnetic resonance spectroscopy;  
3 Tesla 
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INTRODUCTION  
Predicting the sensitivity of a tumor to chemotherapy in cancer patients would enable 
individualization of therapy, by which unnecessary toxicity in nonresponding patients 
could be avoided. A correlation between response to therapy and pharmacokinetic 
parameters measured with fluorine-19 magnetic resonance spectroscopy (19F MRS)  
has been shown for the widely used cytotoxic drug 5-fluorouracil (FU).1 Since 19F MRS 
is a noninvasive technique which allows the measurement of FU metabolism at specific 
sites of interest, it is an attractive tool for the prediction of therapy outcome.  
 In patients with advanced colorectal cancer, oral capecitabine is used with 
increasing frequency as an alternative to intravenous FU treatment, due to its 
comparable efficacy, ease of administration and more favorable toxicity profile.2,3,3 
Capecitabine is preferentially metabolized to FU in tumors and liver by a three step 
enzymatic process,4 involving conversion into 5′deoxy-5-fluorocytidine (5′DFCR), 
followed by conversion into 5′deoxy-5-fluorouridine (5′DFUR). In the third step 5′DFUR 
is metabolized into FU by the enzyme thymidine phosphorylase (TP). In preclinical 
studies the rate of 5′DFUR conversion as determined by 19F MRS has been related to 
the level of TP in tumors5 and a strong correlation between TP levels in tumors and 
tumor response has been observed.6 FU is further metabolized via different 
biochemical pathways to cytotoxic metabolites. FU catabolites like α-fluoro-β-alanine 
(FBAL) have been associated with FU related systemic toxicity.7 This study reports for 
the first time that the metabolism of capecitabine after oral intake can be monitored in 
vivo by 19F MRS. 
 Until now human 19F MRS studies have been performed at standard clinical MR 
systems operating at 1.5 Tesla (T) field strength. Recently, 3 T MR scanners have 
become available for clinical application. For 19F MRS the use of higher field strengths 
is expected to result in an increased signal-to-noise ratio (SNR) and an improvement of 
spectral resolution, which would better facilitate its use in clinical examinations of 
fluorinated drugs. Therefore, in this study a first investigation of  19F MRS on patients at 
3 T is included. 
 
MATERIALS AND METHODS 
Since the liver is the primary site of capecitabine metabolism as well as the 
predominant site for metastasis of colorectal cancer, nine 19F MRS measurements in 
the liver of five patients with advanced colorectal cancer were performed (table 1). 
Patients were treated with oral capecitabine during two weeks. All patients had a 
Karnofsky performance status ≥ 90% and a normal liver function. 19F MRS 
measurements were performed during at least 40 min, starting approximately  1 h after  
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Table 1  Patient characteristics, 19F MRS measurables and treatment response 
no. 
sex 
age 
tumor 
site  
MR field 
strength 
treatment % change of 
DFUR+DFCR 
during 
measurement 
interval 
% change of 
FU  
catabolites 
during 
measurement 
interval 
follow-up 
(1) 
M 
60 
liver  
 
 
 
 
1.5T 
capecitabine 1000 
mg/m², twice daily, 
day 1-14, irinotecan 
250 mg/m², day 1  
 
cycle 2, day 9 
 
 
 
 
 
 
-59%   
(59-105 min) 
 
 
 
 
 
-19% 
(59-113 min) 
 
partial 
response 
after three 
cycles 
(2) 
M 
57 
liver  
 
 
 
1.5T 
 
3.0T 
 
1.5T 
capecitabine 1250 
mg/m², twice daily, 
day 1-14 
 
cycle 1, day 10 
 
cycle 16, day 9 
 
cycle 16, day 10 
 
 
 
 
 
-59%  
(76-119 min) 
-100% 
(51-54 min) 
no 
DFUR+DFCR 
(42-63 min) 
 
 
 
 
+17% 
(76-119 min) 
+5% 
(51-75min) 
-1%  
(42-63 min) 
 
stable 
disease after 
three cycles, 
partial 
response 
after six 
cycles, 
continued 
partial 
response 
after 15 
cycles 
 
(3) 
M 
72 
lung  
 
 
 
 
3.0T 
 
1.5T 
capecitabine 1250 
mg/m²  
twice daily, day 1-14 
 
 
cycle 5, day 11 
 
cycle 5, day 12 
 
 
 
 
 
-39%  
(60-84 min) 
-40% 
(63-85 min) 
 
 
 
 
 
+64% 
(60-84 min) 
+19% 
(63-85 min) 
 
partial 
response 
after three 
cycles 
(4) 
M 
55 
liver  
 
 
 
 
3.0T 
 
1.5T 
capecitabine 1250 
mg/m²  
twice daily, day 1-14 
 
 
cycle 7, day 2 
 
cycle 7, day 3 
 
 
 
 
 
+334%  
(35-75 min) 
+48%  
(45-81 min) 
 
 
 
 
 
 
+592% 
(35-75 min) 
-5%  
(45-89 min) 
continued 
partial 
response 
after six 
cycles 
(5) 
F 
70 
lung 
 
 
 
 
 
 
1.5T 
capecitabine 1250 
mg/m²  
twice daily, day 1-14 
 
 
cycle 3, day 11 
 
 
 
 
 
+130%  
(41-79 min) 
 
 
 
 
 
+64%  
(41-84 min) 
stable 
disease after 
three cycles 
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oral intake of capecitabine in the two-week period of oral capecitabine intake. Patients 
gave written informed consent and the experiments were approved by the institutional 
review board of the Radboud University Nijmegen Medical Centre, the Netherlands. 
 19F MRS measurements were performed on both a clinical 1.5 T and a 3 T 
whole body Siemens MR system. A flexible 16 cm 19F MR coil was used to enable 
optimal positioning across the liver region in order to receive the MR signals of 
capecitabine and its metabolites from that region. For all measurements a pulse 
acquire sequence was used with a repetition time of 470 ms. In patient 2, 3 and 4 
(table 1) pulse acquire measurements were interleaved with localized measurements 
by 19F MR spectroscopic imaging (MRSI).8 The use of MRSI gives the opportunity to 
differentiate between the conversion of capecitabine in tumor and normal liver tissue.  
An 8 x 8 x 8 MRSI was used with a voxel size of 4 x 4 x 4 cm. Both pulse acquire and 
MRSI measurements were optimized for signal to noise9 with a temporal resolution of 4 
min. No respiratory gating was used. Resonances in the 19F MR spectra were analyzed 
using MRUI software.10 Percentual changes during the measurement interval in 19F MR 
spectral peak areas obtained by the pulse acquire sequence were determined for 
5′DFCR + 5′DFUR and the FU catabolites. For 5′DFCR + 5′DFUR the difference in MR 
peak area of the last spectrum that showed the MR peak of 5′DFCR + 5′DFUR and the 
peak area of the first spectrum that showed this MR peak was normalized to the peak 
area of the first spectrum. For FU catabolites the same method was applied.   
 To confirm peak assignments of the capecitabine metabolites 5′DFCR and 
5′DFUR referenced to the spectral position of the FU signal, urine of patient 2 collected 
from 3-10 h after capecitabine intake was measured at 1.5 T using the same MR 
protocol, after which 5′DFCR, 5′DFUR (Roche, Mijdrecht, the Netherlands) and FU 
(Teva Pharma, Mijdrecht, the Netherlands) were added consecutively. The 
dependence of spectral peak position on pH was examined by adding HCl and NaOH 
to solutions of FU with 5′DFCR or 5′DFUR in normal saline (0.9%), measuring pH by an 
EcoScan pH meter (Eutec, Amsterdam, the Netherlands) and peak position by the 
aforementioned MR protocol. 
 To quantify the improvement of SNR at 3 T in comparison with 1.5 T the 
amplitude of the catabolite peaks in the 19F MR spectra of patient 2, 3 and 4 were 
obtained at a similar timepoint after capecitabine intake from the 1.5 T and 3 T 
measurements. The amplitude was divided by the standard deviation of the noise from 
the same spectrum. This ratio acquired for the measurement at 3 T was divided by the 
ratio for that at 1.5 T to obtain the factor of improvement in SNR for each patient. 
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Figure 1  Sequential 19F MR spectra of the liver of patient 1, obtained by a pulse acquire sequence at 1.5 
T and starting 60 min after oral capecitabine intake. Inset: expanded spectrum of the region 
from -5 to 15 ppm, showing the average of spectra taken from 60 till 76 min after capecitabine 
intake. 5′DFCR = 5′deoxy-5-fluorocytidine; 5′DFUR = 5′deoxy-5-fluorouridine; FUPA = α-fluoro-
β-ureidopropionic acid; FBAL = α-fluoro-β-alanine  
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RESULTS AND DISCUSSION 
19F MR spectra taken from the liver showed distinct resonances for capecitabine and its 
metabolic products (figure 1). Spectra obtained at 3 T showed a factor 1.3-3 higher 
signal-to-noise ratio and an improved spectral resolution in comparison with those 
obtained at 1.5 T (figure 2), as may be expected from measurements at higher field 
strengths. 
 Peak assignments to 5′DFCR and 5′DFUR were confirmed in measurements of 
urine samples (pH 5.87) at 4.0 and 3.4 ppm, respectively. The spectral peak position of 
5′DFUR showed pH dependence, with upfield shifting (more towards FU) at lower pH. 
A similar pH dependent upfield shifting has been described for various other FU 
anabolites.11 The data were fitted to the Henderson Hasselbalch equation pH = pKa + 
log{(x-a)/(b-x)} with x representing the spectral peak position in ppm. A dissociation 
constant pKa of  7.41 was found, with a = 3.35 and b = 5.53 (R2 = 0.995). Since the pKa 
of 5′DFUR falls within the physiological pH range and as this range corresponds with a 
relatively large shift in ppm values,  5′DFUR can be used as an in vivo marker of tissue 
pH. From the spectra the pH of liver tissue was found to be 7.39 which agrees with in 
vivo pH values in liver tissue measured by 31P MRS.12 In isolated tumor cells 
intra/extracellular FU ratio correlated with extracellular pH, intracellular pH and the pH 
gradient across the cell membrane.13 In an animal model a decrease in local tissue pH 
from 7.3 to 6.9 was associated with a 2.5 times increase of the t½ of FU, indicating a 
trapping of FU in the tumor.14 Because of the relation between trapping of FU in the 
tumor and tumor response,1 in vivo measurement of  pH by the 5′DFUR signal shift can 
be useful in the prediction of therapy outcome. 
 The time course of capecitabine metabolism is shown in figure 1 for patient 1. In  
this patient the concentration of capecitabine in the liver declined to below MR 
detectable levels within 80 min after intake due to its conversion and clearance (figure 
1). The conversion and clearance of capecitabine metabolites was highly variable 
between patients, as is indicated in table 1. In all patients  5′DFCR and 5′DFUR were 
MR detectable for a prolonged time compared with capecitabine. This is in accordance 
with pharmacokinetic parameters in plasma which showed a longer t½  for 5′DFCR and 
5′DFUR compared with capecitabine.15 In fasting patients a delay in occurrence of 
maximum plasma concentration and area under the plasma concentration curve has 
been described for capecitabine and its metabolites, with no effect on the apparent 
elimination half life.16 In all patients capecitabine was administered in non-fasting 
condition, as has been the procedure in clinical trials.  
 FU concentration was below MR detectable levels due to its rapid metabolic 
conversion.  FBAL, a FU catabolite, was detected in both the unlocalized (figure 1) and 
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Figure 2  19F MR spectra of the liver of patient 4, obtained by a pulse acquire sequence at 1.5 T (A) and 3 
T (B),  showing the average of two spectra taken 68 and 76 min after oral capecitabine intake. 
To facilitate comparison the 3 T spectrum have been scaled to equal noise levels with the 1.5 T 
spectrum.  
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Figure 3  Localized spectra obtained by 19F MR spectroscopic imaging at 1.5 T of patient 2, 60 min after 
oral capecitabine intake on day 10. Figure 3A and 3B show the spectra from five tumor voxels 
and four liver voxels as indicated on the T1 weighted image (figure 3D), respectively. The tumor 
has a maximum diameter of approximately 7 cm and its centre is located at a distance of at 
least 8 cm from the coil. Figure 3C shows the spectrum from four gallbladders voxels as 
indicated on the T2 weighted image (figure 3E). A = anterior; R = right; S = superior; other 
abbreviations as in figure 1. 
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localized spectra (figure 3). Others have shown in humans that in urine FBAL was the 
major metabolite of capecitabine.17 The large peak in the spectra 2-2.5 ppm downfield 
from FBAL is usually assigned to the FU catabolite α-fluoro-β-ureidopropionic acid.18 
Recently, at this spectral position a contribution from FBAL-bile acid conjugate has 
been described.19 Evidence from both 19F NMR spectroscopic studies20 and high-
performance liquid chromatography21 indicate that the major biliary metabolites of FU 
are conjugates of FBAL. The amplitude of the peak in localized spectra from 
gallbladder voxels (figure 3C) supports this latter assignment. FBAL-bile acid 
conjugates would be able to undergo entero-hepatic recirculation. Protracted venous 
infusion (PVI) of FU may establish a higher pool of recirculating catabolite compared 
with bolus infusion of FU, resulting in higher biliary catabolite levels.19 The mimicking of 
conventional PVI of FU is one of the claimed properties of oral fluoropyrimidines. Since 
hepatic catabolite levels are correlated with toxicity in patients receiving PVI of FU,22 
FBAL kinetics measured by 19F MRS may be an early predictor of capecitabine-related 
toxicity.  
 If the correlation between the rate of 5′DFUR conversion and tumor response5,6 
is confirmed in the clinical setting, 19F MRS can also be used as a noninvasive method 
for predicting the antitumor response of capecitabine. This would be highly relevant 
since advanced colorectal cancer is a frequently occurring cancer and only a subset of 
patients responds to fluoropyrimidine-based therapy. In conclusion, 19F MRS of 
capecitabine metabolism, or of other orally administered prodrugs,23 is a promising tool 
for the individualization of chemotherapy, especially when higher field strengths can be 
applied for better sensitivity. 
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ABSTRACT  
Systemic chemotherapy is effective in only a subset of patients with metastasized 
colorectal cancer. Therefore, early selection of patients who are most likely to benefit 
from chemotherapy is desirable. Response to treatment may be determined by the 
supply of the drug to the tumor and by the amount of intracellular uptake, metabolic 
activation and catabolism, as well as other factors. This study investigated the relation 
between the potential for tumor drug supply measured by dynamic contrast enhanced 
MRI (DCE-MRI) and response to first-line chemotherapy in patients with liver 
metastases of colorectal cancer, as well as the relation between 5-fluorouracil (FU) 
uptake and metabolism measured by fluorine-19 MR spectroscopy (19F MRS) and 
response to FU therapy. Since FU uptake and metabolism may depend on supply of 
the drug to the tumor, the relationship between 19F MRS and DCE-MRI parameters 
was also examined. Thirty-seven patients were included. Kinetic parameters of DCE-
MRI before start of treatment did not predict tumor response after two months, 
suggesting that the delivery of chemotherapeutic agents by tumor vasculature is not a 
major factor determining response in first-line treatment. No evident correlations 
between 19F MRS parameters and tumor response were found. This may imply that in 
liver metastases which are not selected on the basis of their tumor diameter, FU uptake 
and catabolism are not limiting factors for response. The transfer constant Ktrans as 
measured by DCE-MRI before start of treatment was negatively correlated with FU half 
life in the liver metastases, which suggests that in metastases with a larger tumor blood 
flow or permeability surface area product FU is washed out faster from the tumor. 
  
KEYWORDS 
colorectal cancer, dynamic contrast enhanced MRI, 5-fluorouracil, 19F MR 
spectroscopy, liver metastases,  
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INTRODUCTION 
In the western world colorectal cancer is one of the most frequently occurring cancers. 
About half of the patients with colorectal cancer develops distant metastases for which 
palliative chemotherapy is usually the treatment of choice. Fluorinated drugs like         
5-fluorouracil (FU) and the FU prodrug capecitabine are currently the most commonly 
used drugs in chemotherapy regimens for colorectal cancer. New classes of drugs like 
irinotecan and oxaliplatin have become available.1 However, chemotherapy is effective 
only in a subset of patients with colorectal cancer. Individual prediction of response of a 
tumor to chemotherapy (‘chemosensitivity’) at an early stage would enable 
individualization of therapy. This would prevent unnecessary toxicity in nonresponding 
patients and reduces health care costs.  
The response of a tumor to chemotherapy is among other factors determined 
by the supply of cytotoxics to the tumor and by the amount of intracellular uptake, 
metabolic activation and catabolism. Tumor drug supply depends, among other factors, 
on the tumor vascular system. Assuming that cytotoxics and the MR contrast agent 
Gadolinium-DTPA (Gd-DTPA) are transported in a similar way by the tumor vascular 
system, the potential for supply of chemotherapy to the tumor can be characterized in 
vivo and noninvasively by dynamic contrast enhanced magnetic resonance imaging 
(DCE-MRI). Analysis of DCE-MRI data yields kinetic parameters like the rate constant 
of contrast exchange between extra vascular extra cellular space and blood plasma 
(kep) and the corresponding volume transfer constant (Ktrans).2 The predictive value of 
DCE-MRI parameters for treatment outcome has been shown for several tumor types 
like sarcoma,3 cervical carcinoma,4 rectal cancer5,6 head and neck cancer,7 glioma,8 
and urinary bladder cancer.9  
The in vivo uptake of fluorinated drugs can be measured noninvasively by 
means of fluorine-19 MR spectroscopy (19F MRS). It has been suggested that an 
increased half life of FU presence in the tumor as measured by 19F MRS, so-called 
tumor trapping, correlates with the response to FU therapy.10 Also the conversion of FU 
to cytoxic anabolites and to catabolites can be monitored by means of 19F MRS. FU 
catabolites have been associated with FU related systemic toxicity.11  
The aims of this study were to investigate the relationship between the potential 
for delivery of the drug to the tumor as measured by DCE-MRI and response to first-
line chemotherapy in patients with liver metastases of colorectal cancer, and to study 
the relationship between FU uptake and metabolism as measured by 19F MRS and 
response to FU therapy. Since it may be hypothesized that FU uptake and metabolism 
are dependent on tumor drug supply, the relationship between 19F MRS and DCE-MRI 
parameters was also examined.  
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MATERIALS AND METHODS 
PATIENTS 
Patients with liver metastases of histologically proven colorectal carcinoma for whom 
start of first-line chemotherapy was planned were eligible for this study. Patients gave 
written informed consent. The study was approved by the institutional review board of 
the Radboud University Nijmegen Medical Centre, the Netherlands. Between August 
2000 and September 2003, 37 patients were included, 20 males and 17 females (mean 
age 59 years, range 33-77 years).  
 
CHEMOTHERAPY 
Patients underwent one of the following four chemotherapy regimens: 1) monthly FU 
(425 mg/m2) and leucovorin (LV, 20 mg/m2) day 1-5, q 4 weeks (n = 27); 2) 
capecitabine (2500 mg/m2) day 1-14, q 3 weeks (n = 5); 3) capecitabine (2000 mg/m2) 
day 1-14 combined with irinotecan (250 mg/m2) on day 1, q 3 weeks (n = 3); 4) 
oxaliplatin (85 mg/ m2) on day 1, 15 and 29 combined with weekly FU (2600 mg/m2) 
and LV (200 mg/ m2) week 1-6, q 7 weeks (n = 2). 
 
DCE-MRI 
DCE-MRI was performed before start of chemotherapy and after one (regimen 4), two 
(regimen 1) or three (regimens 2 and 3) cycles of chemotherapy. Measurements were 
performed on a 1.5 T Siemens Vision MR scanner, using a body phased array coil. 
After a scout image, conventional T1 and T2 weighted images were acquired. Just 
before Gd-DTPA injection proton density weighted images were recorded with the 
same sequence parameters as the DCE-MRI (except for the flip angle flip angle 8° and 
repetition time (TR) 200 ms) to calculate the concentration of Gd-DTPA in arbitrary 
units, using the method described by Hittmair et al.12 Then 15 ml 0.5 M Gadolinium-
DTPA (Gd-DTPA, Magnevist, Schering, Berlin, Germany) was administered 
intravenously at an injection rate of 2.5 ml/s by a SpectrisTM MR injection system 
(Medrad, Inc., Maastricht, the Netherlands). An axial T1 weighted fast low-angle shot 
(FLASH) sequence was used to monitor Gd-DTPA uptake in the tumor and the bolus 
passage in vessels in the spleen with a temporal resolution of two seconds (TR 50 ms, 
echo time 4.4 ms, flip angle 90°, slice thickness 7 mm, 4 slices, matrix 160x256, field of 
view (FoV) 263x350, acquisition time 90 seconds). The sequence was a 2D variant of 
the 3D time-resolved imaging of contrast kinetics (3D TRICKS),13 as described by 
Rijpkema et al.14 In case of multiple metastases for DCE-MRI the metastasis to be 
monitored was chosen as the one which was most readily detected on the T1 weighted 
images and/or the one which was most suitable for 19F MRS (see below). If the slices 
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could not fully cover the tumor in the head-foot direction, slices were positioned in such 
a way that the largest diameter of the tumor (measured left to right on the coronal view) 
was covered.  
DCE-MRI data were analyzed as described previously.15 In brief, using a 
vascular normalization function (VNF) from pixels in the spleen, the data were fitted to 
a physiological pharmacokinetic model.2 From this model the rate constant kep (s-1) and 
the transfer constant Ktrans (a.u. s-1) were calculated for the liver metastasis according to 
the equation: Ct(t) = Ktrans · e-kep· t * Cp(t), in which Ct = tissue concentration of Gd-DTPA; 
Cp = the concentration of contrast agent in plasma of a capillary; * denotes a 
convolution operation.16 In Larsson’s model,2 the Gd-DTPA uptake rate constant kep is 
directly related to tumor blood flow, the product of the permeability of perfused 
capillaries and the total surface area of perfused capillaries, according to: kep = (1 – 
exp(-PS/TBF)) · TBF/ve, in which ve = extra vascular extra cellular space per unit 
volume of tissue; P = permeability of capillaries (cm s-1); S = total surface area of 
vessels (cm2); PS = permeability surface area product (ml s-1); TBF = tumor blood flow 
(ml s-1).  
  The spatial distribution of the values of kep and Ktrans was represented in a map. 
On a T1 weighted MR image recorded directly before Gd-DTPA injection a region of 
interest was drawn which comprised the metastases. This region of interest was 
applied to the maps of kep and Ktrans in order to select the single values of kep and Ktrans 
for all tumor pixels. The mean of kep and Ktrans of these pixels was calculated after log 
transformation and averaged over all slices containing tumor tissue. Back 
transformation of this average log transformed value resulted in an average value of kep 
and Ktrans for the whole tumor.15 The average value of ve was calculated by dividing the 
average value of Ktrans by the average value of kep . 
 
19F MRS 
19F MRS measurements were performed on a 1.5 T Siemens Vision MR system on 21 
patients receiving FU and LV according to the Mayo Clinics schedule on the first day of 
treatment. FU (425 mg/m2) was administered as a bolus injection within 3 min. A 
flexible circular polarized coil was used consisting of a 16 cm circular coil element and 
a 2 x 14 cm butterfly coil element, placed across the liver region. For all patients either 
an 8 x 8 x 8 chemical shift imaging (CSI) sequence (TR 470ms, nominal voxel size 4 x 
4 x 4 cm) or an optimized technique using spherical k-space sampling with Hamming 
weighted averaging was used to obtain optimum signal-to-noise ratio (SNR) in CSI 
data sets (TR 450 ms, voxel size 4 x 4 x 4 cm).17 The first 19F MRS measurement was 
started at the time the FU bolus was injected. Acquisitions took place during a period of 
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40 min with a time resolution of 4 min. T1 and T2 weighted images were used for 
determination of the locations of the CSI voxels in tumor or in normal liver tissue. 
Quantitative changes during the measurement period in resonance amplitude of FU 
and α-fluoro-β-alanine (FBAL), the major MR visible FU catabolite, were fitted to a 
monoexponential function. The half life of FU retention and time to 50% of maximum 
catabolite resonance amplitude in liver metastases and normal liver tissue were used 
for correlation with other parameters (see below) if R2 of the fit was ≥ 0.80. 
 
RESPONSE 
To assess response measured the largest tumor diameter of the liver metastasis for 
which DCE-MRI and 19F MRS data were acquired was measured before and after one 
cycle (regimen 4), two cycles (regimen 1) or three cycles (regimen 2 and 3) of 
chemotherapy. In case of multiple liver metastases the diameters of up to five 
metastases were measured and summed to compare the sum of those diameters 
before and after treatment. Overall response (including response at sites other than the 
liver, measured with conventional computer tomography (CT) scans) was determined 
using the response evaluation criteria in solid tumors (RECIST) criteria.18 Response 
was assessed by one of the researchers (H.W.M.v.L.), blinded for the DCE-MRI and 
19F MRS data. Overall response was also determined by the attending clinical 
radiologist. When the overall response was scored differently between the two 
reviewers, the images were re-analyzed to reach a consensus for each patient. 
 
STATISTICS 
Mean differences between DCE-MRI parameters before and after treatment were 
calculated using the Student’s t-test for paired samples. To assess the relation 
between DCE-MRI parameters, 19F MRS parameters and overall response according 
to the RECIST criteria Spearman’s rho was calculated; for the relation with tumor 
diameter Pearson’s correlation coefficient was used. For the relation between DCE-
MRI and 19F MRS parameters Pearson’s correlation coefficient was calculated. All 
statistical calculations were performed with SPSS (version 12.0.1). Values of p smaller 
than .05 were regarded statistically significant. 
 
RESULTS  
STUDIES PERFORMED  
DCE-MRI before start of treatment was performed on all 37 patients. The mean time 
between DCE-MRI and start of treatment was six days (range 2-16 days). In five of 37 
patients DCE-MRI data could not be analyzed because the spleen was not included in 
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the FoV, which was necessary to determine the VNF. These data were excluded from 
the DCE-MRI analysis, so DCE-MRI data before start of treatment were available for 
32 patients. DCE-MRI after one, two or three cycles of treatment (depending on the 
chemotherapy regimen) could not be performed in three of 37 patients because of 
physical deterioration and in one of 37 patients because of technical failure. Thus, 
DCE-MRI after treatment was performed in 33 patients. The mean time between the 
first and second DCE-MRI was 56 days (range 42-64 days). In six of 33 patients no 
spleen was included in the FoV or the algorithm could not select a VNF, possibly due to 
interfering breathing or motion artifacts. These patients were excluded from the 
analysis of the second DCE-MRI, so DCE-MRI data after treatment were available for 
27 patients. 
 19F MRS was performed on 22 of 37 patients. In one patient no data were 
available due to a technical failure, so 19F MRS data of 21 patients were available for 
analysis. On 12 of 21 patients the conventional 8 x 8 x 8 CSI was used, and on nine of 
21 patients the optimized CSI technique (see Materials and Methods) was employed. 
In 15 of 21 cases DCE-MRI data before start of treatment were obtained for the same 
metastases on which 19F MRS was performed. For 13 of 21 patients DCE-MRI data 
after two cycles of treatment were available. 
 MRI data to determine response and data to determine overall response were 
available for all 37 patients, except for the three patients who were physically unable to 
undergo the second MRI. In one patient on capecitabine therapy evaluation took place 
after two instead of three therapy cycles.  
 
DCE-MRI FINDINGS AND OUTCOME 
The liver metastases could easily be detected in all patients on the T1 weighted MR 
images. A typical example and a corresponding map of kep is shown in figure 1. The 
mean values of kep, Ktrans and ve before and after treatment for the whole population are 
presented in table 1. A significant negative correlation was found between kep and Ktrans 
before start of chemotherapy and the diameter of the same metastasis (r = -.46, p = 
.009; r = -.42, p = .017; respectively), as is illustrated in figure 2 for kep. Values of kep 
and Ktrans were not correlated with the tumor diameter after treatment. 
 After one, two, or three courses of chemotherapy (depending on the 
chemotherapy regimen used) five of 32 patients showed an overall objective response 
to treatment according to the RECIST criteria, five of 32 patients showed progression 
and the remaining 22 patients had stable disease. kep, Ktrans and ve before start of 
treatment were not correlated with the change in diameter of the corresponding tumor  
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Figure 1  T1 weighted MR image before two cycles of FU/LV treatment (A) and the corresponding map of 
the Gd-DTPA uptake rate kep (B). The metastasis is indicated with the arrow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1  Average values and standard deviations of kep (s-1), Ktrans (a.u. s-1) and ve (a.u.) before and after 
one, two or three cycles of treatment for the whole population. 
 
 
 
 
 
 
 
 
 
 
Figure 2  Relation between the Gd-DTPA uptake rate kep and tumor diameter before start of 
chemotherapy. The solid line indicates the regression line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 average before treatment 
(standard deviation) 
average after treatment 
(standard deviation) 
kep 0.032 (0.018) 0.031 (0.017) 
Ktrans 0.019 (0.014) 0.019 (0.015) 
ve 0.585 (0.228) 0.598 (0.201) 
A B 
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nor with overall changes in tumor diameter in up to five liver metastases or overall 
response according to the RECIST criteria. Although the difference between the mean 
kep in the group of patients who showed a partial response and the mean kep in the 
group of patients who showed progression was larger than the repeatability coefficient 
which was determined in a separate study,15 a considerable overlap between the 
parameters of DCE-MRI before start of treatment and the overall response categories 
was observed (figure 3). 
Due to the large individual variation, no significant differences were found 
between mean values of kep, Ktrans and ve before and after treatment for the whole 
population (p > .05). On an individual patient level in 13 cases a positive or negative 
change in kep was found which was larger than the repeatability coefficient. No 
significant correlation was found between percentual change in kep and Ktrans before 
and after treatment and overall response according to the RECIST criteria, and a 
considerable overlap between the percentual change in kep and Ktrans and the overall 
response categories was present (figure 4A). When regarding only the 13 patients who 
showed a change in kep which was larger than the repeatability coefficient a similar 
result was found (figure 4B). 
 
19F MRS and response to FU treatment 
The diameter of the liver metastases in the patients measured with 19F MRS ranged 
from 1.6 cm to 11.3 cm (mean 4.2 cm). In three of 21 patients no 19F MRS signals were 
detectable. These patients were all measured with the 8 x 8 x 8 nonoptimized CSI 
technique. FU was detected in liver metastases in eleven out of 18 patients and in 
normal liver in nine patients; a catabolite resonance was detected in voxels located in 
liver metastases in 12 patients and in voxels located in normal liver in 15 patients. A 
typical spectrum is shown in figure 5. Using the fits of FU retention and catabolite 
formation with an R2 ≥ 0.80, the mean half life of FU was 9 min in metastases (range 4-
16 min; n = 9) and 8 min in normal liver (range 2-12 min; n = 8). The mean time to 50% 
of maximum catabolite resonance amplitude was 16 min in metastases (range 7-27 
min; n = 5) and 26 min in normal liver (range 13-52 min;  n = 8).  A significant negative 
correlation was found between the half life of FU in metastases and Ktrans of the 
metastases before start of treatment (r = -.82, p = .02; figure 6).  
After two courses of chemotherapy four of 21 patients showed an overall 
objective response to treatment according to the RECIST criteria, three of 21 patients 
showed progression and 13 of patients had stable disease (one patient was physically 
unable to undergo response assessment).  Although the patient with the shortest half 
life of FU in the metastasis was shown to be progressive according to the overall RECIST 
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Figure 3  Relation between the rate constant kep before start of treatment and overall response according 
to the RECIST criteria for the whole population.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4  Relation between percentual change in rate constant kep before and after one, two or three 
cycles of treatment and overall response according to the RECIST criteria for the whole 
population (A) and for the patients who showed a change in kep which was larger than the 
coefficient of reproducibility (B). 
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Figure 5  19F MRS of a metastasis in the liver of a patient. On the left three orthogonal T1 weighted MR 
images of slices through the liver are shown with the grid for 3D CSI projected on top of the 
images. 19F MRS was performed with an optimized CSI (see Materials and Methods). On the 
right 19F MR spectra are shown, selected from the voxel indicated by a white square. They show 
the changes in signals of FU and catabolites in time after FU administration. 
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Figure 6  Relation between Ktrans and half life of FU in the liver metastases. The solid line indicates the 
regression line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
criteria, and the patient with the longest half life of FU had a partial response, there was 
no correlation between FU half life in liver metastases and the change in corresponding 
tumor diameter nor with overall changes in tumor diameter in up to five liver 
metastases. FU half life in normal liver tissue and time to 50% of maximum catabolite 
resonance amplitude in liver metastases or normal liver tissue were not correlated with 
any of the response criteria. 
 
DISCUSSION 
DCE-MRI 
Nowadays the importance of tumor vasculature for tumor growth and metastasis is well 
established.19 Microvascular density (MVD) is currently regarded as the standard to 
investigate tumor vascularity, and increased MVD has most frequently been associated 
with a poor prognosis in various tumor types although not all studies confirm these 
results.20 Usually, MVD includes both perfused, i.e. functional, and non-perfused, i.e. 
nonfunctional vessels. The investigation of functional tumor vasculature is likely to be 
more relevant in the clinical setting. Parameters of DCE-MRI can provide an in vivo 
measure to assess functional tumor vasculature. According to Larsson’s 
pharmacokinetic model the parameters kep and Ktrans may be interpreted in terms of 
tumor blood flow and the PS product of perfused vasculature (Permeability and the 
total Surface area of perfused capillaries).2 In this study a negative correlation was 
observed between kep and Ktrans and tumor diameter which suggests that at larger 
tumor diameters tumor vascularity is inadequate.  
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 A difference in mean kep was observed between the group of patients who 
showed a partial response versus the group of patients who showed progression. This 
difference was greater than the repeatability coefficient, which provides direct insight 
into the probability that differences between two measurements in the patient 
population are due to real biological differences and not due to the measurement 
protocol.21 Therefore, it may be concluded that prior to treatment partial responders 
have on average a higher kep compared to nonresponders. However, a considerable 
overlap between the values of kep and the overall response categories was observed 
which precludes the use of this parameter for individual treatment selection. Moreover, 
the pretreatment values of kep, Ktrans and ve did not correlate with response after 
approximately two months of chemotherapy. These results may suggest that for 
colorectal liver metastases the supply of chemotherapy by the tumor vasculature is not 
a major limiting factor for response in first-line treatment.  
In two previous studies of primary rectal cancer a relation has been reported 
between DCE-MRI parameters and response to therapy.5,6 Both studies combined the 
use of chemotherapy and radiation. However, DCE-MRI parameters did not have 
predictive value for the effect of chemotherapy alone.6 In bone sarcoma a high kep 
before the start of treatment was associated with a higher disease-free survival after 
preoperative chemotherapy and surgical resection.3 DCE-MRI parameters did not 
predict the outcome in pediatric patients with Ewing sarcoma family of tumors who 
were treated with chemotherapy combined with surgery or radiotherapy.22 In breast 
cancer the parameters of DCE-MRI before the start of treatment have been associated 
with tumor response to neoadjuvant chemotherapy.23  
These results suggest that the predictive value of pretreatment parameters of 
DCE-MRI may depend on the tumor type studied and/or the kind of chemotherapy 
administered. With respect to the former it should be noted that the vasculature of liver 
metastases may consist of neoangiogenic vessels or liver vessels that have been co-
opted by the tumor.24 The degree of angiogenesis and co-option can vary between liver 
metastases24 and may be related to malignancy and therapy outcome. DCE-MRI may 
not have sufficient sensitivity to differentiate between various degrees of angiogenesis 
and co-option in the liver.  
In 13 patients a change in kep was observed which was greater than the 
repeatability coefficient which was determined in a separate study.15 Therefore, the 
changes in kep that were observed in these 13 patients may have been induced by the 
chemotherapy. Previous preclinical studies have shown antiangiogenic activity of FU 
and its derivatives.25,26 However, this effect appears less pronounced compared to 
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other cytotoxics27 and may depend on the schedule used.28 In the present study, no 
correlation between percentual change in kep before and after treatment and overall 
response according to the RECIST criteria was observed. In breast cancer several 
studies have reported a correlation between a change in DCE-MRI parameters during 
therapy and response.23,29,30 In one study the change in DCE-MRI parameters even 
preceded the volumetric changes.31 
 
19F MRS 
19F MRS is a potentially powerful tool for the in vivo monitoring of fluorinated drugs. 
However, its clinical application is hampered by the relatively low signal-to-noise ratio 
(SNR) of 19F MR spectra due to low tissue concentration of the drugs.17 The importance 
of optimizing SNR is further illustrated by the observation in this study that all cases 
without detectable 19F MRS signals were measured with the 8 x 8 x 8 nonoptimized 
CSI technique. Apart from the improvement in RF coil technology the application of 
higher magnetic fields for enhanced SNR will be crucial for the further development of 
19F MRS measurement techniques and their clinical use.32 
 A catabolite resonance was present both in liver metastases and in normal liver 
tissue. In the first preclinical 19F MRS studies no catabolite products were detected in 
tumor tissue. This confirmed the hypothesis that the liver degrades FU, leading to the 
formation of catabolites, whereas in the tumor this pathway is reduced.33 In later 
experiments resonances of catabolites have been observed in the tumor, but Prior et 
al.34 showed that a resonance of FBAL was present in rat tumors after intravenous 
administration of FBAL. This suggests that catabolites measured in tumors are not 
necessarily produced in the tumor, but enter the tumor via the blood circulation, as has 
also been shown in later experiments.35,36  
In the patients for whom DCE-MRI data were available of the same tumor of 
which 19F MRS data were acquired a negative correlation was observed between Ktrans 
and FU half life in the liver metastases. If Ktrans is interpreted in terms of tumor blood 
flow and the PS product (Permeability and the total Surface area of perfused 
capillaries), this correlation may suggest that a larger tumor blood flow, vessel 
permeability or surface area results in a faster wash out of FU from the tumor. 
 Previously it has been suggested that the half life of FU in the tumor reflects the 
so-called tumor trapping of FU.37 Although the patient with the shortest half life of FU in 
the metastasis was shown to be progressive according to the overall RECIST criteria 
and the patient with the longest half life of FU had a partial response, the lack of 
correlation between FU half life and the other parameters of response, suggests that 
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FU half life is not a major factor determining response to treatment in these patients. In 
previous clinical studies the ‘trapping’ of FU has been related to therapy outcome in 
various tumor types.10,38,39 Specifically for patients with liver metastases of colorectal 
cancer, a relation between 19F MRS parameters and response to treatment was 
reported in a group of six patients with a volume of metastases > 20 cm3.40 Responders 
showed enhanced FU levels in comparison with nonresponders. Recently, a positive 
correlation was reported between the increase in tumor size after treatment in patients 
with relatively large metastases in the field of view of the coil and the measured 
maximum concentration of catabolites.41 This might reflect a higher degradation of FU 
into catabolites, resulting in poorer response to treatment. No correlation was found 
between decrease in tumor size and FU tumor half life. In all these studies the volume 
of the tumor was relatively large to minimize contamination with normal liver tissue, 
since no localized MR techniques were applied beyond the use of a surface coil. The 
use of a CSI technique, which has been advocated previously,42 allowed the inclusion 
of smaller metastases in the present study, which could explain the lack of a correlation 
between parameters from 19F MRS measurements and response in this study. It may 
be hypothesized that due to impaired vascularization in larger tumors the importance of 
tumor trapping increases to ensure adequate exposure to the drug and enable a tumor 
response. In smaller tumors the availability of FU in the tumor may not be a limiting 
factor for response, but rather other mechanisms like FU conversion into anabolites. 
Due to the low SNR no anabolites have been observed in the 19F MR spectra. Since 
the sample size of this study was small, it should be expanded in a future follow-up, 
preferably at a higher field strength.  
 In conclusion, this study investigated the relationship between kinetic 
parameters of DCE-MRI, FU uptake and metabolism as measured by 19F MRS, and 
response to chemotherapy in liver metastases of colorectal cancer. Kinetic parameters 
of DCE-MRI before start of treatment did not predict tumor response after two months, 
which may suggest that for colorectal liver metastases supply of this chemotherapy by 
the tumor vasculature is not a major factor determining response in first-line treatment. 
In liver metastases of colorectal cancer  which are not selected on the basis of their 
tumor diameter, no evident correlation between 19F MRS parameters and tumor 
response was found. This could imply that  FU uptake and catabolism are not limiting 
factors for tumor response. The DCE-MRI parameter Ktrans before start of treatment 
was negatively correlated with FU half life which suggests that in tumors with a larger 
tumor blood flow or permeability surface area product the wash out of FU from the 
tumor is increased.  
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Vascularization, oxygenation, and metabolism are important parameters of a tumor, 
determining its development and treatment response. The overall goals of this thesis 
were: 1) to describe these parameters in colorectal cancer, both in animal models and 
in humans; 2) to explore the possibility to manipulate vascularization, oxygenation and 
metabolism for the improvement of cytotoxic treatment; 3) to monitor uptake and 
metabolism of fluorinated cytotoxic drugs in colorectal cancer in an early stage of the 
treatment. For this purpose immunohistochemical and noninvasive magnetic 
resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), as well as 
positron emission tomography (PET) methods were used. The specific questions were 
addressed whether vascularization as measured  by dynamic contrast enhanced MRI 
(DCE-MRI) and uptake and metabolism of 5-fluorouracil (FU) as measured by fluorine-
19 magnetic resonance spectroscopy (19F MRS) could predict response to cytotoxic 
treatment.  
 
The current options for systemic treatment of advanced colorectal cancer (ACC) are 
reviewed in chapter 1. For ACC, FU-based chemotherapy has been the standard for 
some decades, and its results may be improved by biochemical modulation and 
schedule modulation of FU. FU in combination with leucovorin (LV) has been regarded 
as standard chemotherapy for almost two decades. The oral formulations capecitabine 
and uracil with ftorafur combined with LV may be regarded as useful alternatives to 
FU/LV for the first-line treatment of ACC. Irinotecan and oxaliplatin are widely accepted 
as part of the standard first-line or second-line treatment. Favorable results have been 
reported for the monoclonal antibody C225 (cetuximab) against the epidermal growth 
factor receptor in patients with irinotecan-refractory ACC. Vascular endothelial growth 
factor (VEGF) is an important angiogenic factor in colorectal cancer and is a marker for 
poor prognosis. Initial results of treatment with anti-VEGF antibody (bevacizumab) in 
combination with chemotherapy showed promising results at the time of publication of 
chapter 1.  Currently, bevacizumab in combination with chemotherapy is regarded as 
the standard first-line treatment. 
 
Quantification of the amount of intracellular uptake, metabolic activation and catabolism 
of the supplied cytotoxic drugs in individual patients at an early stage of the treatment 
may assist in the individualization of therapy and may be of value for the strategic 
development of new anticancer drugs. 19F MRS offers unique possibilities to monitor 
the pharmacokinetics of fluoropyrimidines in tumors and normal tissue in vivo in a 
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noninvasive way, both in animals and in patients. This method may therefore be useful 
for predicting response to fluoropyrimidine-based therapy with or without the effects of 
modulating agents. In chapter 2 the principles of MR and 19F MRS are explained and 
the major in vivo 19F MRS studies dealing with FU and other fluoropyrimidines in 
rodents and patients are reviewed. 19F MRS has been very valuable in elucidating the 
basic aspects of fluoropyrimidine metabolism, especially in animal studies. Studies in 
humans have indicated its clinical potential, but widespread application has been 
hampered by its low sensitivity. The recent introduction of clinical MR scanners with 
magnetic fields above 1.5 T may improve these results. 
 
A detailed investigation of oxygenation, perfusion and cell proliferation in two murine 
colon carcinoma lines and the effect of nicotinamide and carbogen (95% oxygen and 
5% carbondioxide) on these parameters is presented in chapter 3. Mice with 
subcutaneously transplanted C38 and C26a murine colon tumors were treated with 
nicotinamide and carbogen and compared with control tumors. Two markers of 
hypoxia, CCI-103F and pimonidazole, were injected before and after treatment with 
nicotinamide/carbogen, respectively, allowing each tumor to serve as its own control. 
Hoechst33342 was used as a perfusion marker and bromodeoxyuridine (BrdUrd) as a 
proliferation marker. Sections from frozen tumors were used for multistep immuno-
staining and computer-controlled microscope scanning for hypoxic fractions, perfused 
fractions, vascular density (VD) and BrdUrd-labeling index. Microscopic observation of 
C38 and C26a tumors showed extensive differences in vascular architecture, 
distribution patterns of hypoxia and BrdUrd labeling. Quantitative analysis of C38 and 
C26a tumors showed a decrease in hypoxic fraction in response to all treatment 
modalities. For C38 tumors the average decrease in hypoxic fraction in response to 
carbogen containing treatments was larger than to nicotinamide alone. In C26a tumors 
no difference in average decrease in hypoxic fraction was observed between the 
treatments. The perfused fraction of C38 and C26a did not change in response to 
treatment. The BrdUrd labeling index of C38 and C26a decreased upon all treatments, 
which was statistically significant in the combination treatment of C38. The mechanism 
that can simultaneously explain all the observed changes in response to treatment may 
be the conversion of metabolism from less oxidative phosphorylation towards 
increased glycolysis due to increased glucose levels (Crabtree effect), although other 
mechanisms cannot be excluded.  
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In chapter 4 the effect of carbogen breathing on tumor blood volume, pH and energy 
status is described, as well as the effect on FU uptake and metabolism in the two colon 
tumor models C38 and C26a. Phosphorus-31 MRS was used to assess tumor pH and 
energy status and 19F MRS to follow FU uptake and metabolism. Advanced MRI 
methods using ultra small particles of iron oxide were performed to assess blood 
volume. The results showed that carbogen breathing significantly decreased 
extracellular pH and increased tumor blood volume. These effects were more 
pronounced in the tumor line with the largest relative vascular area, i.e. the C38 tumor 
line. An increase in FU uptake in both tumor lines was observed, but systemic toxicity 
was also enhanced.  
 
Since murine liver metastases are a more adequate, orthotopic model for advanced 
colorectal cancer in patients than subcutaneously implanted tumors, the effect of the 
hypoxia modulating agents nicotinamide and carbogen on tumor hypoxia, tumor blood 
perfusion and proliferative activity in liver metastases of the murine colon carcinoma 
line C26a was studied, as presented in chapter 5. In untreated C26a liver metastases a 
considerable amount of hypoxia was observed, similar to the amount of hypoxia in liver 
metastases of patients with colorectal cancer (see below). Mice which were treated 
with nicotinamide and carbogen breathing as single agents or in combination showed a 
significantly smaller hypoxic fraction in the liver metastases compared to the untreated 
mice. In the group of mice which underwent carbogen breathing a significantly lower 
tumor perfusion was observed compared to the untreated group, but the decrease was 
only marginal. The proliferative activity was similar in all groups. In subcutaneous C26a 
tumors a similar effect on hypoxia was observed, which, however, was accompanied 
by a decrease in proliferative activity. The differential effects of nicotinamide and 
carbogen on parameters of the tumor microenvironment in liver metastases and 
subcutaneous tumors may suggest an influence of the host tissue on the mechanism 
by which nicotinamide and carbogen exert their effects. Since tumor hypoxia may be a 
relevant factor in the treatment of colorectal liver metastases, further research on the 
effect of hypoxic modifiers on colorectal liver metastases seems warranted in order to 
improve therapy outcome. 
 
A description of hypoxia measured by pimonidazole binding, glucose transporter-1 
(GLUT-1) and carbonic anhydrase-IX (CA-IX) expression, proliferation and vascularity 
in liver metastases of patients with colorectal cancer is presented in chapter 6. GLUT-1 
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and CA-IX expression in liver metastases was compared with the corresponding 
primary tumors. Twenty-five patients with liver metastases of colorectal cancer, 
planned for metastasectomy, were included. The hypoxia marker pimonidazole and 
proliferation marker iododeoxyuridine were administered before surgery. After 
immunofluorescent staining of the frozen metastases, pimonidazole binding, vascularity 
and proliferation were analyzed quantitatively. Thirteen paraffin embedded primary 
tumors were stained immunohistochemically for GLUT-1 and CA-IX expression, which 
was analyzed semi-quantitatively in primary tumors and corresponding liver 
metastases. In liver metastases pimonidazole binding showed a pattern consistent with 
diffusion limited hypoxia. The mean pimonidazole positive fraction was 0.146; the mean 
distance from vessels to pimonidazole positive areas was 80 µm. When GLUT-1 or CA-
IX were expressed, co-localization was often observed between pimonidazole binding 
and GLUT-1 or CA-IX, but microregional areas of mismatch were also observed. No 
correlation between the level of pimonidazole binding and GLUT-1 or CA-IX expression 
was observed. In some patients a large fraction (up to 30%) of proliferating cells was 
present in pimonidazole stained areas. CA-IX expression in primary tumors and 
metastases showed a significant correlation, which was absent for GLUT-1 expression. 
In conclusion, compared to other tumor types, liver metastases of colorectal cancer 
contain large amounts of hypoxic cells. The lack of correlation with pimonidazole 
binding questions the value of GLUT-1 and CA-IX as endogenous markers of hypoxia.  
 
DCE-MRI is a powerful approach to assess tumor vascularity in vivo. To be able to 
properly interpret the data obtained by DCE-MRI, the reproducibility of the method 
should be established. Therefore, the reproducibility of DCE-MRI in colorectal liver 
metastases was tested, using a vascular normalization function (VNF) from pixels in 
the spleen. The results were compared with a technique using an arterial input function 
(AIF) from pixels in the aorta. This study is described in chapter 7. DCE-MRI with 
Gadolinium-DTPA (Gd-DTPA) was performed in 12 patients with colorectal liver 
metastases. The VNF and AIF were determined with an automated algorithm. Using a 
physiological pharmacokinetic model the average Gd-DTPA uptake rate constant (kep) 
was calculated for the metastases. To calculate the repeatability coefficient of the 
measurements of kep the protocol was repeated on a second day. Using the VNF from 
the spleen the overall mean kep of the two sessions was 0.033 s-1 and the repeatability 
coefficient 0.009 s-1. Using the AIF from the aorta these values were 0.031 s-1 and 
0.028 s-1, respectively. In conclusion, the mean Gd-DTPA uptake rate constant using a 
vascular normalization function taken from the spleen can be determined with 
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adequate reproducibility in colorectal liver metastases. The use of a VNF from pixels in 
the spleen resulted in a better reproducibility compared with an AIF from pixels in the 
aorta, and VNF from spleen pixels is recommended when this DCE-MRI technique is 
used for the prediction and monitoring of therapy outcome in colorectal liver 
metastases. 
 
Chapter 8 describes an examination of the in vivo relationship between 2-deoxy-2-18F-
fluoro-D-glucose (FDG) uptake as measured by PET, and functional tumor vasculature 
as measured by DCE-MRI in patients with liver metastases of colorectal cancer. 
Twenty-six patients with liver metastases of colorectal cancer who were prepared for 
liver metastasectomy were included. Whole body FDG-PET was performed and tumor 
to non-tumor ratios of FDG uptake (T/NT) in the metastases were calculated. DCE-MRI 
was performed and the rate constant kep (s-1) of Gadolinium-DTPA uptake in the 
metastases was determined. Tumor hypoxia and vascular density of the metastases 
were determined by immunohistochemistry with the use of the hypoxic marker 
pimonidazole. To assess any correlation between FDG uptake, rate constant kep of Gd-
DTPA uptake, HF and VD the Pearson’s correlation coefficient r was calculated. A 
negative correlation between T/NT and kep was observed. No correlation between 
tumor hypoxia and T/NT or kep was found. A positive correlation was observed between 
VD and kep, but not with T/NT. The negative correlation between T/NT and kep suggests 
that lower values of Gd-DTPA uptake rate imply an acutely reduced supply of oxygen 
which necessitates a higher uptake of glucose to maintain tumor energy levels. The 
positive correlation of VD with kep, but not with T/NT, emphasizes the potential of DCE-
MRI to measure tumor vascularity in vivo and its additional value compared to ex vivo 
methods.  
 
The oral FU prodrug capecitabine is increasingly used as an alternative to intravenous 
FU administration in metastatic colorectal cancer. The rate of  conversion of 
capecitabine into 5′deoxy-5-fluorouridine (5′DFUR) has been related to tumor 
response, and FU catabolites have been associated with FU-related systemic toxicity. 
As described in chapter 9, it was demonstrated for the first time that capecitabine, its 
metabolites 5′deoxy-5-fluorocytidine and 5′DFUR and its catabolites α-fluoro-β-
ureidopropionic acid, α-fluoro-β-alanine (FBAL) and FBAL-bile acid conjugate can be 
monitored in vivo by 19F MRS in the liver of patients with metastatic colorectal cancer. 
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Moreover, an improved signal-to-noise ratio and spectral resolution of the 19F MRS 
spectra was shown when measurements are performed at 3 Tesla (T) field strength as 
compared to measurements at the field strength of 1.5 T which is commonly used in 
the clinic. Therefore, the assessment of capecitabine metabolism in patients by 19F 
MRS is a promising noninvasive tool for the prediction of its efficacy and toxicity, 
especially at the currently available field strength of 3 T. 
 
Chapter 10 describes an investigation of the correlation between the potential for tumor 
drug supply measured by DCE-MRI and response to first-line chemotherapy in patients 
with liver metastases of colorectal cancer, as well as the relation between FU uptake 
and metabolism  measured by 19F MRS and response to FU therapy. Since FU uptake 
and metabolism may depend on supply of the drug to the tumor, the relationship 
between 19F MRS and DCE-MRI parameters was also examined. Thirty-seven patients 
were included. Kinetic parameters of DCE-MRI before start of treatment did not predict 
tumor response after two months, suggesting that the supply of chemotherapy by 
tumor vasculature is not a major determining factor in the response to first-line 
treatment. No evident correlations between 19F MRS parameters and tumor response 
were found. This may imply that in liver metastases which are not selected on basis of 
their tumor diameter, FU uptake and catabolism are not limiting factors for response. 
The transfer constant Ktrans, as measured by DCE-MRI before start of treatment, was 
negatively correlated with FU half life in the liver metastases which suggests that FU is 
washed out faster in metastases with a larger tumor blood flow or permeability surface 
area product. 
 
CONCLUDING REMARKS 
This research shows that nicotinamide and carbogen can decrease tumor hypoxia in 
murine colon carcinoma, both in subcutaneously implanted tumors and in an orthotopic 
liver metastases model. Moreover, carbogen induces an increase in blood volume, a 
decrease in extracellular pH and an increase in FU uptake in murine colon carcinoma. 
Thus, vascularization, oxygenation and metabolism can be modulated in colorectal 
cancer. Since a considerable amount of hypoxia is present in liver metastases of 
patients with colorectal cancer, the improvement of tumor oxygenation by nicotinamide 
and/or carbogen may be translated into the clinical situation.   
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 In this research it is demonstrated that DCE-MRI is a reproducible method to 
assess tumor vascularization of colorectal liver metastases. In combination with the 
measurement of pimonidazole binding and FDG uptake it can elucidate the complex 
relationship between vascularization, oxygenation and metabolism in tumor tissue. 
Clinical studies with new MR contrast agents that can differentiate between blood flow 
and blood volume (for example ultra small particles of iron oxide) and noninvasive 
techniques to investigate oxygenation (for example fluorine-18 misonidazole PET) may 
lead to further understanding of this relation. Kinetic parameters of DCE-MRI before 
start of first-line cytotoxic treatment did not predict tumor response after two months, 
suggesting that the supply of chemotherapy by tumor vasculature is not a major 
determining factor in the response to first-line treatment. Further studies will have to 
show whether DCE-MRI has a predictive value for tumor response in second-line or 
third-line cytotoxic treatment. 
 Finally, in this research it is shown that 19F MRS can be used to monitor both 
FU and capecitabine uptake and metabolism in the livers and liver metastases of 
patients with colorectal cancer. No evident correlations between 19F MRS parameters 
and tumor response were found which may imply that in liver metastases FU uptake 
and catabolism are not limiting factors for response. However, the measurement of 
anabolites of FU and the absolute quantification of metabolite concentrations is not 
possible at the current field strength of 1.5 T. These may be more relevant for the 
prediction of response to fluoropyrimidine therapy than kinetic parameters of FU uptake 
and catabolism. Therefore, the application of higher magnetic fields is mandatory in 
further clinical studies of colorectal liver metastases using 19F MRS. 
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De groei van kankerweefsel wordt mede bepaald door de bloedvoorziening, de 
zuurstofvoorziening en de stofwisseling van dit weefsel. Ook de remming van de 
tumorgroei door een behandeling met bijvoorbeeld cytotoxische geneesmiddelen is 
mede afhankelijk van deze factoren. Het doel van dit onderzoek was drieledig: 1) het 
beschrijven van de bloedvoorziening, de zuurstofvoorziening en de stofwisseling van 
dikkedarmkanker, zowel in diermodellen als bij patiënten; 2) het beïnvloeden van deze 
processen met als doel de werkzaamheid van cytotoxische middelen te verbeteren; 3) 
het vervolgen van de opname van gefluorineerde cytotoxische middelen in het lichaam 
van proefdieren en patiënten en de omzetting van deze middelen in werkzame stoffen 
en afbraakprodukten in een vroeg stadium van de behandeling. Hiervoor werden 
immunohistochemische methoden gebruikt, niet-invasieve magnetische resonantie 
(MR) technieken - zowel beeldvorming (MRI) als spectroscopie (MRS) - en positron 
emissie tomografie (PET). Specifiek werd onderzocht of de bloedvoorziening van een 
tumor, gemeten met dynamische contrast MRI (DCE-MRI), de respons op behandeling 
met cytotoxische geneesmiddelen kon voorspellen en of door het meten van de 
opname en omzetting van 5-fluorouracil (FU) in levermetastasen met fluor-19 (19F) 
MRS, de uitkomst van de behandeling met FU in een vroeg stadium van de 
behandeling kon worden bepaald. 
 
De huidige mogelijkheden voor de systemische behandeling van uitgezaaide 
dikkedarmkanker worden beschreven in hoofdstuk 1. Voor de behandeling van 
uitgezaaide dikkedarmkanker is FU-bevattende therapie decennia lang de standaard 
geweest. De resultaten van FU-therapie kunnen worden verbeterd door biochemische 
beïnvloeding van FU of door aanpassingen in het toedieningsschema. De afgelopen 
twintig jaar werd FU in combinatie met leukovorin (LV) beschouwd als de therapie van 
eerste keus. De orale middelen capecitabine en uracil met ftorafur gecombineerd met 
leukovorin zijn thans bruikbare alternatieven in de eerstelijns behandeling. 
Tegenwoordig worden ook irinotecan en oxaliplatin toegepast als onderdeel van zowel 
de eerstelijns als de tweedelijns behandeling. Voor patiënten die progressieve 
tumorgroei vertoonden na behandeling met irinotecan zijn hoopgevende resultaten 
gerapporteerd voor het gebruik van het monoklonale antilichaam C225 (cetuximab) 
tegen de epidermale groeifactor receptor. De vasculaire endotheliale groeifactor 
(VEGF) is een belangrijke angiogenetische factor voor dikkedarmkanker en is 
geassocieerd met een slechte prognose. De resultaten van behandeling met een anti-
VEGF-antilichaam (bevacizumab) in combinatie met chemotherapie waren ten tijde van 
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de publicatie van hoofdstuk 1 veelbelovend. Thans is bevacizumab in combinatie met 
chemotherapie de standaard eerstelijns behandeling.  
 
Kwantificering van de opname van cytotoxische middelen in tumorcellen en de 
omzetting van deze middelen in werkzame stoffen en afbraakprodukten bij individuele 
patiënten in een vroeg stadium van de behandeling kan bijdragen aan het afstemmen 
van de therapie op de individuele patiënt. Daarnaast kan deze kwantificering van nut 
zijn voor een efficiënte ontwikkeling van nieuwe geneesmiddelen tegen kanker. 19F 
MRS biedt unieke mogelijkheden om de farmacokinetiek van cytotoxische 
fluoropyrimidines in tumoren en normaal weefsel niet-invasief in vivo te vervolgen, 
zowel bij proefdieren als bij patiënten. Daarom zou deze methode gebruikt kunnen 
worden om de respons van een tumor op fluoropyrimidine-bevattende therapie (met of 
zonder modulerende middelen) te voorspellen. In hoofdstuk 2 worden de principes van 
MR en 19F MRS uitgelegd en de belangrijkste in vivo 19F MRS studies naar FU en 
andere fluoropyrimidines bij proefdieren en patiënten besproken. 19F MRS is een 
waardevol hulpmiddel gebleken voor het verkrijgen van inzicht in de basale aspecten 
van het fluoropyrimidine metabolisme, met name in proefdierstudies. Ook voor humane 
studies biedt 19F MRS perspectief, maar een uitgebreide klinische toepassing van 19F 
MRS wordt beperkt door de lage gevoeligheid. De recente introductie van klinische MR 
scanners met magneetvelden die sterker zijn dan 1.5 T zou de resultaten kunnen 
verbeteren. 
 
Een gedetailleerd onderzoek naar de zuurstofvoorziening, doorbloeding en 
celdelingsactiviteit van twee dikkedarmtumorlijnen in muizen wordt beschreven in 
hoofdstuk 3. Tevens wordt het effect van nicotinamide en carbogeen (95% zuurstof en 
5% koolstofdioxide) op deze parameters gerapporteerd. Muizen met onderhuids 
geïmplanteerde C38 en C26a dikkedarmtumoren werden behandeld met nicotinamide 
en carbogeen en vergeleken met onbehandelde tumoren. Twee merkstoffen voor 
zuurstoftekort, CCI-103F en pimonidazol, werden toegediend - CCI-103F vóór de 
behandeling met nicotinamide/carbogeen en pimonidazol erna. Zo kon iedere tumor als 
zijn eigen controle worden gebruikt. De merkstof voor doorbloeding was Hoechst33342 
en de merkstof voor celdelingsactiviteit bromodeoxyuridine (BrdUrd). 
Immunohistochemische kleuringen vonden plaats in verschillende stappen op coupes 
van de ingevroren tumoren. Met een door een computer aangestuurde microscoop 
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werden de coupes gescand om de mate van zuurstoftekort in tumorcellen, de 
hoeveelheid doorbloede vaten, de vaatdichtheid en de mate van celdelingsactiviteit te 
bepalen. Op microscopisch niveau vertoonden de C38 en C26a tumorlijnen uitgebreide 
verschillen in architectuur van de bloedvaten en verdelingspatronen van zuurstoftekort 
en celdelingsactiviteit. Kwantitatieve analyse van beide tumorlijnen liet een daling zien 
in de mate van zuurstoftekort in respons op alle vormen van behandeling. Bij C38 
tumoren was de gemiddelde daling in respons op carbogeen bevattende 
behandelingen groter dan op nicotinamide. Bij C26a tumoren werd geen verschil 
gezien in de gemiddelde daling van het zuurstoftekort tussen de behandelingen. In 
geen van beide tumorlijnen veranderde de doorbloeding door de behandelingen. De 
celdelingsactiviteit van C38 en C26a tumoren nam af na alle onderzochte vormen van 
behandeling. Voor de combinatiebehandeling bij C38 tumoren was dit statistisch 
significant. Een mechanisme dat dit alles zou kunnen verklaren is het zogenaamde 
Crabtree effect. Dit betreft een verschuiving in de stofwisseling van een tumor, waarbij 
de oxidatieve fosforylering afneemt en de glycolyse toeneemt ten gevolge van een 
verhoogde glucose concentratie. Andere mechanismen kunnen echter niet worden 
uitgesloten. 
 
In hoofdstuk 4 wordt het effect beschreven van carbogeen op het bloedvolume van een 
tumor, de pH, en energie status en op de opname, omzetting en afbraak van FU bij de 
dikkedarmtumorlijnen C38 en C26a. Fosfor-31 (31P) MRS werd gebruikt voor het meten 
van tumor pH en energie status en 19F MRS voor het vervolgen van de opname, 
omzetting en afbraak van FU. Voor de meting van het bloedvolume werden 
geavanceerde MRI methoden met ultra-kleine ijzerdeeltjes ingezet. Carbogeen 
ademen leidde tot een significante daling van de extracellulaire pH en een toename 
van het bloedvolume van de tumor. Deze effecten waren het meest uitgesproken in de 
tumorlijn met het grootste relatieve vaatoppervlak, namelijk de C38 tumor. Na 
carbogeen ademen nam de FU opname in beide tumorlijnen toe, maar namen ook de 
bijwerkingen toe. 
 
Aangezien proefdieren met uitzaaiïngen in de lever in vergelijking met onderhuids 
geïmplanteerde tumoren een relevanter model zijn voor uitgezaaide dikkedarmkanker 
bij patiënten, is het effect van nicotinamide en carbogeen op zuurstofvoorziening, 
doorbloeding en celdelingsactiviteit ook bestudeerd in uitzaaiïngen van de C26a 
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dikkedarmtumorlijn in de lever. Dit wordt beschreven in hoofdstuk 5. In onbehandelde 
uitzaaiïngen van de C26a tumorlijn is sprake van een grote mate van zuurstoftekort, 
welke overeenkomt met de uitgebreide hoeveelheid zuurstoftekort in uitzaaiïngen in de 
lever van patiënten met een dikkedarmtumor (zie onder). Muizen die werden 
behandeld met nicotinamide of carbogeen als monotherapie of met de combinatie van 
nicotinamide en carbogeen hadden significant minder zuurstoftekort in de uitzaaiïngen 
in vergelijking met onbehandelde muizen. Hoewel in de groep muizen die carbogeen 
ademde de uitzaaiïngen significant minder goed waren doorbloed in vergelijking met de 
onbehandelde groep, was dit verschil slechts marginaal. De celdelingsactiviteit was 
vergelijkbaar in alle groepen. In de onderhuids geïmplanteerde C26a tumoren was 
eerder (zie hoofdstuk 3) een gelijksoortig effect op zuurstoftekort waargenomen, dat 
echter samenging met een afname van de celdelingsactiviteit. De verschillende 
uitwerking van nicotinamide en carbogeen op uitzaaiïngen in de lever en op 
onderhuidse tumoren zou kunnen wijzen op een invloed van het gastweefsel (lever 
versus onderhuids weefsel) op het mechanisme waardoor nicotinamide en carbogeen 
effect hebben. Aangezien zuurstoftekort in de tumor een relevante factor kan zijn voor 
de behandeling van uitzaaiïngen van dikkedarmkanker is verder onderzoek nodig naar 
het effect van middelen die zuurstoftekort in uitzaaiïngen in de lever kunnen 
beïnvloeden. 
 
Hoofdstuk 6 beschrijft pimonidazolbinding, glucose transporter-1 (GLUT-1) en carbonic 
anhydrase-IX (CA-IX) expressie, celdelingsactiviteit en vaatvoorziening in uitzaaiïngen 
in de lever van patiënten met een dikkedarmtumor. De mate van GLUT-1 en CA-IX 
expressie in de uitzaaiïngen werd vergeleken met de bijbehorende primaire 
dikkedarmtumoren. In de literatuur worden GLUT-1 en CA-IX genoemd als endogene 
merkstoffen van zuurstoftekort. Vijfentwintig patiënten met uitzaaiïngen in de lever van 
een dikkedarmtumor bij wie een resectie van de uitzaaiïngen was gepland, namen deel 
aan de studie. Voor de operatie kregen zij pimonidazol - als merkstof voor 
zuurstoftekort - en iododeoxyuridine – als merkstof voor celdelingsactiviteit - 
toegediend. Na immunofluorescentiekleuring van het ingevroren weefsel van de 
verwijderde uitzaaiïngen werd de mate van pimonidazolbinding, vaatvoorziening en 
celdelingsactiviteit kwantitatief geanalyseerd. Immunohistochemische kleuring van het 
paraffinemateriaal van de primaire tumoren van 13 patiënten vond plaats voor analyse 
van GLUT-1 en CA-IX expressie. In zowel de primaire tumoren als de bijbehorende 
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uitzaaiïngen in de lever werd de expressie semi-kwantitatief geanalyseerd. Het 
bindingspatroon van pimonidazol in de uitzaaiïngen wees op zuurstoftekort dat ontstaat 
door een te grote afstand tot de bloedvaten (diffusie gelimiteerd zuurstoftekort). De 
gemiddelde pimonidazol positieve fractie was 0.146; de gemiddelde afstand van 
bloedvaten tot pimonidazol positieve gebieden was 80 µm. Wanneer GLUT-1 of CA-IX 
in de uitzaaiïngen tot expressie kwam, was er vaak sprake van co-lokalisatie met 
pimonidazolbinding, maar er waren ook gebieden in de uitzaaiïngen waar geen overlap 
werd gevonden. De hoeveelheid pimonidazolbinding en de mate van GLUT-1 of CA-IX 
expressie was niet gecorreleerd. Bij enkele patiënten was een hoog percentage (tot 
30%) van de delende cellen aanwezig in gebieden die aankleurden met pimonidazol. 
CA-IX expressie in de primaire tumoren en uitzaaiïngen was significant gecorreleerd. 
Voor GLUT-1 expressie werd geen correlatie gevonden. In vergelijking met andere 
tumortypes bevatten uitzaaiïngen van dikkedarmtumoren in de lever een grote 
hoeveelheid cellen met zuurstoftekort. Het ontbreken van een correlatie tussen 
pimonidazolbinding en GLUT-1 en CA-IX expressie trekt de waarde van GLUT-1 en 
CA-IX als endogene merkstoffen van zuurstoftekort in twijfel.  
 
De opname van een contrastmiddel, zoals Gadolinium-DTPA (Gd-DTPA) gemeten met 
DCE-MRI kan dienen als een maat voor de bloedvoorziening van een tumor. Het 
voordeel van DCE-MRI ten opzichte van andere methodes is dat de meting in vivo kan 
plaatsvinden. Om DCE-MRI data goed te kunnen interpreteren moet de 
reproduceerbaarheid van de methode bekend zijn. Hoofdstuk 7 beschrijft de 
reproduceerbaarheid van DCE-MRI in uitzaaiïngen van dikkedarmkanker in de lever. 
Twaalf patiënten participeerden in het onderzoek. Voor normalisatie van de data werd 
gebruikt gemaakt van een vasculaire normalisatie functie (VNF) die was verkregen uit 
pixels in de milt, gebruik makend van een geautomatiseerd algoritme. De resultaten 
werden vergeleken met een methode waarbij de data waren genormaliseerd middels 
een arteriële input functie (AIF), bepaald met hetzelfde algoritme, maar met pixels in de 
aorta. Door toepassing van een fysiologisch farmacokinetisch model op de data kon de 
gemiddelde snelheidsconstante van Gd-DTPA opname (kep) in de uitzaaiïngen worden 
bepaald. Het protocol werd op een andere dag herhaald om de 
reproduceerbaarheidscoëfficiënt van de metingen van kep te berekenen. Met de VNF 
uit de milt was de gemiddelde kep van de twee sessies gemiddeld over alle patiënten 
0.033 s-1 en de reproduceerbaarheidscoëfficiënt 0.009 s-1. Met de AIF uit de aorta 
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waren deze waarden respectievelijk 0.031 s-1 en 0.028 s-1. De gemiddelde 
snelheidsconstante van de opname van Gd-DTPA kan, gebruik makend van een VNF 
uit de milt, met een adequate reproduceerbaarheid worden bepaald voor uitzaaiïngen 
van dikkedarmkanker in de lever. Het gebruik van een VNF uit de milt resulteerde in 
een betere reproduceerbaarheid dan het gebruik van een AIF uit de aorta. Het gebruik 
van een VNF uit de milt wordt dan ook aanbevolen als deze DCE-MRI techniek wordt 
gebruikt voor het voorspellen en vervolgen van de effecten van behandeling van 
uitzaaiïngen van dikkedarmkanker in de lever. 
 
Hoofdstuk 8 beschrijft een onderzoek naar de relatie in vivo tussen 2-deoxy-2-18F-
fluoro-D-glucose (FDG) opname gemeten met PET en functionele bloedvaten gemeten 
met DCE-MRI bij patiënten met uitzaaiïngen van dikkedarmkanker in de lever. 
Zesentwintig patiënten met uitzaaiïngen in de lever van een dikkedarmtumor bij wie 
een resectie van de uitzaaiïngen zou plaatsvinden, participeerden in de studie. Na 
FDG-PET scan van het hele lichaam werden de ratio’s van de opname van FDG in de 
uitzaaiïngen ten opzichte van normaal leverweefsel (T/NT) uitgerekend. Uit de DCE-
MRI data werd de snelheidsconstante van Gd-DTPA opname, kep, in de uitzaaiïngen 
berekend. Het zuurstoftekort en de vaatdichtheid in de uitzaaiïngen werden met behulp 
van immunohistochemie bepaald, na toediening van de merkstof pimonidazol. Tussen 
T/NT en kep bestond een negatieve correlatie. Er was geen correlatie tussen de mate 
van zuurstoftekort in de uitzaaiïngen en T/NT of kep, noch tussen de vaatdichtheid van 
de uitzaaiïngen en T/NT, maar wel tussen de vaatdichtheid en kep. De negatieve 
correlatie tussen T/NT and kep suggereert dat lagere waarden van de 
snelheidsconstante van Gd-DTPA opname zijn geassocieerd met een acute reductie in 
de toelevering van zuurstof. Het hierdoor ontstane zuurstoftekort leidt tot een hogere 
opname van glucose in de uitzaaiïngen om zo het energieniveau van de uitzaaiïngen te 
kunnen handhaven. De positieve correlatie tussen vaatdichtheid en kep, maar niet 
tussen vaatdichtheid en T/NT, onderstreept de waarde van DCE-MRI voor de meting 
van bloedvoorziening van tumoren in vivo in vergelijking met ex vivo methoden. 
 
Bij uitgezaaide dikkedarmkanker wordt capecitabine, een orale pro-drug van FU, in 
toenemende mate gebruikt als een alternatief voor het intraveneus toegediende FU. De 
omzettingssnelheid van capecitabine naar 5′deoxy-5-fluorouridine (5′DFUR) is in 
eerdere studies gerelateerd aan respons op therapie en de afbraakprodukten van FU 
SAMENVATTING 
 256
zijn geassocieerd met FU-gerelateerde bijwerkingen. In hoofdstuk 9 wordt voor het 
eerst aangetoond dat capecitabine, de omzettingsprodukten 5′deoxy-5-fluorocytidine 
en 5′DFUR en de afbraakprodukten α-fluoro-β-ureidopropionzuur, α-fluoro-β-alanine 
(FBAL) en FBAL-galzuur conjugaat in vivo vervolgd kunnen worden met 19F MRS in de 
lever van patiënten met uitgezaaide dikkedarmkanker. De signaal-ruis verhouding en 
de spectrale resolutie van de 19F MRS spectra metingen verbeterden als zij werden 
uitgevoerd bij 3 Tesla (T) veldsterkte in plaats van 1.5 T veldsterkte, zoals gebruikelijk 
is in de kliniek. Derhalve is het vervolgen van de omzetting en afbraak van 
capecitabine bij patiënten middels 19F MRS een veelbelovende niet-invasieve methode 
om de effectiviteit en de bijwerkingen van de behandeling met capecitabine te 
voorspellen, met name bij de inmiddels voor de kliniek beschikbaar geworden 3 T 
veldsterkte. 
 
De bloedvoorziening van tumoren is de weg waarlangs toelevering van cytotoxische 
middelen aan een tumor plaatsvindt. Hoofdstuk 10 beschrijft een onderzoek naar de 
correlatie tussen enerzijds de bloedvoorziening van uitzaaiïngen van dikkedarmkanker 
in de lever gemeten met DCE-MRI en anderzijds de respons op eerstelijns behandeling 
met chemotherapie. Daarnaast wordt in hoofdstuk 10 de relatie bestudeerd tussen FU 
opname en afbraak gemeten met 19F MRS en respons op FU therapie. Aangezien FU 
opname en afbraak afhankelijk kunnen zijn van de toevoer van FU naar de tumor wordt 
ook de relatie tussen 19F MRS en DCE-MRI parameters beschreven. Zevenendertig 
patiënten participeerden in de studie. De kinetische DCE-MRI parameters gemeten 
voorafgaand aan de behandeling bleken niet voorspellend te zijn voor de respons op 
therapie na twee maanden. Dit suggereert dat de bloedvoorziening van de uitzaaiïngen 
als weg voor het aanbod van cytotoxische middelen aan de uitzaaiïngen geen 
limiterende factor is voor de respons op eerstelijns behandeling. Tussen 19F MRS 
parameters en tumorrespons waren geen duidelijke correlaties aanwezig. Dit zou 
kunnen betekenen dat bij uitzaaiïngen in de lever die niet zijn geselecteerd op basis 
van tumorgrootte de opname en afbraak van FU geen beperkende factoren zijn voor 
de respons op therapie met FU. De transferconstante Ktrans was negatief gecorreleerd 
met de halfwaardetijd van FU in de uitzaaiïngen. Dit wijst erop dat in uitzaaiïngen met 
een grotere bloeddoorstroming of met een groter permeabiliteit-vaatoppervlak-produkt 
FU sneller wordt uitgewassen. 
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SLOTOPMERKINGEN 
In dit onderzoek wordt aangetoond dat nicotinamide en carbogeen het zuurstoftekort 
van dikkedarmtumoren in proefdieren kunnen verminderen, zowel bij onderhuids 
geïmplanteerde tumoren als bij uitzaaiïngen in de lever. Bovendien induceert 
carbogeen een toename in bloedvolume, een vermindering van extracellulaire pH en 
een toename van opname van FU in onderhuids geïmplanteerde tumoren. De 
doorbloeding, de zuurstofvoorziening en de stofwisseling van dikkedarmtumoren kan 
derhalve worden beïnvloed. Aangezien uitzaaiïngen van dikkedarmtumoren in de lever 
relatief veel zuurstoftekort hebben in vergelijking met andere tumorsoorten, zou de 
verbetering van de zuurstofvoorziening door nicotinamide en/of carbogeen toegepast 
kunnen worden in de klinische situatie. 
 Dit onderzoek laat zien dat DCE-MRI een reproduceerbare methode is om de 
bloedvoorziening van uitzaaiïngen van dikkedarmtumoren in de lever in kaart te 
brengen. In combinatie met de bepaling van pimonidazolbinding en opname van FDG 
werpt DCE-MRI nieuw licht op de complexe relatie tussen bloedvoorziening, 
zuurstofvoorziening en stofwisseling in tumor weefsel. Klinische studies met nieuwe 
MR contrastmiddelen (bijvoorbeeld ultra-kleine deeltjes ijzeroxide) waarbij onderscheid 
gemaakt kan worden tussen bloeddoorstroming en bloedvolume en met niet-invasieve 
technieken om zuurstofvoorziening te meten (bijvoorbeeld fluor-18 misonidazole PET) 
kunnen het inzicht in deze relatie verder verdiepen. Kinetische DCE-MRI parameters 
voor start van eerstelijns behandeling met cytotoxische geneesmiddelen waren niet 
voorspellend voor de respons na twee maanden, hetgeen suggereert dat de 
bloedvoorziening als weg voor de toelevering van cytotoxische middelen aan de tumor 
geen limiterende factor is voor de respons op eerstelijns behandeling. Vervolgstudies 
zullen moeten aantonen of DCE-MRI voorspellende waarde heeft voor tumorrespons 
na tweedelijns of derdelijns behandeling. 
 Ten slotte wordt in dit onderzoek aangetoond dat 19F MRS gebruikt kan worden 
om zowel FU als capecitabine opname, omzetting en afbraak te vervolgen in de lever 
en in uitzaaiïngen in de lever van patiënten met dikkedarmkanker. Er werden geen 
duidelijke correlaties gevonden tussen 19F MRS parameters en tumorrespons, wat kan 
betekenen dat in uitzaaiïngen in de lever de opname en afbraak van FU geen 
beperkende factoren zijn voor respons. Echter, de meting van de actieve 
omzettingsprodukten van FU en absolute kwantificering van concentraties van 
metabolieten is niet mogelijk bij een veldsterkte van 1.5 T. Deze gegevens kunnen 
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relevanter zijn voor het voorspellen van respons op therapie met fluoropyrimidines dan 
kinetische parameters van FU opname en afbraak. Derhalve dient in klinische 
vervolgstudies met 19F MRS bij uitzaaiïngen van dikkedarmkanker in de lever gebruik 
gemaakt te worden van hogere veldsterktes.  
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United World College of the Adriatic in Duino, Italië, waar zij haar International 
Baccalaureate behaalde. Vanaf 1991 studeerde zij geneeskunde aan de Katholieke 
Universiteit Nijmegen (thans Radboud Universiteit Nijmegen), waar zij de propedeuse 
in 1992 (cum laude), het doctoraal examen in 1995 (cum laude) en artsexamen in 1998 
(cum laude) behaalde. In 1993 startte zij aan dezelfde universiteit met de studie 
theologie, die zij na haar propedeuse in 1994 (cum laude) met het doctoraalexamen in 
1999 (cum laude) afsloot. Haar doctoraalscriptie werd bekroond met de Universitaire 
Studieprijs. 
In 1999 begon ze als arts-assistent op de afdeling Interne Geneeskunde in het 
Canisius Wilhelmina Ziekenhuis te Nijmegen, waar zij in datzelfde jaar met de opleiding 
tot internist begon (opleider: dr. R.W. de Koning). Van 2000 tot 2005 zette zij de 
opleiding voort in het Universitair Medisch Centrum (UMC) St Radboud te Nijmegen 
(opleiders: prof. dr. J.W.M. van der Meer, prof. dr. P.M.J. Stuyt, dr. J. de Graaf) in de 
vorm van een zogenaamde agiko-constructie. In deze periode nam zij deel aan de 
poliklinische spreekuren van medische oncologie onder begeleiding van dr. L.V.A.M. 
Beex en werkte zij onder leiding van prof. dr. D.J.Th. Wagener (medische oncologie), 
prof. dr. A. Heerschap (radiologie) en prof. dr. A.J. van der Kogel (radiotherapie) aan 
het onderzoek waarvan dit proefschrift het resultaat is. Na het emiritaat van prof. 
Wagener werd de onderzoeksbegeleiding vanuit de afdeling medische oncologie 
overgenomen door prof. dr. C.J.A. Punt. Naast enkele reisbeurzen ontving zij in 2003 
het dr. I.B.M. Frye Stipendium voor het onderzoek dat in dit proefschrift is 
weergegeven.  
In 2001 startte zij met een onderzoek naar kwaliteit van leven bij 
kankerpatiënten vanuit de Faculteit der Theologie van de Radboud Universiteit 
Nijmegen onder leiding van prof. dr. J.A. van der Ven en dr. J.B.A.M. Schilderman, 
waarvan de patiënteninclusie thans wordt afgerond.  
Zij voltooit momenteel haar opleiding interne geneeskunde in het  UMC St 
Radboud. 
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